WO2014101373A1 - Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds for treatment of central nervous system disorder - Google Patents

Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds for treatment of central nervous system disorder Download PDF

Info

Publication number
WO2014101373A1
WO2014101373A1 PCT/CN2013/076853 CN2013076853W WO2014101373A1 WO 2014101373 A1 WO2014101373 A1 WO 2014101373A1 CN 2013076853 W CN2013076853 W CN 2013076853W WO 2014101373 A1 WO2014101373 A1 WO 2014101373A1
Authority
WO
WIPO (PCT)
Prior art keywords
triazolo
quinazolin
amine
methoxy
ethyl
Prior art date
Application number
PCT/CN2013/076853
Other languages
French (fr)
Inventor
Amjad Ali
Michael Man-Chu Lo
Yeon-Hee Lim
Andrew Stamford
Rongze Kuang
Paul Tempest
Younong Yu
Xianhai Huang
Timothy J. Henderson
Jae-Hun Kim
Christopher Boyce
Pauline Ting
Junying Zheng
Edward Metzger
Nicolas Zorn
Dong Xiao
Gioconda V. Gallo
Walter Won
Heping Wu
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Priority to SI201330980T priority Critical patent/SI2945632T1/en
Priority to AU2013370977A priority patent/AU2013370977B2/en
Priority to NO13866588A priority patent/NO2945632T3/no
Priority to CA2896056A priority patent/CA2896056C/en
Priority to RU2018136104A priority patent/RU2018136104A/en
Priority to LTEP13866588.0T priority patent/LT2945632T/en
Priority to HUE13866588A priority patent/HUE037950T2/en
Priority to KR1020157020147A priority patent/KR102165113B1/en
Priority to MX2015008481A priority patent/MX370017B/en
Priority to PCT/US2013/076781 priority patent/WO2014105666A1/en
Priority to EP13866588.0A priority patent/EP2945632B1/en
Priority to PT138665880T priority patent/PT2945632T/en
Priority to DK13866588.0T priority patent/DK2945632T3/en
Priority to BR112015015468A priority patent/BR112015015468B8/en
Priority to RU2015131148A priority patent/RU2671628C2/en
Priority to RS20180410A priority patent/RS57162B1/en
Priority to PL13866588T priority patent/PL2945632T3/en
Priority to JP2015550682A priority patent/JP6306049B2/en
Priority to CN201380073910.6A priority patent/CN105025899B/en
Priority to US14/655,648 priority patent/US9708347B2/en
Priority to MEP-2018-97A priority patent/ME03034B/en
Priority to ES13866588.0T priority patent/ES2667477T3/en
Publication of WO2014101373A1 publication Critical patent/WO2014101373A1/en
Priority to US15/423,238 priority patent/US10011615B2/en
Priority to HRP20180678TT priority patent/HRP20180678T1/en
Priority to CY20181100472T priority patent/CY1120258T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • Adenosine is known to be an endogenous modulator of a number of physiological functions. At the cardiovascular system level, adenosine is a strong vasodilator and a cardiac depressor. On the central nervous system, adenosine induces sedative, anxiolytic and anti epileptic effects. On the respiratory system, adenosine induces bronchoconstriction. At the kidney level, it exerts a biphasic action, inducing vasoconstriction at low concentrations and vasodilation at high doses. Adenosine acts as a lipolysis inhibitor on fat cells and as an anti- aggregant on platelets.
  • Adenosine action is mediated by the interaction with different membrane specific receptors which belong to the family of receptors coupled with G proteins.
  • Biochemical and pharmacological studies, together with advances in molecular biology, have allowed the identification of at least four subtypes of adenosine receptors: Ai, A 2 A, A 3 ⁇ 4 and A 3 .
  • a and A 3 are high-affinity, inhibiting the activity of the enzyme adenylate cyclase, and
  • a 2 A and A 2b are low-affinity, stimulating the activity of the same enzyme.
  • a 2A antagonists can have antidepressant properties and stimulate cognitive functions.
  • a 2 A receptors are present in high density in the basal ganglia, known to be important in the control of movement.
  • a 2A antagonists can improve motor impairment due to neurodegenerative diseases, for example, Parkinson's disease, senile dementia as in Alzheimer's disease, and psychoses of organic origin.
  • xanthine-related compounds have been found to be Ai receptor selective antagonists, and xanthine and non-xanthine compounds have been found to have high A 2 A affinity with varying degrees of A 2A vs. ⁇ selectivity.
  • Triazolo-pyrimidine adenosine A 2A receptor antagonists with different substitution at the 7-position have been disclosed previously, for example in PCT International Application Publication Nos. WO 95/01356; US 5,565,460; WO 97/05138; and WO 98/52568.
  • Parkinson's disease is characterized by progressive degeneration of the nigrostriatal dopaminergic pathway. The subsequent reduction in striatal dopamine levels is responsible for motor symptoms associated with Parkinson's disease, e.g., the loss of fine motor control or motor impairment manifested in those suffering from the disease.
  • Current methodologies for alleviating motor symptoms associated with Parkinson's disease seek to replace dopamine either within the presynaptic terminal, for example, by administration of L- Dopa, directly through stimulation of the postsynaptic D 2 receptors, or by inhibiting metabolism, for example, by administration of monoamine oxidase type B (MAO-B) or catechol-O- methyltransferase (COMT). Long term use of such therapies is often associated with adverse events.
  • L-Dopa long term therapy with L-Dopa (currently the standard of care) is often associated with adverse events (e.g. motor complications), for example, “wearing-off ', "random on-of ' oscillations, or dyskinesia.
  • adverse events e.g. motor complications
  • motor complications for example, “wearing-off ', "random on-of ' oscillations, or dyskinesia.
  • a 2 A receptors are present in high density in the basal ganglia and are known to be important in the control of fine motor movement. Highly selective A 2 A antagonists have demonstrated their efficacy in reducing motor symptoms associated with neurodegenerative diseases. Accordingly, compounds which are A 2 A receptor antagonists are believed to be useful in alleviating motor symptoms associated with Parkinson's disease.
  • U.S. Patent No. 6,630,475 to Neustadt et al. (the '475 patent) describes the preparation of the compound of Formula PI: Formula PI.
  • a 2 A receptor antagonists in the potential treatment of central nervous system diseases, in particular Parkinson's disease, and to pharmaceutical compositions comprising said compounds has elevated the need for potent, moderately lipophilic, brain penetrant inhibitors of the A 2 A receptor.
  • Such compounds would provide an expansion of the arsenal of compounds which are believed to have value in the treatment of central nervous system disorders, in particular treating or managing the progression of such diseases, for example, but not limited to, Parkinson's disease.
  • the invention provides one or more compounds, or a pharmaceutically acceptable salt thereof, believed to have utility as an A 2 A-receptor antagonist that have the structure of Formula GI:
  • G dl through G d4 are independently hydrogen or a C ⁇ -alkyl, and when alkyl is preferably methyl; p is 1 or 2;
  • X, Y, and Z together with W and the carbon to which they are bonded form a 5 to 6 member aromatic or heteroaromatic moiety, and are independently:
  • Ci-8-alkyl optionally substituted with one or more halogen atoms
  • halogen wherein in some embodiments the halogen is F, Br or CI, and is preferably F or CI;
  • a mono- or polycyclic heterocyclic moiety comprising up to 10 carbon atoms and one or more heteroatoms selected from N, S, or O, optionally substituted with one or more Ci-6-alkyl, morpholino, phenyl (optionally substituted with halogen), heteroaryl or halogen, and when the substituent is a monocyclic heterocyclic moiety, preferably it is independently:
  • 6-alkyl moieties (2) piperazine, wherein the 4-N nitrogen is bonded to a substituent which is: (ai) H; (aii) Ci_6-alkyl; (aiii) morpholino; (aiv) phenyl, optionally substituted with a halogen; (av) halogen; or (avi) heteroaryl;
  • halogen is F
  • R G2 is: (i) H; (ii) Ci_g-alkyl; or (iii) an aromatic moiety of up to 10 carbon atoms, preferably aryl;
  • R G3 is a moiety of the structure:
  • t 0, 1 or 2;
  • R Gal is 1 to 3 substituents replacing an H on a ring carbon atom which are independently for each occurrence: (a) Ci_ 4 -alkoxy, wherein the alkyl portion of the alkoxy moiety is optionally substituted with one or more halogen, and when halogen-substituted, preferably the halogen is F; (b) Ci_g-alkyl which is optionally substituted with one or more halogen atoms; (c) halogen, preferably F or CI; (d) -N(R G4 )2 , wherein at least one of R G4 is Ci_6alkyl and the other is H or Ci_6-alkyl; or (e) -CN.
  • R G3 is a moiety of the structure:
  • the invention is a pharmaceutical formulation comprising at least one compound of Formula GI or a pharmaceutically acceptable salt thereof.
  • the invention is directed to the use of compounds, and pharmaceutical formulations thereof, in the potential treatment of movement disorders in which A2A receptors are involved.
  • the present invention is the provision of a method of treating central nervous system disorders by administering to a subject in need thereof a thera eutic amount of at least one compound of Formula GI or a pharmaceutically acceptable salt thereof.
  • the invention provides one or more compounds believed to have utility as an A2A-receptor antagonist which have the structure of Formula GI.
  • Formula GI or a pharmaceutically acceptable salt thereof, where p, m, n, W, X, Y, Z, R to R , and R have been defined above.
  • compounds of Formula GI preferably have the structure of Formula Gil:
  • R Gaa , R Gba , and R Gca are independently for each occurrence: (a) H; (b) Ci-6-alkyl; (c) Ci_4-alkoxy, which is optionally substituted with one or more fluorine atoms; (d) F; (e) CI; (f) Br; (g) CN; or (h) -N(R G9 ) 2 , wherein R G9 is independently for each occurrence Ci-e-alkyl or H; and wherein R Gaa , R Gba , and R Gca are selected such that at least one of R Gaa , R Gba , and R Gca is H and at least one of R Gaa , R Gba , and R Gca is not H;
  • R Gf is: (a) -CH2-; (b) ethyl, which is optionally substituted with Ci_6-alkyl (optionally substituted with one or more fluorine atoms); (c) propyl; or (d) -C(0)-CH 2 -; and,
  • R Ge is a heteroaryl bicyclic moiety having up to 12 ring atoms of the structure:
  • X', Y', and Z' together with W and the carbon to which they are bonded form a 5 to 6 member aromatic or heteroaromatic moiety, and are independently:
  • Ci_ 8 -alkyl optionally substituted with one or more halogen atoms (e.g., CF 3 );
  • halogen wherein in some embodiments the halogen is F, Br or CI, and is preferably F or CI;
  • Ci_6-alkyl (aiii) morpholino; (aiv) phenyl, optionally substituted with a halogen; (av) halogen; or (avi) heteroaryl;
  • halogen is F
  • phenyl which is optionally substituted with one or more halogen atoms or Ci_ 6 -alkyl (which optionally substituted with one or more halogen atoms), and when the aryl is substituted with halogen, preferably the halogen is F;
  • R G2 is: (i) H; (ii) Ci_ 8 -alkyl; or (iii) an aromatic moiety of up to 10 carbon atoms;
  • R Gaa is preferably methoxy and R Gba and R Gca are both H.
  • R e is preferably a moiety of Formula R ⁇ : Formula R'
  • R Ge is preferably a moiety of Formula R GeB :
  • R ⁇ is preferably a moiety of Formula R ⁇ 0 : Formula R
  • R e is preferably a moiety of Formula R 060 :
  • R ⁇ is preferably a moiety of Formula R GeE :
  • R e is preferably the following moiety:
  • R is preferably -CH 2 -.
  • R Gf is preferably -(CH2)2--
  • R Gf is preferably CH(CH 3 )-CH 2 -.
  • a compound in treatment means that an amount of the compound, generally presented as a component of a formulation that comprises other excipients, is administered in aliquots of an amount, and at time intervals, which provides and maintains at least a therapeutic serum level of at least one pharmaceutically active form of the compound over the time interval between dose
  • Absolute stereochemistry is illustrated by the use of hashed and solid wedge bonds.
  • Illus-I and Illus-II Accordingly, the methyl group of Illus-I is emerging from the page of the paper and the ethyl group in Illus-II is descending into the page, where the cyclohexene ring resides within the plane of the paper.
  • the hydrogen on the same carbon as the methyl group of Illus-I desends into the page and the hydrogen on the same carbon as the ethyl group of Illus-II emerges from the page.
  • the convention is the same where both a hashed and solid rectangle are appended to the same carbon as in Illus-III, the Methyl group is emerging from the plane of the paper and the ethyl group is descending into the plane of the paper
  • compositions for example, “at least one pharmaceutical excipient” means that one member of the specified group is present in the composition, and more than one may additionally be present.
  • Components of a composition are typically aliquots of isolated pure material added to the composition, where the purity level of the isolated material added into the composition is the normally accepted purity level of a substance appropriate for pharmaceutical use.
  • “sequentially” refers to a series administration of therapeutic agents that awaits a period of efficacy to transpire between administering each additional agent; this is to say that after administration of one component, the next component is administered after an effective time period after the first component; the effective time period is the amount of time given for realization of a benefit from the administration of the first component;
  • an effective amount or “therapeutically effective amount” is meant to describe the provision of an amount of at least one compound of the invention or of a pharmaceutical composition comprising at least one compound of the invention which is effective in treating or inhibiting a disease, disorder or condition described herein, and thus produce the desired therapeutic, ameliorative, inhibitory or preventative effect.
  • an effective amount or “therapeutically effective amount” is meant to describe the provision of an amount of at least one compound of the invention or of a pharmaceutical composition comprising at least one compound of the invention which is effective in treating or inhibiting a disease, disorder or condition described herein, and thus produce the desired therapeutic, ameliorative, inhibitory or preventative effect.
  • an effective amount or “therapeutically effective amount” is meant to describe the provision of an amount of at least one compound of the invention or of a pharmaceutical composition comprising at least one compound of the invention which is effective in treating or inhibiting a disease, disorder or condition described herein, and thus produce the desired therapeutic, ameliorative, inhibitory or preventative effect.
  • an effective amount or “therapeutically effective amount” is meant to describe
  • “therapeutically effective amount”) means, for example, providing the amount of at least one compound or pharmaceutically acceptable salt thereof of Formula GI that results in a therapeutic response in a patient afflicted with a central nervous system disorder, including a response suitable to manage, alleviate, ameliorate, or treat the disorder or alleviate, ameliorate, reduce, or eradicate one or more symptoms attributed to the disorder and/or long-term stabilization of the disorder, for example, as may be determined by the analysis of pharmacodynamic markers or clinical evaluation of patients afflicted with the disorder; "patient” and “subject” means an animal, such as a mammal (e.g., a human being) and is preferably a human being;
  • prodrug means compounds that are rapidly transformed, for example, by hydrolysis in blood, in vivo to the parent compound, e.g., conversion of a prodrug of Formula GI to a compound of Formula GI, or to a pharmaceutically acceptable salt thereof; a thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1 87, both of which are incorporated herein by reference; the scope of this invention includes prodrugs of the novel compounds of this invention;
  • solvate means a physical association of a compound of this invention with one or more solvent molecules; this physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding; in certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid; "solvate” encompasses both solution-phase and isolatable solvates; non- limiting examples of suitable solvates include ethanolates, methanolates, and the like; "hydrate” is a solvate wherein the solvent molecule is H 2 0.
  • substituted means that one or more of the enumerated substituents (or, where a list of substituents are not specifically enumerated, the default substituents specified in this "Definitions" section for the particular type of substrate which contains variable substituents) can occupy one or more of the bonding positions on the substrate typically occupied by "-H", provided that such substitution does not exceed the normal valency rules for the atom in the bonding configuration present in the substrate, and that the substitution ultimate provides a stable compound, e.g., mutually reactive substituents are not present geminal or vicinal to each other, and wherein such a compound is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture; when the text indicates optional substitution of a moiety (e.g.
  • the term means "if present, one or more of the enumerated (or default substituents for the specified substrate) can be present on the substrate in a bonding position normally occupied by a hydrogen atom" in accordance with the definition of "substituted” presented herein.
  • moieties As used herein, unless otherwise specified, the following terms used to describe moieties, whether comprising the entire definition of a variable portion of a structural representation of a compound of the invention or a substituent appended to a variable portion of a structural representation of a group of compounds of the invention have the following meanings, and unless otherwise specified, the definitions of each term (i.e., moiety or substituent) apply when that term is used individually or as a component of another term (e.g., the definition of aryl is the same for aryl and for the aryl portion of arylalkyl, alkylaryl, arylalkynyl moieties, and the like); moieties are equivalently described herein by structure, typographical
  • acyl means an R'-C(O)-, where R' is linear, branched or cyclic alkyl; linear, branched or cyclic alkenyl; or linear, branched or cyclic alkynyl moiety, each of which moieties can be substituted; wherein the acyl substituent is bonded through the carbonyl carbon to the substrate of which it is a substituent, or -NH-SO2-R', where -R' is as previously defined; non- limiting examples of suitable acyl groups include formyl, acetyl, propanoyl, 2-methylpropanoyl, butanoyl and cyclohexanoyl;
  • alkenyl means an aliphatic hydrocarbon moiety which is not aromatic but includes in its structure at least one constituent of the structure -(R'OCR'2) or -(R'OCR')-, where R' is a defined substituent, for example -H or -alkyl; the alkenyl moiety can be incorporated into a linear hydrocarbon chain, or incorporated into a cyclic hydrocarbon chain (termed “cycloalkenyl”) and can comprise further, linear, branched, or cyclic substituents depending from the carbon atoms of the chain, preferably the chain comprises about 2 to about 15 carbon atoms; more preferably from about 2 to about 12 carbon atoms; and more preferably chains comprise from about 2 to about 6 carbon atoms;
  • substituted alkenyl unless specified otherwise by a recitation of specific substituents defining the term, means that the alkenyl group is substituted by one or more substituents which are independently for each occurrence: CMO alkyl, C3_io cycloalkyl, and Ci_io alkoxy ;
  • alkoxy means a moiety of the structure: alkyl-O- (i.e., the bond to the substrate moiety is through the ether oxygen), wherein the alkyl portion of the moiety is as defined below for alkyl; non-limiting examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy and heptoxy;
  • alkoxyalkyl means a moiety of the structure: alkoxy-alkyl- (i.e., the bond to the substrate moiety is through an alkyl moiety, which is terminated by, or substituted with, an alkoxy substituent that is not itself bonded to the substrate, non- limiting examples of alkoxyalkyl groups include H 3 C-(CH 2 ) y -0-CH 2 -(CH 2 ) x - wherein "y” and "x" are independently an integer of from 0 to 6;
  • alkoxycarbonyl means a moiety of the structure alkyl-O-C(O)-, equivalently represented as [alkyl-O-(OO)-] and also as R-O(OO)-, where "R” is a defined alkyl moiety,
  • alkoxycarbonyl groups include methoxycarbonyl and ethoxycarbonyl
  • “-alkyl” (including the alkyl portions of other moieties, such as trifluoromethyl- alkyl- and (-alkoxy) means an aliphatic hydrocarbon chain comprising from about 1 to about 20 carbon atoms (that is, “Ci_ 2 o alkyl”), preferably 1 to about 10 carbon atoms (herein “Cuo alkyl”), unless the term is modified by an indication that a shorter chain is contemplated, for example, an alkyl moiety of up to 8 carbon atoms (designated herein “Ci_8-alkyl”); the term “alkyl”, unless specifically limited by another term, for example, “linear”, “branched”, or “cyclic”, includes alkyl moieties which are linear (a hydrocarbon chain with no aliphatic hydrocarbon "branches” appended to it); branched (a main hydrocarbon chain comprising up to the maximum specified number of carbon atoms with a lower-alkyl chain appended to one or more carbon atoms comprising
  • alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, heptyl, nonyl, decyl, fluoromethyl, trifiuoromethyl and cyclopropylmethyl, where the term "alkyl” is indicated with two hyphens (i.e., "-alkyl-” it indicates that the alkyl moiety is bonded in a manner that the alkyl moiety connects a substrate with another moiety, for example, "-alkyl-OH” indicates an alkyl moiety connecting a hydroxyl moiety to a substrate;
  • lower alkyl means a group comprising about 1 to about 6 carbon atoms in the chain (i.e. Ci_6); non-limiting examples of suitable lower alkyl groups include methyl, ethyl, n- propyl, isopropyl, n-butyl, t-butyl, n-pentyl, and hexyl;
  • alkylaryl (or alkaryl) means an alkyl-aryl- group (i.e., the bond to the parent moiety is through the aryl group) wherein the alkyl group is unsubstituted or substituted as defined above, and the aryl group is unsubstituted or substituted as defined below; preferred alkylaryl moieties comprise a lower alkyl group; non-limiting examples of suitable alkylaryl groups include o-tolyl, p-tolyl and xylyl;
  • a substituent which is the called out by the combination of terms used to define two other substituent fragments indicates that the substituent called out by the last term used is bonded to the substrate whilst the preceding term called out is bonded in turn to the substituent fragment it precedes, proceeding right to left to understand the order in which the various fragments are bonded to the substrate;
  • alkynyl means an aliphatic hydrocarbon group (chain) comprising at least one moiety of the structure: s a defined substituent, the alkynyl moiety can be incorporated into a linear or branched
  • non-aromatic hydrocarbon chain or incorporated into a cyclic hydrocarbon chain (non-aromatic, termed
  • cycloalkynyl preferably hydrocarbon chains of an alkynyl moiety comprises about 2 to about 15 carbon atoms; more preferably alkynyl groups comprise about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain;
  • amino means an -NR 2 group wherein R is selected independently for each occurrence from -H or alkyl, alkylamino means -NR' 2 , wherein one R' is -alkyl and the other is -H or -alkyl selected independently for each occurrence, non-limiting examples of alkylamino moieties are -NH-CH3 (methylamino-) and -N(Cf3 ⁇ 4) 2 (dimethylamino);
  • ammonium ion means -N R3' wherein R is independently -H, alkyl, substituted alkyl, or the cationic portion of a dissociated acid capable of producing an ammonium ion from an amine; when not explicitly shown in representations herein the presence of an ammonium ion presumes that a charge-balancing anion is associated with the ammonium ion moiety, which anion is derived from the anionic portion of the acid used to provide said ammonium ion, it will be appreciated that many of the nitrogen atoms present in compounds of the invention can be converted to an ammonium ion thereby providing a salt of the parent compound, which is within the scope of the invention;
  • aryl (sometimes abbreviated “ar”) means an aromatic monocyclic or multicyclic ring system comprising about 6 to about 14 carbon atoms (denoted herein also as “C6-i4-aryl”), preferably about 6 to about 10 carbon atoms (“C6-io-aryl”); the aryl group can be optionally substituted with one or more independently selected “ring system substituents” (defined below).
  • suitable aryl groups include naphthyl
  • aryloxy means an aryl-O- group (i.e., the moiety is bonded to a substrate through the ether oxygen) wherein the aryl group is unsubstituted or substituted as defined above; non- limiting examples of suitable aryloxy groups include phenoxy and naphthoxy;
  • aryloxycarbonyl means an aryl-O-C(O)- group (i.e., the bond to a substrate is through the carbonyl carbon) wherein the aryl group is unsubstituted or substituted as previously defined; non-limiting examples of suitable aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl;
  • a “carboxylic acid” moiety means a substituent having the formula "-C(0)-OH", wherein the moiety is bonded to a substrate is through the carbonyl carbon;
  • cycloalkyl defined above with the “alkyl” definition, means a non-aromatic mono- or multicyclic ring system comprising about 3 to about 20 carbon atoms which may be substituted as defined herein; the term includes multicyclic cycloalkyls, for example, 1 -decalin, norbornyl, adamantyl and the like;
  • halogen means fluorine, chlorine, bromine, or iodine; preferred halogens, unless specified otherwise where the term is used, are fluorine, chlorine and bromine, a substituent which is a halogen atom means -F, -CI, -Br, or—I, and "halo" means fiuoro, chloro, bromo, or iodo substituents bonded to the moiety defined, for example, "haloalkyl” means an alkyl, as defined above, wherein one or more of the bonding positions on the alkyl moiety typically occupied by hydrogen atoms are instead occupied by a halo group, perhaloalkyl means that all bonding positions not participating in bonding the alkyl substituent to a substrate are occupied by a halogen, for example, perfluoroalkyl, where alkyl is methyl, means -CF 3 ;
  • heteroaryl means an aromatic monocyclic or multicyclic ring system comprising about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the ring atoms is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination; preferred heteroaryl moieties comprise 5 ring atoms, for example, thiazole thiadiazole, imidazole, isothiazole, oxazole, oxadiazole, or pyrazole; the "heteroaryl” can be optionally substituted at chemically available ring atoms by one or more independently selected "ring system substituents" (defined below); the prefix aza, azo, oxa, oxo, thia or thio before the heteroaryl root name means that at least a nitrogen, oxygen or sulfur atom, respectively, is present as a ring atom, and in some embodiments 2 or more heteroatoms are present in a ring, for
  • heterocyclyl (or heterocycloalkyl) means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination; there are no adjacent oxygen and/or sulfur atoms present in the ring system; preferred heterocyclyl moieties contain about 5 to about 6 ring atoms; the prefix aza, oxa or thia before the heterocyclyl root name means that at least one nitrogen, oxygen or sulfur atom, respectively, is present as a ring atom; the heterocyclyl can be optionally substituted by one or more independently selected "ring system substituents" (defined below); the nitrogen or sulfur atom of the heterocyclyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide; non-ring system substitu
  • morpholinyl - 0 3 (where unless otherwise noted the moiety is bonded to the substrate through any of ring carbon atoms C2, C3, C5, or C6), thiomorpholinyl, thiazolidinyl, 1 ,3- dioxolanyl, 1 ,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like;
  • moiety means a 6-member cyclic ether of the formula: the bond line having an open end in the center of the structure and terminated at the other end with a wavy line indicates that the substituent is bonded to the substrate to which it is attached through any of carbon atoms 1 to 5, and wherein any of the bonding positions on carbons 1 to 5 normally occupied by a hydrogen atom, that is, the bonding positions on carbon atoms 1 to 5 which are not occupied by the bond to the substrate can optionally be occupied by specified or optional substituents;
  • piperidinyl means: where, the open bond line terminated on one end with a wavy line indicates the ring atom through which the moiety is bonded to the substrate (i.e., any of carbon atoms 2 to 6 (left-hand structure) or the ring nitrogen atom (right-hand structure), and wherein any of the bonding positions on the nitrogen atom or on carbon atoms 2 to 6 not participating in a bond to the substrate and normally occupied by a hydrogen atom can be bonded to a specified or optional substituent, and wherein R', if present, is either -H or another specified substituent;
  • the bond-terminated- with-wavy-line indicates that the pyridinyl moiety is bonded to the substrate at any of carbon atoms 2 to 6, and wherein any of the bonding positions on carbons 2 to 6 normally occupied by a hydrogen atom, that is, any position on carbon 2 to 6 which is not the bond to the substrate, can optionally be occupied by a specified substituent;
  • the bond-terminated- with-wavy-line indicates that the moiety is bonded to the substrate through any of carbon atoms 2 to 8, and wherein any of the bonding positions on carbon atoms 2 to 8 normally occupied by a hydrogen atom, that is, any bonding positions on carbon atoms 2 to 8 which are not bonded to the substrate, can optionally be occupied by one of a list of enumerated substituents;
  • hydroxyl moiety and "hydroxy” means an HO- group
  • hydroxyalkyl means a substituent of the formula: "HO-alkyl-",wherein the alkyl group is bonded to the substrate and may be substituted or unsubstituted as defined above; preferred hydroxyalkyl moieties comprise a lower alkyl;
  • suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl;
  • bonding sequence is indicated by hyphens where moieties are represented in text, for example -alkyl, indicates a single bond between a substrate and an alkyl moiety, -alkyl-X, indicates that an alkyl group bonds an "X" substituent to a substrate, and in structural representatio indicated by a wavy line terminating a bond representation,
  • a bond representation terminated with a wavy line and drawn into a structure without any particular indication of an atom to which it is bonded indicates that the moiety may be bonded to a substrate via any of the atoms in the moiety which bonding, for example: , indicates that the naphthalene moiety may be bonded to the substrate through any of carbons 1 to 8.
  • a saturated nitrogen moiety for example, where one definition of "A” in the structure: A i.s methyl-substituted nitrogen, thus .
  • TM i& — when defining "A" the nitrogen moiety can be represented herein in text as: >N-C3 ⁇ 4, or alternatively -(N-CH3)-.
  • composition encompasses both the bulk composition and individual dosage units comprised of more than one (e.g., two)
  • compositions such as, for example, a compound of the present invention and an additional agent as described herein, along with any pharmaceutically inactive excipients.
  • excipients are any constituent which adapts the composition to a particular route of administration or aids the processing of a composition into a dosage form without itself exerting an active pharmaceutical effect.
  • the bulk composition and each individual dosage unit can contain fixed amounts of the afore-said "more than one pharmaceutically active agents".
  • the bulk composition is material that has not yet been formed into individual dosage units.
  • This invention also includes the compounds of this invention in isolated and purified form obtained by routine techniques. Polymorphic forms of the compounds of Formula GI, and of the salts thereof, are intended to be included in the present invention. Certain compounds of the invention may exist in different isomeric (e.g., enantiomers, diastereoisomers, atropisomers) forms. The invention contemplates all such isomers both in pure form and in admixture, including racemic mixtures.
  • All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds including prodrugs of compounds of the invention as well as the salts and solvates of the inventive compounds and their prodrugs), such as those which may exist due to asymmetric carbons present in a compound of the invention, and including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention.
  • Individual stereoisomers of the compounds of the invention may be isolated in a pure form, for example, substantially free of other isomers, or may be isolated as an admixture of two or more stereoisomers or as a racemate.
  • the chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1914 Recommendations.
  • the use of the terms “salt”, “solvate” “prodrug” and the like, is intended to equally apply to salts, solvates and prodrugs of isolated enantiomers, stereoisomer pairs or groups, rotamers, tautomers, or racemates of the inventive compounds.
  • diasteromeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, for example, by chiral chromatography and/or fractional crystallization.
  • enantiomers can also be separated by converting the enantiomeric mixture into a diasteromeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individually isolated diastereomers to the corresponding enantiomers.
  • an appropriate optically active compound e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride
  • salts are also within the scope of this invention.
  • Reference to a compound of the invention herein is understood to include reference to salts thereof, unless otherwise indicated.
  • salts of the compounds of the invention may be formed, for example, by reacting a compound of the invention with an amount of acid or base, for example, an equivalent amount, in a medium in which the salt precipitates or in an aqueous medium wherein the product is obtained by lyophilization.
  • Acids (and bases) which are generally considered suitable for the formation of pharmaceutically useful salts from basic (or acidic) pharmaceutical compounds are discussed, for example, by S. Berge et al., Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33 201-217; Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; in The Orange Book (Food & Drug Administration, Washington, D.C. on their website); and P. Heinrich Stahl, Camille G. Wermuth (Eds.), Handbook of Pharmaceutical Salts: Properties, Selection, and Use, (2002) Int'l. Union of Pure and Applied Chemistry, pp. 330-331. These disclosures are incorporated herein by reference.
  • acid addition salts include, but are not limited to, acetates, including trifluoroacetate salts, adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, digluconates, dodecylsulfates, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides, hydrobromides, hydroiodides, 2- hydroxyethanesulfonates, lactates, maleates, methanesulfonates, methyl sulfates, 2- naphthalenesulfonates, nico
  • Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, aluminum salts, zinc salts, salts with organic bases (for example, organic amines) such as benzathines, diethylamine, dicyclohexylamines, hydrabamines (formed with N,N- bis(dehydroabietyl)ethylenediamine), N-methyl-D-glucamines, N-methyl-D-glucamides, t-buryl amines, piperazine, phenylcyclohexyl-amine, choline, tromethamine, and salts with amino acids such as arginine, lysine and the like.
  • organic bases for example, organic amines
  • organic bases for example, organic amines
  • Basic nitrogen-containing groups may be converted to an ammonium ion or quartemized with agents such as lower alkyl halides (e.g. methyl, ethyl, propyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g. dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g. decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides), aralkyl halides (e.g. benzyl and phenethyl bromides), and others.
  • lower alkyl halides e.g. methyl, ethyl, propyl, and butyl chlorides, bromides and iodides
  • dialkyl sulfates e.g. dimethyl, diethyl, dibutyl, and diamyl
  • tautomeric forms may exist in exist in different tautomeric forms. All such forms are embraced and included within the scope of the invention. Examples of well- known tautomeric forms include, but are not limited to, ketone/enol tautomeric forms, imine- enamine tautomeric forms, and for example heteroar forms such as the following moieties:
  • purified refers to the physical state of said compound after being isolated from a synthetic process or natural source or combination thereof.
  • purified refers to the physical state of said compound after being obtained from a purification process or processes described herein or well known to the skilled artisan, and in sufficient purity to be characterized by standard analytical techniques described herein or well known to the skilled artisan.
  • a functional group in a compound termed “protected” means that the group is in modified form to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W. Greene et al, Protective Groups in organic Synthesis (1991), Wiley, New York.
  • variable e.g., aryl, heterocycl, R 3 , etc.
  • the selection of moieties defining that variable for each occurrence is independent of its definition at every other occurrence unless specified otherwise in the variable definition.
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, and any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • the present invention also embraces isotopically-labeled compounds of the present invention which are structurally identical to those recited herein, but for the fact that a statistically significant percentage of one or more atoms in that form of the compound are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number of the most abundant isotope usually found in nature, thus altering the naturally occurring abundance of that isotope present in a compound of the invention.
  • isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen (such as 2H and 3H), carbon (such as 1 lC, 13c and 1 Q, nitrogen (such as 13N and 1 5 N), oxygen (such as 15(3, 17(3 and 18(3), phosphorus (such as 32p) 5 sulfur (such as 35s), fluorine (such as 18F), iodine (such as 123i and 125]) and chlorine (such as 36Q). It will be appreciated that other isotopes may be incorporated by known means also.
  • Certain isotopically-labeled compounds of the invention are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3 H) and carbon- 14 (i.e., 14 C) isotopes are particularly useful for their ease of preparation and detection. Further, substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances.
  • Isotopically labeled compounds of the invention can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples herein below, by substituting an appropriate isotopically labeled reagent for a non-isotopically labeled reagent. Such compounds are included also in the present invention.
  • the present invention provides pharmaceutical formulations (pharmaceutical compositions) for use in antagonizing A2A receptors an to potentially treat central nervous system (CNS) disorders, for example, movement disorders associated with Parkinson's disease or the treatment thereof, wherein the compositions comprising at least one compound, or pharmaceutically acceptable salt thereof, of Formula GI, as defined herein.
  • CNS central nervous system
  • the invention provides pharmaceutical formulations (pharmaceutical compositions) suitable for use in blocking adenosine A2a receptors found in the basal ganglia, comprising at least one compound of Formula GI presented above, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier (described below).
  • pharmaceutically formulations of the invention may comprise more than one compound of the invention, for example, the combination of two or three compounds of the invention, each present by adding to the formulation the desired amount of the compound in a pharmaceutically acceptably pure form.
  • compositions of the invention may comprise, in addition to one or more of compounds of the invention, one or more other compounds which also have pharmacological activity, for example, as described herein below.
  • dosage forms of the invention may be employed in bulk form, it will be appreciated that for most applications the inventive formulations will be incorporated into a dosage form suitable for administration to a patient, each dosage form comprising an amount of the selected formulation which contains an effective amount of said one or more compounds of the invention.
  • suitable dosage forms include, but are not limited to, dosage forms adapted for: (i) oral administration, e.g., a liquid, gel, powder, solid or semi-solid pharmaceutical composition which is loaded into a capsule or pressed into a tablet and may comprise
  • a dosage form adapted for intramuscular administration for example, an injectable solution or suspension, and which may be adapted to form a depot having extended release properties
  • a dosage form adapted for intravenous administration for example, a solution or suspension, for example, as an IV solution or a concentrate to be injected into a saline IV bag
  • a dosage form adapted for administration through tissues of the oral cavity for example, a rapidly dissolving tablet, a lozenge, a solution, a gel, a sachette or a needle array suitable for providing intramucosal administration
  • a dosage form adapted for administration via the mucosa of the nasal or upper respiratory cavity for example a solution, suspension or emulsion formulation for dispersion in the nose or airway
  • compositions from the compounds described by this invention generally pharmaceutically active compounds are combined with one or more pharmaceutically inactive excipients.
  • pharmaceutically inactive excipients impart to the composition properties which make it easier to handle or process, for example, lubricants or pressing aids in powdered medicaments intended to be tableted, or adapt the formulation to a desired route of administration, for example, excipients which provide a formulation for oral administration, for example, via absorption from the gastrointestinal tract, transdermal or transmucosal administration, for example, via adhesive skin “patch” or buccal administration, or injection, for example, intramuscular or intravenous, routes of administration.
  • a carrier a carrier
  • compositions can be solid, semi-solid or liquid.
  • Solid form preparations can be adapted to a variety of modes of administration and include powders, dispersible granules, mini-tablets, beads, and the like for example, for tableting, encapsulation, or direct administration.
  • formulations may comprise up to about 95 percent active ingredient, although formulations with greater amounts may be prepared.
  • Liquid form preparations include solutions, suspensions and emulsions.
  • liquid forms of medicament include, but are not limited to, water or water/surfactant mixtures, for example a water-propylene glycol solution, which can be employed in the preparation of formulations intended, for example, for parenteral injection, for example, as a solvent or as a suspending medium for the preparation of suspensions and emulsions where a medicament comprises constituents which are insoluble in water or water/surfactant mixtures.
  • Liquid form preparations may also include solutions or suspensions for intranasal administration and may also include, for example, viscosity modifiers to adapt the formulation for application to particular mucosa tissues accessible via nasal administration.
  • Aerosol preparations for example, suitable for administration via inhalation or via nasal mucosa, may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable propellant, for example, an inert compressed gas, e.g.
  • a pharmaceutically acceptable propellant for example, an inert compressed gas, e.g.
  • solid form preparations which are intended to be converted, shortly before use, to a suspension or a solution, for example, for oral or parenteral administration.
  • Such solid forms include freeze dried formulations and liquid formulations adsorbed into a solid absorbent medium.
  • transdermal compositions can take also the form of creams, lotions, aerosols and/or emulsions and can be provided in a unit dosage form which includes a transdermal patch of any know in the art, for example, a patch which incorporates either a matrix comprising the pharmaceutically active compound or a reservoir which comprises a solid or liquid form of the pharmaceutically active compound.
  • the pharmaceutical preparation is in a unit dosage form.
  • the preparations subdivided into suitably sized unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
  • the actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill in the art. For convenience, the total daily dosage may be divided and administered in portions during the day as required.
  • the present invention provides for use of the compounds described herein for the potential treatment, management, alleviation or amelioration of conditions or disease states which can be, or are believed to be, treated, managed, alleviated or ameliorated by specific blocking of adenosine A2a receptors, for example, central nervous system diseases or disorders, including but not limited to the treatment of movement disorders (e.g., tremors, bradykinesias, gait, dystonias, dyskinesias, tardive dyskinesias, other movement disorders (e.g., tremors, bradykinesias, gait, dystonias, dyskinesias, tardive dyskinesias, other movement disorders (e.g., tremors, bradykinesias, gait, dystonias, dyskinesias, tardive dyskinesias, other movement disorders (e.g., tremors, bradykinesias, gait, dystonias
  • the compounds of the invention also have the potential for use in preventing or lessening the effect of drugs that cause movement disorders.
  • blocking adenosine A2a receptors is accomplished by administering to a patient in need of such therapy an effective amount of one or more compounds of the invention, or a pharmaceutically acceptable salt thereof.
  • the compound in some embodiments it is preferred for the compound to be administered in the form of a pharmaceutical composition
  • a pharmaceutical composition comprising the compound of the invention, or a salt thereof, and at least one pharmaceutically acceptable carrier (described below).
  • pharmaceutically formulations of the invention may comprise more than one compound of the invention or a salt thereof, for example, the combination of two or three compounds of the invention, each present by adding to the formulation the desired amount of the compound or a salt thereof which has been isolated in a pharmaceutically acceptably pure form.
  • administration of a compound of the invention to effect antagonism of A2a receptor sites is preferably accomplished by incorporating the compound into a pharmaceutical formulation incorporated into a dosage form, for example, one of the above- described dosage forms comprising an effective amount of at least one compound of the invention (e.g., 1, 2 or 3, or 1 or 2, or 1, and usually 1 compound of the invention), or a pharmaceutically acceptable salt thereof, for example.
  • a pharmaceutical formulation incorporated into a dosage form for example, one of the above- described dosage forms comprising an effective amount of at least one compound of the invention (e.g., 1, 2 or 3, or 1 or 2, or 1, and usually 1 compound of the invention), or a pharmaceutically acceptable salt thereof, for example.
  • the amount and frequency of administration of the compounds of the invention and/or the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated.
  • Compounds of the instant invention can be administered at a total daily dosage of up to 1 ,000 mg, which can be administered in one daily dose or can be divided into two to four doses per day.
  • the dosage form administered will contain an amount of at least one compound of the invention, or a salt thereof, which will provide a therapeutically effective serum level of the compound in some form for a period of at least 2 hours, preferably at least four hours, and preferably longer.
  • dosages of a pharmaceutical composition providing a therapeutically effective serum level of a compound of the invention e.g., a compound of Formula GI or Gil, or a pharmaceutically acceptable salt thereof, can be spaced in time to provide serum level meeting or exceeding the minimum therapeutically effective serum level on a continuous basis throughout the period during which treatment is administered.
  • the dosage form administered may also be in a form providing an extended release period for the pharmaceutically active compound which will provide a therapeutic serum level for a longer period, necessitating less frequent dosage intervals.
  • a composition of the invention can incorporate additional pharmaceutically active components or be administered simultaneously,
  • Such additional therapeutic agents can include compounds with dopaminergic activity, for example, i) L-DOPA; ii) DOPA
  • decarboxylase inhibitors e.g., decarboxylase inhibitors; and iii) COMT inhibitors.
  • treatment protocols utilizing at least one compound of the invention can be varied according to the needs of the subject or patient.
  • compounds of the invention used in the methods of this invention can be administered in variations of the protocols described above.
  • the compounds of this invention can be administered discontinuously rather than continuously during the treatment cycle.
  • DMF dimethylformamide
  • DCM diichloromethane
  • DMB diimethoxybenzene
  • EtOAc ethylacetate
  • Hex hexanes
  • RT room temperature, nominally about 25°C
  • THF tetrahydrofuran
  • BSTA N,0-Bis(trimethylsilyl)acetamide
  • NMP N-methyl-2-pyrrolidone
  • TFA Trifluoroacetic acid
  • EXAMPLE 1 Preparation of dimethoxybenzene -protected 2-(5-amino-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-2-yl)ethyl methanesulfonates (compound s and preparation of 7- methoxy-2-(2-(3-(methylthio)-5,6-dihydro-[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine (Ex-1)
  • Step G To a round bottom flask of 8 (3.5 g, 7.18 mmol) was added TFA (71.8 mL). The reaction mixture was stirred at 50°C for 16 hours and cooled down to RT. TFA was evaporated, and the residue was charged with DCM and saturated aqueous sodium bicarbonate solution. The precipitate was collected by filtration, and the aqueous layer was extracted with DCM (x5). The organic extracts were combined with the precipitate and concentrated in vacuo. The crude solid was purified by column chromatography (100% ethyl acetate to 10%
  • EXAMPLE 3 Preparation of dimethoxybenzene-protected 2-(5-amino-7-methoxy- [l ,2,4]triazolo[l ,5-c]quinazolin-2-yl)ethyl methanesulfonates ("right-side” precursor compounds) and preparation of 2-(2-(4-(4-ethylpiperazin- 1 -yl)-5 ,6-dihydro- 1 ,7-naphthyridin-7(8H)-yl)ethyl)- 7-methoxy-[l ,2,4]triazolo[ l ,5-c]quinazolin-5-amine (Ex-73)
  • Step A To a stirred suspension of dimethylbenzene (DMB)-protected compound Ex-6 (prepared in Example 1 , 45 mg, 0.074 mmol), 1 -ethylpiperazine (19 ⁇ iL, 0.15 mmol), potassium fert-butoxide (21 mg, 0.19 mmol) and 2-dicyclohexylphosphino-2',6'-di-i- propoxy-l, l'-biphenyl (7.0 mg, 0.015 mmol) in dioxane (573 ⁇ ) was added
  • Step A ethyl 3-[2-(2-amino-8-methoxyquinazolin-4-yl)hvdrazinyl]-3- oxopropanoate
  • Step B (5-amino-7-methoxy[ l ,2,41triazolo[l ,5-clquinazolin-2-yl)acetic acid
  • Step C 2-(5-amino-7-methoxy[l ,2.41triazolo[l ,5-c1quinazolin-2-yn-l-(5,7- dihydro-6H-pyrrolo[3,4-i?lpyridin-6-yl)ethanone
  • Step A 2-(2-f5H-pyrrolor3.4- ⁇ 1pyridin-6(7H)-yl)ethvn-5-amino- ri.2,41triazolori,5-c1quinazolin-7-ol
  • Step B 2-C2-i5H-pyrrolor3.4- 7lDyridin-6( ' 7H)-ylkthvn-7-( ' fluoromethoxyV
  • Step A 3.3-dimethoxypropanehydrazide
  • step B 8-Chloroquinazoline-2,4-diol (step B, 15 g, 75.8 mmol) was added to POCI3 (70 mL, 763 mmol, 10 equiv.) in small portions.
  • Dimethylaniline (3.7 g, 30.5 mmol, 0.4 equiv.) was added.
  • the reaction mixture was stirred in 140°C for 16 hours. The mixture was cooled to room temperature, and added drop wise to ice-water (500 mL). The precipitate was collected and washed with ice-water.
  • Step D /V-(2,8-dichloroqumazolin-4-yl)-3,3-dimethoxypropanehvdrazide
  • Step E /V l -i8-chloro-2-(2.4-dimethoxybenzylammo)quinazolin-4-yl)-3,3- dimethoxypropanehydrazide
  • Step F 7-chloro-iV-(2.4-dimethoxybenzyl)-2-(2.2-dimethoxyethyl)- rL2,41triazolori ,5-c1quinazolin-5-amine
  • step E The solution of N'-(8-chloro-2-(2,4-dimethoxybenzylamino)quinazolin-4-yl)-3,3- dimethoxypropanehydrazide (step E, 7.8 g, 16.4 mmol) in BSA (30 mL) was stirred at 140°C overnight. The mixture was then concentrated by rotovap at 70°C to remove all BSA. The residue was added methanol (50 mL), stirred in cold ice bath for a while. The resulting suspension was filtered, dried under vacuum to obtain the title compound as a yellow solid which was characterized by proton NMR and LC/MS.
  • Step G 2-(7-chloro-5-(2,4-dimethoxybenzylammo)-[ 1.2,41triazolorL5- clquinazolin-2-yl)acetaldehvde
  • Step H 7-chloro-5-(2.4-dimethoxyphenylV2-r2-(5-fluoroisoindolin-2-vnethylV ri.2,41triazolori ,5-c1quinazoline
  • Step I 7-chloro-2-(2-f5-fluoroisoindolin-2-vnethylVri.2.41triazolori .5- clquinazolin-5-amine
  • Example 6 The synthesis of Example 6 was employed with appropriate "left-side" reagents to prepare the compounds presented in Table X. These compounds were characterized by LC/MS, which data is also reported in Table X.
  • Step A methyl 4,4-difluoro-3-(5 /-pyrrolo[3,4-j?lpyridin-6(7H)-ynbutanoate
  • acetonitrile 20 mL
  • DBU 0.373 mL, 2.497 mmol
  • Step B ( ⁇ )-4,4-difluoro-3-(5g-pyrrolo[3,4-fclpyridin-6(7H)-yl)butanehydrazide To an ethanol (50 mL) solution of methyl 4,4-difluoro-3-(5H-pyrrolo[3,4-)
  • step A 1.35 g, 4.99 mmol
  • hydrazine hydrate 2.423 mL, 49.9 mmol
  • the reaction mixture was stirred in a sealed tube at 80°C for 4 h and concentrated in vacuo.
  • the crude product was purified by flash chromatography (CH 2 Cl 2 :MeOH 10:1 to CH 2 CI 2 :MeOH : 1 ) to yield the title compound which was characterized by LC/MS .
  • LC/MS 257 [M+l].
  • Step C ( ⁇ )-jV'-(2-amino-8-methoxyquinazolin-4-yl)-4,4-difiuoro-3-(5g- pyrrolo[3.4-fc1pyridin-6(7H)-yl)butanehydrazide
  • N-(8-methoxy-4-(lH-l ,2,4-triazol- l - yl)quinazolin-2-yl)acetamide 600 mg, 2.1 1 1 mmol
  • step B 595 mg, 2.322 mmol
  • DIPEA 0.441 mL, 2.53 mmol
  • Step D ( ⁇ V2-( ' 3,3-difluoro-2-f5H-pyrrolor3.4- ⁇ lpyridin-6( ' 7H)-vnpropyn-7- methoxy-ri,2,41triazolori ,5-c]quinazolin-5-amine
  • step C 1.1 g, 2.56 mmol
  • BSTA 6.35 mL, 25.6 mmol
  • the reaction mixture was concentrated in vacuo with heating. The residue was purified by flash chromatography
  • Table XIV were prepared in the racemic form. The enantiomeric forms were separated through chiral HPLC.
  • Step A Preparation of 2-(chloromethyl)-7-methoxy-[l ,2,41triazolori,5-c1- quinazolin-5-amine
  • Step B 2-((5-fluoroisoindolin-2-yl)methyl)-7-methoxy-rL2,41triazolo[l ,5-c1- quinazolin-5-amine
  • the "right-side” precursor 2-(chloromethyl)-7-methoxy-[l,2,4]triazolo[l ,5- c]quinazolin-5-amine (150 mg, 0.54 mmol), and "left-side” precursor 5-fiuoroisoindoline (92 mg, 1.1 mmol) were placed in a reaction vessel with DIPEA (105 mg, 0.81 mmol) and KI (269 mg, 1.62 mmol) in DMF (50 mL) and the mixture was stirred at 80°C for 18 h. The mixture was cooled to RT, diluted with DCM, washed with H 2 0 (3X), dried and concentrated.
  • EXAMPLE 10 Preparation of "right-side" precursors having various substituents at 7-C from (7-bromo-5-(2,4-dimethoxybenzylamino)-[l,2,4]triazolo[l,5-c]quinazolin-2-yl)methanol and preparation of compounds of the invention therefrom.
  • Step-1 A mixture of 7-Bromo-5-(2,4-dimethoxybenzyl amino)-2- hydroxymethyl-[l,2,4]-triazolo[l,5-c]quinazoline (200 mg; 0.45 mmol, prepared in accordance with Schemes 1 and 7, above, using 2-amino-3-bromo-benzoic acid starting material in lieu of 2 amino-3-methoxy benzoic acid ), zinc cyanide (31.7 mg; 0.27 mmol) and PdCl 2 (dppf) 2 :CH 2 Cl 2 were dissolved in DMF (1 mL) and water (0.1 mL). The resulting clear red solution was degassed with nitrogen, stirred and heated at 120° C for 14 hr.
  • Step-2 A solution of compound (140 mg; 0.36 mmol) in CH 2 CI 2 (2 mL) and
  • CDCI 3 (2 mL) was cooled in an ice bath and treated sequentially with Et 3 N (40 mg; 55 uL; 0.395 mmol) and MsCI (49 mg; 0.43 mmol), taking care not to use even a slight excess of Et 3 N to avoid quaternary salt formation.
  • the ice bath was removed after 5 minutes and the reaction mixture was stirred at T for 45 minutes when the analysis (TLC, MS) showed absence of alcohol.
  • the reaction mixture was diluted with EtOAc and washed with water, brine, dried and concentrated to obtain the crude mesylate.
  • Step-1 A clear amber solution of 7-cyano tricyclic chloride 12 previously prepared (110 mg; 0.27 mmol), 5,6,7,8-tetrahydro-l ,7-naphthyridine (85 mg; 0.37 mmol) and Hunig's base (0.14 mL; 104 mg; 0.807 mmol) in anhydrous DMF (1 mL) was stirred and heated at 80° C for 18 hr. The reaction mixture was cooled to RT, diluted with water and extracted with EtOAc. The organic extract was washed with water and brine. Combined aqueous layers were back extracted with CH 2 CI 2 .
  • Step-2 The DMB-protected form of compound Ex-196, prepared above, was dissolved in CH 2 Ci 2 :TFA (1 mL each) and stirred at 57° C for 4hr. The clear reaction mixture had become deep purple and MS showed complete deprotection of the DMB group to give the compound Ex-196, 5-amino-2-((5 ,6-dihydro- 1 ,7-naphthyridin-7(8H)-yl)methyl)- [l,2,4]triazolo[l,5-c]quinazoline-7-carbonitrile.
  • Step D N-f8-(Methoxymethyl)-4-oxo-3,4-dihvdroquinazolin-2-yl)acetamide
  • Step E N-(8-(MethoxymethYl -4-(4H-1.2,4-triazol-4-yl)quinazolin-2- vDacetamide
  • Step F N-(4-(2-(2-Hvdroxyacetyl)hvdrazinyl)-8-(methoxymethyl)quinazolin-2- vDacetamide
  • Step G (5-Amino-7-rmethoxymethvn-ri.2,41triazolori,5-clquinazolin-2- vDmethanol
  • Step H 2-(Chloromethyl)-7-(methoxymethvn-n.2.41triazolori.5-c1qumazolin- 5 -amine
  • Step A N'-(2-Chloro-8-methylquinazolin-4-vn-2-hvdroxyacetohvdrazide
  • Step B N'-(2-((2,4-Dimethoxybenzyl)amino -8-methylquinazolin-4-yl -2- hydroxyacetohydrazide
  • Step C 5-(i2.4-Dimethoxybenzyl)amino)-7-methyl-n .2.41triazoloi 1.5- clquinazolin-2-yl)methanol
  • Step D 2-(Chloromethyl)-N-(2,4-dimethoxybenzyl -7-methyl- ri,2,41triazolori,5-c1quinazolin-5-amine
  • Step E 2-(f5H-Pyrrolor3.4-blpyridine-6(7HVvnmethylVN-(2.4- dimethoxybenzvn-7-methyl-[l ,2.41triazolori.5-clquinazolin-5-amine
  • Step F 2-((5H-pYrrolor3,4-blpyridine-6(7H)-vnmethylV7-methyl- rL2,41triazolori,5-c1quinazolin-5-amine (Ex-200)
  • Step A 5 -amino-2-((5.6-dihydro- 1 ,7-naphthyridin-7(8H)-yl)methyl)- [l,2,41triazolo[l,5-clquinazolin-7-ol
  • Step B 2-((5 ,6-dihydro- 1 -naphthyridin-7(8H)-yl)methyl -7-(2-fluoroethoxy)-
  • Step 2 ( ⁇ )-N , -(2-chloro-8-methoxyquinazolin-4-yl)-3-hvdroxybutanehvdrazide To a stirred suspension of 2,4-dichloro-8-methoxyquinazoline (25g, 109 mmol) in
  • 1,4-dioxane (404 ml) was added DIPEA (42.9 ml, 246 mmol) and ( ⁇ )-3-hydroxybutane- hydrazide (14.18 g, 120 mmol) at room temperature.
  • the reaction mixture was heated to 60°C for 16 h. After cooling, the reaction mixture was used for the next step without aqueous workup and purification.
  • LC/MS 31 1 [M+l].
  • Step 3 ( ⁇ )-N'-(2-((2,4-dimethoxybenzyl)amino)-8-methoxyquinazolin-4-yl)-3- hydroxybutanehydrazide
  • Step 4 ( ⁇ )-l-(5-((2,4-dimethoxYbenzyl)amino)-7-methoxy-ri,2,41triazolori,5- clquinazolin-2-yl)propan-2-ol
  • Step 5 ( ⁇ )- 1 -(5-((2,4-dimethoxybenzyl)amino)-7-methoxy-r 1 ,2,41triazok>ri ,5- c1quinazolin-2-yl)propan-2-yl 4-methylbenzenesulfonate
  • Step 6 ( ⁇ )-! -( 5 -amino-7-methoxy-r 1.2.41triazolo [ 1.5-c1quinazolin-2-yl)propan- 2-yl 4-methylbenzenesulfonate
  • Step 7 ( ⁇ )-7-methoxy-2-(2-(2-methyl-6J-dihvdrooxazolo[4,5-clpyridin-5(4H)- yl)propyl)-[ l ,2,41triazolo[l,5-c1quinazolin-5-amine (Ex-210) ⁇
  • EXAMPLE 13 Preparation of 2-(3-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)propyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine (EX-227)
  • Step A Preparation of 2-(3-chloropropyl)-7-methoxy-[l,2,4]triazolo[l ,5- clquinazolin-5-amine (Intermediate- 15)
  • Step B Preparation of 2-(3-r5H-pyrrolo[3.4-b]pyridin-6(7H)-yl)propyl)-7- methoxy-[l,2,41triazolori ,5-c1quinazolin-5-amine (Ex-227)
  • Step A Benzyl 3.3-dimethyl-4-oxopiperidine-l-carboxylate
  • Step B Benzyl 5-bromo-3.3-dimethyl-4-oxopiperidine-l-carboxylate Benzyl 3,3-dimethyl-4-oxopiperidine-l-carboxylate (0.7 g, 2.7 mmol) in DCM (10 ml) was mixed with phenyltrimethylammonium tribromide (1.1 g, 3.0 mmol) and stirred at room temperature for 4 hours. Mixture was diluted with DCM, and washed with water and dried over anhydrous sodium sulfate. The crude mixture was concentrated, diethyl ether added, and the resulting precipitate filtered off. The solution was concentrated to afford the titled compound, and used in the next step without further purification.
  • Step C Benzyl 2.7,7-trimethyl-6.7-dihvdrooxazolor5,4-clpyridine-5(4H)- carboxylate
  • Benzyl 5-bromo-3, 3-dimethyl-4-oxopiperidine-l-carboxylate (0.85 g, 2.5 mmol) from step B was mixed with acetamide (0.74 g, 12.5 mmol), and heated to 120°C and stirred for an additional 1.5 hours. After cooling to room temperature, mixture was diluted with DCM, washed with water, dried over anhydrous sodium sulfate, and the solution was concentrated. The concentrate was purified by silica gel flash chromatography, elutmg with gradient (1 :2 ether/DCM - hexane). UV wavelength for collection was set to 210 nm. The titled product was obtained as colorless oil.
  • Step D 2.7.7-Trimethyl-4.5,6.7-tetrahvdrooxazolo[5.4-clpyridine
  • Step E 7-Methoxy-2-(2-(2,7,7-trimethyl-6,7-dihvdrooxazolor5.4-c1pyridin- 5(4H)-vnethyl)-ri,2,41triazolori,5-clquinazolin-5-amine.
  • Scheme 14a illustrates a variation on the preparation shown in Scheme 14.
  • Step A 3.3-Dimethyl-l-tosylpiperidin-4-one
  • Step B 5-Bromo-3. 3 -dimethyl- l-tosylpiperidin-4-one
  • tetrabutylammonium tribromide (8.3 g, 17.2 mmol) and the mixture was stirred overnight.
  • the reaction mixture was diluted with ethyl acetate (100 ml) and washed with 1 N HC1 (47 ml), water (50 ml), and brine (50 ml), then dried over anhydrous sodium sulfate, and concentrated.
  • the crude was chromatographed on silica, eluting with hexane/ethyl acetate (0 - 100%, 30 min) to give the titled product as a white solid.
  • Step C 2.7.7-Trimethyl-5-tosyl-4.5.6.7-tetrahydrothiazolor5.4-clpyridine
  • Step D 2,7,7-Trimethyl-4,5,6,7-tetrahvdrothiazolor5,4-clpyridine
  • 2,7,7-trimethyl-5-tosyl-4,5,6,7- tetrahydrothiazolo[5,4-c]pyridine (1.42 g, 4.22 mmol) was added HBr (25 ml, 244 mmol), and phenol (0.4 g, 4.22 mmol).
  • the reaction was stirred at 90 °C for 1 hour and then cooled to room temperature.
  • the reaction mixture was diluted with water (30 ml) and extracted with diethyl ether ( 2 x 50 ml).
  • Step E Preparation of 7-Methoxy-2-(2-(2.7.7-trimethyl-6.7-dihvdrothiazolor5.4- clpyridin-5(4H)-yl)ethvn-ri,2,41triazolo[1.5-c1quinazolin-5-amine (Ex- 240)
  • 2-(5-amino-7-methoxy-[ l ,2,4]triazolo[l ,5-c]quinazolin- 2-yl)ethyl methanesulfonate (1.39 g, 4.1 mmol) in dioxane/water (4: 1, 20 ml) was added 2,7,7- trimethyl-4,5,6,7-tetrahydrothiazo [5,4-c]pyridine (0.50 g, 2.7 mmol), KI (0.46 g, 2.7 mmol), and Hunig's base (0.50 ml, 2.7 mmol).
  • the reaction mixture was stirred at 70°C for 15 hours.
  • the reaction mixture was loaded on to a 100 gram C18-reverse phase Biotage column eluting with water/acetonitrile + 0.1%TFA (0-30%, 30 min).
  • the product was collected and acetonitrile was evaporated.
  • EXAMPLE 15 Preparation of 2-(2-(2,4-dimethyl-6,7-dihydrooxazolo[5,4-c]pyridin-5(4H)- yl)ethyl)-7-methoxy-[l,2,4]triazolo[l ,5-c]qumazolin-5-amine (Ex-236) and Preparation of 2-(2- (2,6-dimethyl-6,7-dihydrooxazolo[5,4-c]pyridin-5(4H)-yl)ethyl)-7-methoxy-[l ,2,4]triazolo[l ,5- c]quinazolin-5-amine (Ex-237)
  • Step C 3-Bromo-2-methyl-l-tosylpiperidin-4-one and 5-bromo-2-methyl-l- tosylpiperidin-4-one
  • Step D 2.4.Dimethyl-5-tosyl-4.5,6.7-tetrahvdrooxazolo[5,4-clpyridme and 2.6.dimethYl-5-tosyl-4.5.6.7-tetrahvdrooxazolor5.4-clpyridine
  • Step E 2.4-Dimethyl-4,5.6.7-tetrahvdrooxazolor5.4-clpyridine and 2.6- dimethyl-4,5.6,7-tetrahvdrooxazolor5,4-clrjyridine
  • Step F Preparation of 2-(2-(2,4-dimethyl-6,7-dihvdrooxazolor5.4-clpyridin- 5(4H)- yl)ethyl)-7-methoxy-ri.2.41triazolo[l ,5-clquinazolin-5-amine (Ex-236) and Preparation of 2-(2-(2.6-dimethyl-6.7-dihydrooxazolor5.4-c1pyridin-5(4H)-yl)ethyl)-7- methoxy- ri,2,41triazolori,5-c1quinazolin-5-amine (Ex-237)
  • reaction mixture was stirred at 70°C for 15 hours.
  • the reaction mixture was loaded on to a 100 grams C18-reverse phase Biotage column eluting with water/acetonitrile + 0.1%TFA (0-30%, 30 min) to afford the product mixture.
  • Step A 2-methyl-5-tosyl-4,5,6,6a-tetrahydro-3aH-pyrrolor3,4-d1thiazol-3a-ol To a stirred solution of 4-bromo-l-tosylpyrrolidin-3-one (lg, 3.14 mmol) in DMF
  • Step B 2-methyl-5-tosyl-5.6-dihvdro-4H-pyrrolo[3.4-dlthiazole
  • 2-methyl-5-tosyl-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4- d]thiazol-3a-ol 982 mg, 3.14 mmol
  • CH2C12 13 mL
  • triethylamine 4381 ⁇ , 31.4 mmol
  • Ms-Cl (490 ⁇ , 6.29 mmol
  • Step D 7-methoxy-2-(2-f 2-methyl-4H-pyrrolor3.4-dlthiazol-5( ' 6H -Ynethyl ' )- ri ,2,41triazolori ,5-c1quinazolin-5-amine
  • the crude product was purified by silica-gel flash column chromatography (40g, 100% Hex to 1/1 EtOAc/Hex to 100%EtOAc) to provide tert-butyl 2-methyl-4H-pyrrolo[3,4-d]oxazole-5(6H)- carboxylate.
  • Step E 7-methoxy-2-(2-(2-methyl-4H-pyrrolor3,4-dloxazol-5(6H)-yl)ethyl - ri,2,41triazolori,5-c1quinazolin-5-amine
  • Binding affinities of compounds of the invention for the human A2a receptor were determined in a competition binding assay using Scintillation Proximity technology.
  • a compound of the invention at concentrations ranging from 3000 nM to 0.15 nM in a reaction mixture containing also 0.5 nM of a tritiated form of 5-amino-7-[2-phenethyl]-2-(furan- 2-yl)-7H-pyrazolo[4,3-e][l,2,4]triazolo[l,5-c]pyrimidine (the tritiated compound) and 100 ⁇ g of wheat germ agglutin-coated yttrium silicate SPA beads for one hour at room temperature with agitation. The beads were then allowed to settle to the bottom of the wells for 1 hr, after which the membrane-associated radioactivity was determined by scintillation counting in
  • HEK293 cells expressing the human, rat, dog or monkey adenosine 2a receptor Purchased from Perkin-Elmer # RBHA2AM400UA.
  • the Tritiated compound was prepared in-house by MRL Radiochemistry according to published methods.
  • Assay Buffer was prepared in house: Dulbecco's calcium and magnesium free phosphate buffered saline + 10 mM MgCl2
  • A2a antagonist standard (9-chloro-l-(2-furanyl)-[l ,2,4]triazolol,5-c]quinazolin-5- amine from Tocris Bioscience)
  • final concentrations of compound used in the assay ranged from 3000 nM to 0.152 nM.
  • Membrane Preparation Use 0.25 ug of membrane/well. Dilute membranes to 9.7 ⁇ in assay buffer. Treat with 20 ug/ml adenosine deaminase (ADA) for 15 minutes at room temperature to degrade endogenous adenosine.
  • ADA adenosine deaminase
  • a curve fitting program i.e., Prism, Activity Base, Chemcart
  • the Ki value is calculated using the Cheng-Prusoff equation.
  • Example number A2a EC50 reported in nM.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Disclosed are compounds of heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine herein, which have specific binding on an A2A-receptor and are useful for quantifying in vivo receptor-site occupancy of various compounds which have an affinity for binding to an A2A-receptor.

Description

HETEROBICYCLO-SUBSTITUTED-[l,2,4]TRIAZOLO[l,5-C]QUINAZOLIN-5-AMINE COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDER
BACKGROUND OF THE INVENTION
Adenosine is known to be an endogenous modulator of a number of physiological functions. At the cardiovascular system level, adenosine is a strong vasodilator and a cardiac depressor. On the central nervous system, adenosine induces sedative, anxiolytic and anti epileptic effects. On the respiratory system, adenosine induces bronchoconstriction. At the kidney level, it exerts a biphasic action, inducing vasoconstriction at low concentrations and vasodilation at high doses. Adenosine acts as a lipolysis inhibitor on fat cells and as an anti- aggregant on platelets.
Adenosine action is mediated by the interaction with different membrane specific receptors which belong to the family of receptors coupled with G proteins. Biochemical and pharmacological studies, together with advances in molecular biology, have allowed the identification of at least four subtypes of adenosine receptors: Ai, A2A, A¾ and A3. A and A3 are high-affinity, inhibiting the activity of the enzyme adenylate cyclase, and A2A and A2b are low-affinity, stimulating the activity of the same enzyme.
Analogs of adenosine able to interact as antagonists with the Als A2A, A2b and A3 receptors have also been identified. Selective antagonists for the A2A receptor are of pharmacological interest because of their reduced level of side effects. In the central nervous system, A2A antagonists can have antidepressant properties and stimulate cognitive functions. Moreover, data has shown that A2A receptors are present in high density in the basal ganglia, known to be important in the control of movement. Hence, A2A antagonists can improve motor impairment due to neurodegenerative diseases, for example, Parkinson's disease, senile dementia as in Alzheimer's disease, and psychoses of organic origin.
Some xanthine-related compounds have been found to be Ai receptor selective antagonists, and xanthine and non-xanthine compounds have been found to have high A2A affinity with varying degrees of A2A vs. Αχ selectivity. Triazolo-pyrimidine adenosine A2A receptor antagonists with different substitution at the 7-position have been disclosed previously, for example in PCT International Application Publication Nos. WO 95/01356; US 5,565,460; WO 97/05138; and WO 98/52568.
Parkinson's disease is characterized by progressive degeneration of the nigrostriatal dopaminergic pathway. The subsequent reduction in striatal dopamine levels is responsible for motor symptoms associated with Parkinson's disease, e.g., the loss of fine motor control or motor impairment manifested in those suffering from the disease. Current methodologies for alleviating motor symptoms associated with Parkinson's disease seek to replace dopamine either within the presynaptic terminal, for example, by administration of L- Dopa, directly through stimulation of the postsynaptic D2 receptors, or by inhibiting metabolism, for example, by administration of monoamine oxidase type B (MAO-B) or catechol-O- methyltransferase (COMT). Long term use of such therapies is often associated with adverse events. For example, long term therapy with L-Dopa (currently the standard of care) is often associated with adverse events (e.g. motor complications), for example, "wearing-off ', "random on-of ' oscillations, or dyskinesia. These motor complications arising from therapy
administered to manage Parkinson's disease often become progressively more severe with continued treatment.
As mentioned above, A2A receptors are present in high density in the basal ganglia and are known to be important in the control of fine motor movement. Highly selective A2A antagonists have demonstrated their efficacy in reducing motor symptoms associated with neurodegenerative diseases. Accordingly, compounds which are A2A receptor antagonists are believed to be useful in alleviating motor symptoms associated with Parkinson's disease. For example, U.S. Patent No. 6,630,475 to Neustadt et al. (the '475 patent) describes the preparation of the compound of Formula PI:
Figure imgf000003_0001
Formula PI.
In the '475 patent example Schemes 1 to 5, along with preparative Schemes 1 to 4, show general methods of preparing compounds of Formula PI. The '475 patent describes also that the compound of Formula I can be prepared as a pharmaceutically acceptable salt which may be useful for treating Parkinson's disease.
The use of A2A receptor antagonists in the potential treatment of central nervous system diseases, in particular Parkinson's disease, and to pharmaceutical compositions comprising said compounds has elevated the need for potent, moderately lipophilic, brain penetrant inhibitors of the A2A receptor. Such compounds would provide an expansion of the arsenal of compounds which are believed to have value in the treatment of central nervous system disorders, in particular treating or managing the progression of such diseases, for example, but not limited to, Parkinson's disease. SUMMARY OF THE INVENTION
In one aspect, the invention provides one or more compounds, or a pharmaceutically acceptable salt thereof, believed to have utility as an A2A-receptor antagonist that have the structure of Formula GI:
Figure imgf000004_0001
Formula GI,
wherein:
W is nitrogen or carbon; m is 1 , 2, 3 , or 4; n is an integer of from 0 to 4, wherein the sum of n + m is at least 2 up to 4, and wherein, when W is N, m is at least 2;
Gdl through Gd4 are independently hydrogen or a C^-alkyl, and when alkyl is preferably methyl; p is 1 or 2;
X, Y, and Z together with W and the carbon to which they are bonded form a 5 to 6 member aromatic or heteroaromatic moiety, and are independently:
(a) -(RG1)C= wherein RQ1 is:
(i) hydrogen;
Ci-8-alkyl, optionally substituted with one or more halogen atoms;
-C(0)-Ci_8-alkyl;
-CN;
-S-Ci-g-alkyl;
-O-Ci-6-alkyl;
(vii) -(CH2)qi-(C=0)q2-N(R2)2, where R2 is independently for each occurrence H, Ci_6-alkyl or heteroaryl, and wherein ql is 0 or 1 and q2 is 0 or 1 ;
(viii) -C(0)0-Ci_8-alkyl;
halogen, wherein in some embodiments the halogen is F, Br or CI, and is preferably F or CI;
a mono- or polycyclic heterocyclic moiety comprising up to 10 carbon atoms and one or more heteroatoms selected from N, S, or O, optionally substituted with one or more Ci-6-alkyl, morpholino, phenyl (optionally substituted with halogen), heteroaryl or halogen, and when the substituent is a monocyclic heterocyclic moiety, preferably it is independently:
(1) morpholine, optionally substituted on any carbon atom thereof by one or more Ci
6-alkyl moieties; (2) piperazine, wherein the 4-N nitrogen is bonded to a substituent which is: (ai) H; (aii) Ci_6-alkyl; (aiii) morpholino; (aiv) phenyl, optionally substituted with a halogen; (av) halogen; or (avi) heteroaryl;
(3) piperidinyl, optionally substituted by Ci_6-alkyl or a morpholine moiety; or (4) pyrrolidine, optionally substituted with one or more halogen atoms, and when substituted with halogen, preferably the halogen is F;
(xi) aryl, which is optionally substituted with one or more halogen atoms or Ci_6-alkyl
(which is optionally substituted with one or more halogen atoms), and when the aryl is substituted with halogen, preferably the halogen is F;
(xii) -NH-C(0)-R3, wherein R3 is Ci_6-alkyl or heteroaryl; or
(xiii) heteroaryl, which is optionally substituted with Ci_6-alkyl (which is optionally
substituted with one or more halogen atoms) or amino;
(b) >NRG2, wherein RG2 is: (i) H; (ii) Ci_g-alkyl; or (iii) an aromatic moiety of up to 10 carbon atoms, preferably aryl;
(c) -N=; (d) -0-; or (e) -S-; and,
RG3 is a moiety of the structure:
Figure imgf000005_0001
wherein:
t is 0, 1 or 2;
R and R are independently for each occurrence: (a) H; (b) Ci io-alkyl, which is optionally substituted with one or more fluorine atoms; or (c) RG5 and RG6 taken together form a carbonyl moiety (C=0) with the proviso that if t=2, RG5 and R06 are not selected to provide two adjacent carbonyl moieties; and,
RGal is 1 to 3 substituents replacing an H on a ring carbon atom which are independently for each occurrence: (a) Ci_4-alkoxy, wherein the alkyl portion of the alkoxy moiety is optionally substituted with one or more halogen, and when halogen-substituted, preferably the halogen is F; (b) Ci_g-alkyl which is optionally substituted with one or more halogen atoms; (c) halogen, preferably F or CI; (d) -N(RG4)2 , wherein at least one of RG4 is Ci_6alkyl and the other is H or Ci_6-alkyl; or (e) -CN.
In some embodiments, preferably RG3 is a moiety of the structure:
Figure imgf000006_0001
wherein:
t is 0, 1 or 2; R^ and R06 are independently for each occurrence: (a) H; (b) Ci-io-alkyl which is optionally substituted with one or more fluorine atoms; or (c) RG5 and RG6 taken together form a carbonyl moiety (C=0) with the proviso that if t=2, RG5 and R06 are not selected to provide two adjacent carbonyl moieties; RGa, RGb, and RGc are independently: (a) H; (b) Ci-4-alkoxy, wherein the alkyl portion of the alkoxy moiety is optionally substituted with one or more halogen, and when halogen-substituted, preferably the halogen is F; (c) Ci-g-alkyl, which is optionally substituted with one or more halogen atoms; (d) halogen, preferably F or CI; (e) -N(RG4)2 , wherein at least one of RG4 is Ci_6- alkyl and the other is H or Ci_6 -alkyl; or (f) -CN; with the proviso that at least one of RGa, RGb, or RGc is H and at least one of RGa, RGb, or RGc is not H.
In another aspect, the invention is a pharmaceutical formulation comprising at least one compound of Formula GI or a pharmaceutically acceptable salt thereof. In another aspect the invention is directed to the use of compounds, and pharmaceutical formulations thereof, in the potential treatment of movement disorders in which A2A receptors are involved.
In some aspects the present invention is the provision of a method of treating central nervous system disorders by administering to a subject in need thereof a thera eutic amount of at least one compound of Formula GI or a pharmaceutically acceptable salt thereof.
DETAILED DESCRIPTION OF THE INVENTION
As mentioned above, in one aspect the invention provides one or more compounds believed to have utility as an A2A-receptor antagonist which have the structure of Formula GI.
Figure imgf000006_0002
Formula GI, or a pharmaceutically acceptable salt thereof, where p, m, n, W, X, Y, Z, R to R , and R have been defined above.
In some embodiments, compounds of Formula GI preferably have the structure of Formula Gil:
Figure imgf000007_0001
, Formula Gil, or a pharmaceutically acceptable salt thereof, wherein:
RGaa , RGba, and RGca are independently for each occurrence: (a) H; (b) Ci-6-alkyl; (c) Ci_4-alkoxy, which is optionally substituted with one or more fluorine atoms; (d) F; (e) CI; (f) Br; (g) CN; or (h) -N(RG9)2, wherein RG9 is independently for each occurrence Ci-e-alkyl or H; and wherein RGaa , RGba, and RGca are selected such that at least one of RGaa , RGba, and RGca is H and at least one of RGaa, RGba, and RGca is not H;
RGf is: (a) -CH2-; (b) ethyl, which is optionally substituted with Ci_6-alkyl (optionally substituted with one or more fluorine atoms); (c) propyl; or (d) -C(0)-CH2-; and,
RGe is a heteroaryl bicyclic moiety having up to 12 ring atoms of the structure:
Figure imgf000007_0002
wherein
W is nitrogen or carbon; m' is 1, 2, 3, or 4; n' is an integer of from 0 to 4, wherein the sum of n' + m' is at least 2 up to 4, and wherein, when W is N, m' is at least 2; p' is 1 or 2; Gdl' through Gd4' are independently H or a
Figure imgf000008_0001
X', Y', and Z' together with W and the carbon to which they are bonded form a 5 to 6 member aromatic or heteroaromatic moiety, and are independently:
(a) -(RG1')C= wherein RG1' is:
(i) hydrogen;
(ii) Ci_8-alkyl, optionally substituted with one or more halogen atoms (e.g., CF3);
(iii) -C(0)-Ci_8-alkyl;
(iv) -CN;
(v) -S-C1-8-alkyl;
(vi) -O-Ci-6-alkyl;
(vii) -(CH2)q-C(0)-N(R2)2, wherein R2 is independently for each occurrence H, Ci_4-alkyl or pyridyl, and wherein q is 0 or 1 ;
(viii) -C(0)0-d_8-alkyl;
(ix) halogen, wherein in some embodiments the halogen is F, Br or CI, and is preferably F or CI;
(x) morpholine, optionally substituted on any carbon atom thereof by one or more Ci_6- alkyl moieties;
(xi) piperazine, wherein the 4-N nitrogen is bonded to a substituent which is: (ai) H; (aii)
Ci_6-alkyl; (aiii) morpholino; (aiv) phenyl, optionally substituted with a halogen; (av) halogen; or (avi) heteroaryl;
(xii) piperidinyl, optionally substituted by Ci_6-alkyl or a morpholine moiety; or
(xiii) pyrrolidine, optionally substituted with one or more halogen atoms, and when
substituted with halogen, preferably the halogen is F;
(xiv) phenyl, which is optionally substituted with one or more halogen atoms or Ci_6-alkyl (which optionally substituted with one or more halogen atoms), and when the aryl is substituted with halogen, preferably the halogen is F;
(xv) -NH-C(0)-R3', wherein R3' is Ci_4-alkyl or pyridinyl;
(χνί) heteroaryl, which is optionally substituted with CF3, Ci_6-alkyl or amino; or
(xvii) -N(R4 )2, wherein R4 is independently for each occurrence H or C^-alkyl;
(b) >NRG2 , wherein RG2 is: (i) H; (ii) Ci_8-alkyl; or (iii) an aromatic moiety of up to 10 carbon atoms;
(c) -N=;
(d) -0-; or
(e) -S-.
In some embodiments, RGaa is preferably methoxy and RGba and RGca are both H. In some embodiments, in compounds of Formula GII, R e is preferably a moiety of Formula R^:
Figure imgf000009_0001
Formula R'
where X1, Y1 and Z1 are defined in Table I below:
Table I
Figure imgf000009_0004
In some embodiments, in compounds of Formula GII, RGe is preferably a moiety of Formula RGeB:
Figure imgf000009_0002
Formula R GeB
where A2, X2, Y2 and Z2 are defined in Table II below:
Table II
Figure imgf000009_0003
Figure imgf000010_0001
In some embodiments, in compounds of Formula Gil, R β is preferably a moiety of Formula R^0 :
Figure imgf000010_0002
Formula R
where X3, Y3, Z3 and A3 are defined in Table III below:
Table III
Figure imgf000010_0003
Figure imgf000011_0001
In some embodiments, in compounds of Formula Gil, R e is preferably a moiety of Formula R060:
Figure imgf000011_0002
where X4, Y4 and Z4 are defined in Table IV below:
Figure imgf000011_0003
Figure imgf000012_0001
In some embodiments, in compounds of Formula GII, R β is preferably a moiety of Formula RGeE:
Figure imgf000012_0002
where X5, Y5 and Z5 are defined in Table V below:
Table V
Figure imgf000012_0004
In some embodiments, in compounds of Formula GII, R e is preferably the following moiety:
Figure imgf000012_0003
H H
Figure imgf000013_0001
In some embodiments R is preferably -CH2-.
In some embodiments RGf is preferably -(CH2)2--
In some embodiments RGf is preferably CH(CH3)-CH2-.
In some embodiments a compound of the invention is:
7-methoxy-2-(2-(3-(methylthio)-5,6-dihydro-[l ,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl)ethyl)-[l,2,4]triazolo[ l ,5-c]quinazolin-5-amine;
7-(2-(5-amino-7-methoxy-[ l ,2,4]triazolo[l ,5-c]qumazolin-2-yl)ethyl)-N-tert- butyl-5,6,7,8-tetrahydro-[l ,2,4]triazolo[4,3-a]pyrazine-3-carboxamide;
2-(2-(3-bromo-5,6-dihydro-[ l ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)ethyl)-7- methoxy-[l ,2,4]triazolo[l ,5-c]quinazolin-5-amine;
ethyl 7-(2-(5-amino-7-methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-2-yl)ethyl)- 5,6,7,8-tetrahydro-[l,2,4]triazolo[4,3-a]pyrazine-3-carboxylate;
2-(2-(2-chloro-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)ethyl)-7-methoxy- [l ,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(4-bromo-5,6-dihydro-l ,7-naphthyridin-7(8H)-yl)ethyl)-7-methoxy- [l ,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(l-cyclopropyl-6,7-dihydro-lH-pyrazolo[4,3-c]pyridin-5(4H)-yl)ethyl)-7- methoxy-[l ,2,4]triazolo[l ,5-c]quinazolin-5-amine;
2-(2-(3-isopropyl-5,6-dihydroimidazo[l ,5-a]pyrazin-7(8H)-yl)ethyl)-7-methoxy- [l ,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(3-(trifluoromethyl)-6,7-dihydroisoxazolo[4,3-c]pyridin-5(4H)- yl)ethyl)-[l,2,4]triazolo[ l ,5-c]quinazolin-5-amine; (7-(2-(5-amino-7-methoxy-[l,2,4]triazolo[l,5-c]quinazolin-2-yl)ethyl)-5,6,7,8- tetrahydroimidazo[ 1 ,2-a]pyrazin-2-yl)(cyclopropyl)methanone;
7-methoxy-2-(2-(2-(trifluoromethyl)-5,6-dihydro-[l ,2,4]triazolo[l,5-a]pyrazin- 7(8H)-yl)ethyl)-[l,2,4]triazolo[l,5-c]q inazolin-5-amine;
2-(2-(2-cyclopropyl-5,6-dihydro-[l,2,4]triazolo[l ,5-a]pyrazin-7(8H)-yl)ethyl)-7- methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
2-(2-(3-ethyl-5,6-dihydroimidazo[l,5-a]pyrazin-7(8H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-methyl-4H-pyrrolo[3,4-d]thiazol-5(6H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
6- (2-(5-amino-7-methoxy-[l ,2,4]triazolo[l,5-c]qumazolm-2-yl)ethyl)-2- cyclopropyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carbonitrile;
7- methoxy-2-(2-(2-(trifluoromethyl)-6,7-dihydro-3H-imidazo[4,5-c]pyridin- 5(4H)-yl)ethyl)-[l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(3-(trifluoromethyl)-5,6-dihydro-[ 1 ,2,4]triazolo[4,3-a]pyrazin-
7(8H)-yl)ethyl)-[l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-(trifluoromethyl)-5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)ethyl)-7-methoxy-[ 1 ,2,4]triazolo[ 1 ,5- c]quinazolin-5-amine;
2-(2-(7,8-dihydro-5H-pyrido[2,3-b]azepin-9(6H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(2,3 -dihydro- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(3-ethyl-5,6-dihydro-[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)ethyl)-7- methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-methyl-5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(isoindolin-2-yl)ethyl)-7-methoxy-[l,2,4]triazolo[l,5-c]quinazolin-5-amine; 7-methoxy-2-(2 2-methyl-6,7-dihydrothiazolo[4,5-c]pyridin-5(4H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-(trifluoromethyl)-6,7-dihydrothiazolo[4,5-c]pyridm-5(4H)- yl)ethyL)-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-methyl-6,7-dihydrooxazolo[4,5-c]pyridin-5(4H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-methyl-6,7-dihydrooxazolo[5,4-c]pyridin-5(4H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine; 7-methoxy-2-(2-(2-methyl-6,7-dihydrothiazolo[5,4-c]pyridin-5(4H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(2-cyclopropyl-6,7-dihydrothiazolo[5,4-c]pyridin-5(4H)-yl)ethyl)-7- methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
2-(2-(2-cyclopropyl-6,7-dihydrooxazolo[5,4-c]pyridin-5(4H)-yl)ethyl)-7- methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(l-methyl-3-(trifluorometliyl)-6,7-dihydro-lH-pyrazolo[4,3- c]pyridin-5(4H)-yl)ethyl)-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
2-(2-(2 -dihydro-lH-imidazo[l,2-b]pyrazol-l-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-phenylpyn-olo[3,4-d]imidazol-5(lH,4H,6H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(6,7-dihydroisoxazolo[4,5-c]pyridin-5(4H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(6,7-dihydro-lH-pyrazolo[4,3-c]pyridin-5(4H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(3-methyl-6,7-dihydro-lH-pyrazolo[4,3-c]pyridin-5(4H)- yl)ethyl)-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(3-(trifluoromethyl)-6,7-dihydro- 1 H-pyrazolo [4,3 -c]pyridin- 5(4H)-yl)ethyl)-[l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(3-cyclopropyl-4,5-dihydro-lH-pyrazolo[3,4-c]pyridin-6(7H)-yl)ethyl)-7- methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-methyl-6,7-dihydropyrazolo[l ,5-a]pyrazin-5(4H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(3-(trifluoromethyl)-4,5 -dihydro- 1 H-pyrazolo [3 ,4-c]pyridin- 6(7H)-yl)ethyl)-[l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(l-methyl-3-(trifluoromethyl)-6,7-dihydro-lH-pyrazolo[4,3- b]pyridm-4(5H)-yl)ethyl)-[l,2,4]triazolo[l ,5-c]quinazolin-5-amme;
2-(2-(6-fluoro-3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-7-metlioxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(5 ,6-dihydro- 1 ,7-naphthyridin-7(8H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(5-(trifluoromethyl)isoindolin-2-yl)ethyl)-[l,2,4]triazolo[l,5- c]quinazolin-5-amine; 2-(2-(5-fluoroisoindolin-2-yl)ethyl)-7-methoxy-[l,2,4]triazolo[l,5-c]quinazolin-
5 -amine;
2-(2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)ethyl)-7-methoxy-[l,2,4]triazolo[l,5- c]quinazolin-5-amine;
7-methoxy-2-(2-(3-phenylpyrrolo[3,4-c]pyrazol-5(lH,4H,6H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(pyrrolo[3,4-c]pyrazol-5(lH,4H,6H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(3-cyclopropyl-6,7-dihydro-lH-pyrazolo[4,3-b]pyridin-4(5H)-yl)ethyl)-7- methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
2-(2-(5,6-dihydropyrido[3,4-d]pyrimidin-7(8H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(7,8-dihydropyrido[4,3-b]pyrazin-6(5H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(6,7-dihydrothiazolo[5,4-c]pyridin-5(4H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(6,7-dihydrothiazolo[4,5-c]pyridin-5(4H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-(trifluoromethyl)-5,6-dihydroimidazo[l ,2-a]pyrazin-7(8H)- yl)ethyL)-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
2-(2-(6,7-dihydropyrazolo[l,5-a]pyrimidin-4(5H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-methyl-7,8-dihydro-4H-pyrazolo[l,5-a][l,4]diazepin-5(6H)- yl)ethyl)-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
5-(2-(5-amino-7-methoxy-[l ,2,4]triazolo[l,5-c]qumazolin-2-yl)ethyl)-5, 6,7,8- tetrahydro-4H-pyrazolo [ 1 ,5 -a] [ 1 ,4]diazepine-2-carbonitrile;
2-(2-(4,4-dimethyl-3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-(4-methylpiperazin-l-yl)-5H-pyrrolo[3,4-b]pyridin-6(7H)- yl)ethyL)-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-morpholino-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-(pyrrolidin-l-yl)-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine; 2-(2-(2-(4-ethylpiperazin-l-yl)-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)ethyl)-7- methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
2-(2-(2-(2,2-dimethylmorpholino)-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)ethyl)-7- methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
2-(2-(2 (2S,6R)-2,6-dimethylmorpholino)-5H-pyrrolo[3,4-b]pyridin-6(7H)- yl)ethyl)-7-methoxy-[ 1 ,2,4]triazolo[ 1 ,5-c]qumazolin-5-amine;
2-(2-(2-(4-(cyclopropylmethyl)piperazin-l-yl)-5H-pyrrolo[3,4-b]pyridm-6(7H)- yl)ethyl)-7-methoxy-[ 1 ,2,4]triazolo[ 1 ,5-c]quinazolin-5-amine;
2-(2 2 4-(4-fluorophenyl)piperazin-l-yl)-5H-pyrrolo[3,4-b]pyridin-6(7H)- yl)ethyl)-7-methoxy-[ 1 ,2,4]triazolo[ 1 ,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-(4-mo holmo iperidin-l-yl)-5H-pyrτolo[3,4-b]pyridin- 6(7H)-yl)ethyl)-[l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2 4 4-ethylpiperazin-l-yl)-5,6-dihydro-l,7-naphthyridin-7(8H)-yl)ethyl)-7- methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
2-(2-(4-(diethylamino)-5,6-dihydro-l ,7-naphthyridin-7(8H)-yl)ethyl)-7-methoxy-
[l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(4-(3,3-difluoropyrrolidin-l-yl)-5,6-dihydro-l,7-naphthyridin-7(8H)- yl)ethyl)-7-methoxy-[ 1 ,2,4]triazolo[ 1 ,5-c]qumazolin-5-amine;
2-(5-ammo-7-methoxy-[l ,2,4]triazolo[l ,5-c]quinazolin-2-yl)-l-(5H-pyrrolo[3,4- b]pyridin-6(7H)-yl)ethanone;
2-(5 -amino-7-methoxy-[ 1 ,2,4]triazolo [ 1 ,5 -c]quinazolin-2-yl)- 1 -(4,5 -dihydro- 1 H- benzo [d] azepin-3 (2H)-yl)ethanone;
2-(2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)ethyl)-7-(fluoromethoxy)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-chloro-2-(2-(5-fluoroisoindolin-2-yl)ethyl)-[l ,2,4]triazolo[l,5-c]quinazolin-5- amine;
7-chloro-2-(2-(3,4-dihydroquinolin-l(2H)-yl)ethyl)-[l,2,4]triazolo[l ,5- c]quinazolin-5-amine;
2-[2-(5,7-dihydro-6//-pyrrolo[3,4- )]pyridm-6-yl)ethyl]-7- fluoro[ 1 ,2,4]triazolo[l ,5-c]quinazolin-5-amine;
2-(2-(3,4-dihydroquinolin- 1 (2H)-yl)ethyl)-7-fluoro-[ 1 ,2,4]triazolo[ 1 ,5- c]quinazolin-5-amine;
7-fluoro-2-(2-(5-fluoroisoindolin-2-yl)ethyl)-[l,2,4]triazolo[l,5-c]quinazolin-5- amine;
2-(2-(3-ethyl-5,6-dihydro-[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)ethyl)-7-fluoro- [l,2,4]triazolo[l,5-c]quinazolin-5-amine; 2-(2-(3,4-dihydroisoquinolin-2( 1 H)-yl)ethyl)-7-fluoro-[ 1 ,2,4]triazolo[l ,5- c]quinazolin-5-amine;
7- rluoro-2-(2-(2-(trifluoromethyl)-5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-fluoro-2-(2-(4-fluoroisoindolin-2-yl)ethyl)-[l,2,4]triazolo[l,5-c]quinazolin-5- amine;
2-(2-(3 ,4-dihydroisoquinolin-2( 1 H)-yl)ethyl)-7-methyl-[ 1 ,2,4]triazolo[ 1,5- c]quinazolin-5-amine;
8- fl oro-2-(2-(5-fluoroisoindolin-2-yl)ethyl)-[l,2,4]triazolo[l,5-c]q mazolin-5- amine;
2-(2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)ethyl)-8-fluoro-[l ,2,4]triazolo[ 1 ,5- c]quinazolin-5-amine;
2-(2-(3,4-dihydroisoquinolin-2( 1 H)-yl)ethyl)-8-fluoro-[ 1 ,2,4]triazolo[l ,5- c]quinazolin-5-amine;
2-(2-(3,4-dihydroquinolin- 1 (2H)-yl)ethyl)-8-fluoro-[ 1 ,2,4]triazolo[ 1 ,5- c]quinazolin-5-amine;
2-(2-(3-ethyl-5,6-dihydro-[l,2,4]triazolo[4,3-a]pyrazm-7(8H)-yl)ethyl)-8-fluoro- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
8-fluoro-2-(2-(4-fluoroisoindolin-2-yl)ethyl)-[l,2,4]triazolo[l,5-c]quinazolin-5- amine;
2-(2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)et yl)-7,8-dimethoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(5H-pyrrolo[3,4-b]pyridm-6(7H)-yl)ethyl)-9-fluoro-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(5H-pyrrolo[3,4-b]pyridm-6(7H)-yl)ethyl)-8,9-difluoro-[l,2,4]triazolo[l,5- c]quinazolin-5-amine;
2-(2-(5H-pyrrolo[3,4-b]pyridm-6(7H)-yl)ethyl)-7,9-difluoro-[l,2,4]triazolo[l,5- c]quinazolin-5-amine;
2-(3,3-difluoro-2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)propyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
(R)-2-(3,3-difluoro-2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)propyl)-7-methoxy- [l,2,4]n-iazolo[l,5-c]quinazolin-5-amine;
(S)-2-(3,3-difluoro-2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)propyl)-7-methoxy- [l,2,4]ttiazolo[l,5-c]quinazolin-5-amme;
2-(3-fluoro-2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)propyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine; 2-(2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)propyl)-7-methoxy-[l ,2,4]triazolo[ 1 ,5- c]quinazolin-5-amine;
(S)-2-(2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)propyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
(R)-2-(2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)propyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(3,3,3-trifluoro-2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)propyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
(S)-7-methoxy-2-(3,3,3-trifluoro-2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)propyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
(R)-7-methoxy-2-(3,3,3-trifluoro-2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)propyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(5H-pyrrolo[3,4-b]pyridm-6(7H)-yl)butyl)-7-methoxy-[l,2,4]triazolo[l,5- c]quinazolin-5-amine;
(R)-2-(2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)butyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
(S)-2-(2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)butyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(5-fluoroisoindolin-2-yl)propyl)-7-methoxy-[l ,2,4]triazolo[l,5-c]quinazolin- 5-amine;
2-(2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)pentyl)-7-methoxy-[l,2,4]triazolo[l,5- c]quinazolin-5-amine;
7-methoxy-2-(2-(2-methyl-6,7-dihydrooxazolo[5,4-c]pyridin-5(4H)-yl)propyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((5-fluoroisoindolin-2-yl)methyl)-7-methoxy-[l,2,4]triazolo[l,5-c]quinazolin-5- amine;
2-((5H^yrrolo[3,4-b]pyridin-6(7H)-yl)methyl)-7-methoxy-[l,2,4]triazolo[l,5- c]quinazolin-5-amine;
2-((3 ,4-dihydroquinolin- 1 (2H)-yl)methyl)-7-methoxy- [ 1 ,2,4]triazolo [1 ,5- c]quinazolin-5-amine;
2-((2H-benzo[b][l,4]oxazin-4(3H)-yl)methyl)-7-methoxy-[l,2,4]triazolo[l ,5- c]quinazolin-5-amine;
2-((3,4-dihydroisoquinolin-2(lH)-yl)methyl)-7-methoxy-[l,2,4]triazolo[l ,5- c]quinazolin-5-amine;
2-((5-amino-7-methoxy-[l ,2,4]triazolo[l,5-c]quinazolin-2-yl)methyl)-l , 2,3,4- tetrahydroisoquinoline-6-carbonitrile; 2-((5,6-dihydro-l,7-naphthyridin-7(8H)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-((7-methoxy-4,5-dihydro-lH-benzo[d]azepin-3(2H)-yl)methyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((3 ,4-dihydro-2,7-naphthyridin-2( 1 H)-yl)methyl)-7-methoxy-
[l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-((8-((4-(pyridin-2-yl)piperazin- 1 -yl)methyl)-3 ,4-dihydroisoquinolin- 2(1 H)-yl)methyl)- [ 1 ,2,4]triazolo [ 1 ,5 -c] quinazolin-5 -amine;
7-methoxy-2-((5-(trifluoromethyl)isoindolin-2-yl)methyl)-[l,2,4]triazolo[l,5- c]quinazolin-5-amine;
7-methoxy-2-((2 ,3 ,4 , 5 -tetrahydro- 1 H-benzo [b] azepin- 1 -yl)methyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-((3-(trifluoromethyl)-7,8-dihydro-l,6-naphthyridin-6(5H)- yl)methyl)-[ 1 ,2,4]triazolo [ 1 ,5 -c]quinazolin-5 -amine;
2-((6-fluoro-3,4-dihydroisoquinolin-2(lH)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((4,5-dihydro-lH-benzo[d]azepin-3(2H)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((4,5-dihydro-lH-benzo[c]azepin-2(3H)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((3,4-dihydro-l ,5-naphthyridin- 1 (2H)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((3 ,4-dihydro- 1 ,6-naphthyridin- 1 (2H)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((3 ,4-dihydro- 1 ,7-naphthyridin- 1 (2H)-yl)methyl)-7-methoxy-
[l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((7-chloro-4-methyl-2,3 ,4,5 -tetrahydro- 1 H-benzo [e][ 1 ,4]diazepin- 1 -yl)methyl)- 7-methoxy- [ 1 ,2,4]triazolo [ 1 ,5 -c]quinazolin-5-amine;
2-((2-chloro-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-((3-(methylthio)-5,6-dihydro-[l,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl)methyl)-[ 1 ,2,4]triazolo [ 1 ,5 -c]quinazolin-5 -amine;
ethyl 7-((5-amino-7-methoxy-[l ,2,4]triazolo[ 1 ,5-c]quinazolin-2-yl)methyl)- 5,6,7,8-tetrahydro-[l,2,4]triazolo[4,3-a]pyrazine-3-carboxylate;
2-((3-bromo-5,6-dihydro-[l ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methyl)-7- methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine; 2-((5,6-dihydro-[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((3-ethyl-5,6-dihydro-[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methyl)-7- methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
7-((5-amino-7-methoxy-[l ,2,4]triazolo[l,5-c]quinazolin-2-yl)methyl)-N-tert- butyl-5,6J,84etrahydro-[l ,2,4]triazolo[4,3-a]pyrazine-3-carboxamide;
7-methoxy-2-((3-methoxy-5,6-dihydro-[l,2,4]triazolo[4,3-a]p3Tazin-7(8H)- yl)methyl)-[ 1 ,2,4]triazolo [ 1 ,5 -c]quinazolin-5 -amine;
2-((5,5-dimethyl-3-(trifluoromethyl)-5,6-dihydro-[l ,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)methyl)-7-methoxy- [ 1 ,2,4]triazolo[ 1 ,5 -c] quinazolin-5 -amine;
2-((8,8-dimethyl-3-(trifluoromethyl)-5,6-dihydro-[l ,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)methyl)-7-methoxy- [ 1 ,2,4]triazolo[ 1 ,5 -c] quinazolin-5 -amine;
2-((4-bromo-5,6-dihydro-l,7-naphthyridin-7(8H)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((2-isopropyl-4H-pyrrolo[3,4-d]thiazol-5(6H)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((7,8-dihydropyrido[4,3-b]pyrazin-6(5H)-yl)methyl)-7-methoxy- [l,2,4]n-iazolo[l,5-c]quinazolin-5-amine;
2-((5 ,6-dihydropyrido [3 ,4-d]pyrimidin-7(8H)-yl)methyl)-7-methoxy- [l,2,4] azolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-((2-(trifluoromethyl)-5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)methyl)- [l,2,4]n"iazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-((3-(trifluoromethyl)-5,6-dihydro-[l ,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)methyl)-[l,2,4]triazolo[l,5-c]quinazoLin-5-amine;
2-((2,3-dihydro-lH-pyrrolo[2,3-b]pyridin- 1 -yl)methyl)-7-methoxy-
[l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((5-bromo-2,3-dihydro-lH-pyrrolo[2,3-b]pyridin-l-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-((7-methyl-3 ,4-dihydro- 1 ,8-naphthyridin- 1 (2H)-yl)methyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((7, 8-dihydro-5H-pyrido [2,3 -b] azepin-9(6H)-yl)methyl)-7-methoxy- [l,2,4]n-iazolo[l,5-c]quinazolin-5-amine;
2-((2,3-dihydro-lH-pyrrolo[2,3-b]pyridin-l-yl)methyl)-7-methoxy- [l,2,4] azolo[l,5-c]quinazolin-5-amine;
2-((2-chloro-7,8-dihydro-5H-pyrido[2,3-b]azepin-9(6H)-yl)methyl)-7-methoxy- [l,2,4]n-iazolo[l,5-c]quinazolin-5-amine; 2-((3,4-dihydro-l ,8-naphthyridin- 1 (2H)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-((2-(pyridin-2-yl)-7,8-dihydro-5H-pyrido[2,3-b]azepin-9(6H)- yl)methyl)-[ 1 ,2,4]triazolo [ 1 ,5 -c]quinazolin-5 -amine;
2-((4,4-dimethyl-3 ,4-dihydroisoquinolin-2( 1 H)-yl)methyl)-7-methoxy-
[l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)methyl)-9-fluoro-7-methoxy- [l,2,4] azolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-((7-( jmmidin-5-yl)-3,4-dihydroisoquinolin-2(lH)-yl)methyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
N-(2-((5-amino-7-methoxy-[l ,2,4]triazolo[ 1 ,5-c]quinazolin-2-yl)methyl)- 1 ,2,3 ,4- tetrahydroisoquinolin-7-yl)picolinamide;
N-(2-((5-amino-7-methoxy-[l ,2,4]triazolo[ 1 ,5-c]quinazolin-2-yl)methyl)- 1 ,2,3 ,4- tetrahydroisoquinolin-7-yl)acetamide;
2-((7-(3,4-difluorophenyl)-3,4-dihydroisoquinolin-2(lH)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(7-(pyrimidin-5-yl)-3 ,4-dihydroisoquinolin-2( 1 H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-((5-ammo-7-methoxy-[l,2,4]triazolo[l,5-c]quinazolin-2-yl)methyL)-l, 2,3,4- tetrahydroisoquinolin-7-yl)-N-(pyridine-3-yl)acetamide;
7-methoxy-2-((5-(pyrimidin-5-yl)isoindolin-2-yl)methyl)-[l,2,4]triazolo[l,5- c]quinazolin-5-amine;
7-methoxy-2-((8-( yrimidin-5-yl)-3,4-dihydroisoquinolin-2(lH)-yl)methyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-((7-(2-(trifluoromethyl)pyrimidm-5-yl)-3,4-dihydroisoquinolin- 2(1 H)-yl)methyl)- [ 1 ,2,4]triazolo [ 1 ,5 -c] quinazolin-5 -amine;
7-methoxy-2-((7-(l-methyl-lH-pyrazol-4-yl)-3,4-dihydroisoquinolin-2(lH)- yl)methyl)-[ 1 ,2,4]triazolo [ 1 ,5 -c]quinazolin-5 -amine;
7-methoxy-2-((7-(l-methyl-5-(trifluoromethyl)-lH-pyrazol-4-yl)-3,4- dihydroisoquinolin-2(lH)-yl)methyl)-[l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-((7-(l-methyl-3-(trifluoromethyl)-lH-pyrazol-4-yl)-3,4- dihydroisoquinolin-2( 1 H)-yl)methyl)- [ 1 ,2,4]triazolo[ 1 ,5-c] quinazolin-5 -amine;
7-methoxy-2-((7-(2-(trifluoromethyl)phenyl)-3,4-dihydroisoquinolin-2(lH)- yl)methyl)-[ 1 ,2,4]triazolo [ 1 ,5 -c]quinazolin-5 -amine;
2-((7-(2-amino-4-(trifluoromethyl)pyrimidin-5-yl)-3,4-dihydroisoquinolin-2(lH)- yl)methyl)-7-methoxy-[ 1 ,2,4]triazolo[ 1 ,5-c]quinazolin-5-amine; 7-methoxy-2-(2-(7-(2-(trifluoromethyl)pyrimidin-5-yl)-3,4-dihydroisoquinolin- 2(lH)-yl)ethyl)-[l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-bromo-2-((5,6-dihydro- 1 ,7-naphthyridin-7(8H)-yl)methyl)-[ 1 ,2,4]triazolo[ 1 ,5- c]quinazolin-5-amine;
2-((5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)methyl)-7-bromo-[l,2,4]triazolo[l ,5- c]quinazolin-5-amine;
5-amino-2-((5,6-dihydro-l ,7-naphthyridin-7(8H)-yl)methyl)-[l,2,4]triazolo[l,5- c]quinazoline-7-carbonitrile;
2-((5H^yrrolo[3,4-b]pyridin-6(7H)-yl)methyl)-5-ammo-[l,2,4]triazolo[l ,5- c]quinazoline-7-carbonitrile;
2-((5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)methyl)-7-(methoxymethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((5,6-dihydro-l,7-naphthyridin-7(8H)-yl)methyl)-7-(methoxymethyL)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)methyl)-7-methyl-[l ,2,4]triazolo[l,5- c]quinazolin-5-amine;
2-((5,6-dihydro-l,7-naphthyridin-7(8H)-yl)methyl)-7-methyl-[l,2,4]triazolo[l,5- c]quinazolin-5-amine;
2-((5,6-dihydro-l,7-naphthyridin-7(8H)-yl)methyl)-7-(2-fluoroethoxy)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)methyl)-7-ethoxy-[l,2,4]triazolo[l,5- c]quinazolin-5-amine;
2-((5,6-dihydro-l,7-naphthyridin-7(8H)-yl)methyl)-7-ethoxy-[l,2,4]triazolo[l,5- c]quinazolin-5-amine;
2-((5,6-dihydro-l,7-naphthyridin-7(8H)-yl)methyl)-7-(fluoromethoxy)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
(R)-7-methoxy-2-(2-(2-methyl-6,7-dihydrooxazolo[5,4-c]pyridin-5(4H)- yl)propyl)-[l ,2,4]triazolo[l,5-c]quinazolin-5-amine;
(S)-7-methoxy-2-(2-(2-methyl-6,7-dihydrooxazolo[5,4-c]pyridin-5(4H)- yl)propyl)-[l ,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-methyl-6,7-dihydrooxazolo[4,5-c]p)Tidm-5(4H)-yl)propyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
(R)-7-methoxy-2-(2-(2-methyl-6,7-dihydrooxazolo[4,5-c]pyridin-5(4H)- yl)propyl)-[l ,2,4]triazolo[l,5-c]quinazolin-5-amine;
(S)-7-methoxy-2-(2-(2-methyl-6,7-dihydrooxazolo[4,5-c]pyridin-5(4H)- yl)propyl)-[l ,2,4]triazolo[l,5-c]quinazolin-5-amine; (R)-7-methoxy-2-(2-(2-methyl-6,7-dihydrothiazolo[5,4-c]pyridin-5(4H)- yl)propyl)-[l ,2,4]triazolo[l,5-c]quinazolin-5-amine;
(S)-7-methoxy-2-(2-(2-methyl-6,7-dihydrothiazolo[5,4-c]pyridin-5(4H)- yl)propyl)-[l ,2,4]triazolo[l,5-c]quinazolin-5-amine;
(R)-7-methoxy-2-(2-(2-methyl-6,7-dihydrothiazolo[4,5-c]pyridin-5(4H)- yl)propyl)-[l ,2,4]triazolo[l,5-c]quinazolin-5-amine;
(S)-7-methoxy-2-(2-(2-methyl-6,7-dihydrothiazolo[4,5-c]pyridin-5(4H)- yl)propyl)-[l ,2,4]triazolo[l,5-c]quinazolin-5-amine;
(R)-7-methoxy-2-(2-(2-methyl-4H-pyrrolo[3,4-d]thiazol-5(6H)-yl)propyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
(R)-7-methoxy-2-(2-(2-methyl-6,7-dihydropyrazolo[l,5-a]pyrazin-5(4H)- yl)propyl)-[l ,2,4]triazolo[l,5-c]quinazolin-5-amine;
(S)-7-methoxy-2-(2-(2-methyl-6,7-dihydropyrazolo[l ,5-a]pyrazin-5(4H)- yl)propyl)-[l ,2,4]triazolo[l,5-c]quinazolin-5-amine;
(R)-2-(2-(2-(difluoromethyl)-6,7-dihydropyrazolo[l,5-a]pyrazin-5(4H)- yl)propyl)-7-methoxy-[l ,2,4]triazolo[l,5-c]quinazolin-5-amine;
(S)-2-(2-(2-(difluoromethyl)-6,7-dihydropyrazolo[l ,5-a]pyrazin-5(4H)- yl)propyl)-7-methoxy-[l ,2,4]triazolo[l,5-c]quinazolin-5-amine;
(R)-2-(2-(2-(difluoromethyl)-6,7-dihydrothiazolo[5,4-c]pyridin-5(4H)-yl)propyl)- 7-methoxy- [ 1 ,2,4]triazolo [ 1 ,5 -c]quinazolin-5-amine;
(S)-7-methoxy-2-(2-(2-(trifluoromethyl)-6,7-dihydrothiazolo[4,5-c]pyridin- 5(4H)-yl)propyl)-[l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(3-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)propyl)-7-methoxy-[l ,2,4]triazolo[ 1 ,5- c]quinazolin-5-amine;
2-(3-(4-fluoroisoindolin-2-yl)propyl)-7-methoxy-[l ,2,4]triazolo[l,5-c]quinazolin- 5 -amine;
2-(3-(5-fluoroisoindolin-2-yl)propyl)-7-methoxy-[l ,2,4]triazolo[l,5-c]quinazolin-
5 -amine;
7-methoxy-2-(3-(5-(trifluoromethyl)isoindolin-2-yl)propyl)-[l,2,4]triazolo[l ,5- c]quinazolin-5-amine;
7-methoxy -2-(2-(2,7,7-trimethyl-6,7-dihydrooxazoLo[5,4-c]p3Tidin-5(4H)- yl)ethyL)-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
2-(2-(2,4-dimethyl-6,7-dihydrooxazolo[5,4-c]pyridin-5(4H)- yl)ethyl)-7-methoxy- [l,2,4]ttiazolo[l,5-c]quinazolin-5-amme;
2-(2-(2,6-dimethyl-6,7-dihydrooxazolo[5,4-c]pyridm-5(4H)-yl)ethyl)-7- methoxy-
[l,2,4]triazolo[l,5-c]quinazolin-5-amine; 7-methoxy-2-(2-(2,7,7 rimethyl-6,7-dihydrothiazolo[5,4-c]pyridin-5(4H)- yl)ethyl)-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
2-(2-(2-cyclopropyl-4H-pyrrolo[3,4-d]thiazol-5(6H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(2-isopropyl-4H-pyrrolo[3,4-d]thiazol-5(6H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(2-ethyl-4H-pyrrolo[3,4-d]thiazol-5(6H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-metriyl-4H-pyrrolo[3,4-d]oxazol-5(6H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(2-cyclopropyl-4H-pyrrolo[3,4-d]oxazol-5(6H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(l-methylpyrrolo[3,4-c]pyrazol-5(lH,4H,6H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
(R)-7-methoxy-2-(2-(2-methyl-4H-pyrrolo[3,4-d]oxazol-5(6H)-yl)propyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine; or
(R)-7-methoxy-2-(2-(2-methyl-4H-pyrrolo[3,4-d]oxazol-5(6H)-yl)butyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine.
As described herein, unless otherwise indicated, the use of a compound in treatment means that an amount of the compound, generally presented as a component of a formulation that comprises other excipients, is administered in aliquots of an amount, and at time intervals, which provides and maintains at least a therapeutic serum level of at least one pharmaceutically active form of the compound over the time interval between dose
administration.
Absolute stereochemistry is illustrated by the use of hashed and solid wedge bonds. As shown in Illus-I and Illus-II. Accordingly, the methyl group of Illus-I is emerging from the page of the paper and the ethyl group in Illus-II is descending into the page, where the cyclohexene ring resides within the plane of the paper. It is assumed that the hydrogen on the same carbon as the methyl group of Illus-I desends into the page and the hydrogen on the same carbon as the ethyl group of Illus-II emerges from the page. The convention is the same where both a hashed and solid rectangle are appended to the same carbon as in Illus-III, the Methyl group is emerging from the plane of the paper and the ethyl group is descending into the plane of the paper
Figure imgf000025_0001
As is conventional, ordinary "stick" bonds or "wavy" bonds are used where there is a mixture of possible isomers present, including a racemic mixture of possible isomers As used herein, unless otherwise specified, the following terms have the following meanings:
The phrase "at least one" used in reference to the number of components comprising a composition, for example, "at least one pharmaceutical excipient" means that one member of the specified group is present in the composition, and more than one may additionally be present. Components of a composition are typically aliquots of isolated pure material added to the composition, where the purity level of the isolated material added into the composition is the normally accepted purity level of a substance appropriate for pharmaceutical use.
The phrase "at least one" used in reference to substituents on a compound or moiety appended to the core structure of a compound means that one substituent of the group of substituents specified is present, and more than one substituent may be bonded to chemically accessible bonding points of the core.
Whether used in reference to a substituent on a compound or a component of a pharmaceutical composition the phrase "one or more", means the same as "at least one";
"concurrently" and "contemporaneously" both include in their meaning (1) simultaneously in time (e.g., at the same time); and (2) at different times but within the course of a common treatment schedule;
"consecutively" means one following the other;
"sequentially" refers to a series administration of therapeutic agents that awaits a period of efficacy to transpire between administering each additional agent; this is to say that after administration of one component, the next component is administered after an effective time period after the first component; the effective time period is the amount of time given for realization of a benefit from the administration of the first component;
"effective amount" or "therapeutically effective amount" is meant to describe the provision of an amount of at least one compound of the invention or of a pharmaceutical composition comprising at least one compound of the invention which is effective in treating or inhibiting a disease, disorder or condition described herein, and thus produce the desired therapeutic, ameliorative, inhibitory or preventative effect. For example, in treating movement disorders with one or more of the compounds described herein "effective amount" (or
"therapeutically effective amount") means, for example, providing the amount of at least one compound or pharmaceutically acceptable salt thereof of Formula GI that results in a therapeutic response in a patient afflicted with a central nervous system disorder, including a response suitable to manage, alleviate, ameliorate, or treat the disorder or alleviate, ameliorate, reduce, or eradicate one or more symptoms attributed to the disorder and/or long-term stabilization of the disorder, for example, as may be determined by the analysis of pharmacodynamic markers or clinical evaluation of patients afflicted with the disorder; "patient" and "subject" means an animal, such as a mammal (e.g., a human being) and is preferably a human being;
"prodrug" means compounds that are rapidly transformed, for example, by hydrolysis in blood, in vivo to the parent compound, e.g., conversion of a prodrug of Formula GI to a compound of Formula GI, or to a pharmaceutically acceptable salt thereof; a thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1 87, both of which are incorporated herein by reference; the scope of this invention includes prodrugs of the novel compounds of this invention;
"solvate" means a physical association of a compound of this invention with one or more solvent molecules; this physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding; in certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid; "solvate" encompasses both solution-phase and isolatable solvates; non- limiting examples of suitable solvates include ethanolates, methanolates, and the like; "hydrate" is a solvate wherein the solvent molecule is H20.
The term "substituted" means that one or more of the enumerated substituents (or, where a list of substituents are not specifically enumerated, the default substituents specified in this "Definitions" section for the particular type of substrate which contains variable substituents) can occupy one or more of the bonding positions on the substrate typically occupied by "-H", provided that such substitution does not exceed the normal valency rules for the atom in the bonding configuration present in the substrate, and that the substitution ultimate provides a stable compound, e.g., mutually reactive substituents are not present geminal or vicinal to each other, and wherein such a compound is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture; when the text indicates optional substitution of a moiety (e.g. "optionally substituted") the term means "if present, one or more of the enumerated (or default substituents for the specified substrate) can be present on the substrate in a bonding position normally occupied by a hydrogen atom" in accordance with the definition of "substituted" presented herein.
As used herein, unless otherwise specified, the following terms used to describe moieties, whether comprising the entire definition of a variable portion of a structural representation of a compound of the invention or a substituent appended to a variable portion of a structural representation of a group of compounds of the invention have the following meanings, and unless otherwise specified, the definitions of each term (i.e., moiety or substituent) apply when that term is used individually or as a component of another term (e.g., the definition of aryl is the same for aryl and for the aryl portion of arylalkyl, alkylaryl, arylalkynyl moieties, and the like); moieties are equivalently described herein by structure, typographical
representation or chemical terminology without intending any differentiation in meaning, for example, the chemical term "acyl", defined below, is equivalently described herein by the term itself, or by typographical representations "R'-(C=0)-" or "R'-C(O)-", or by the structural representation:
Figure imgf000028_0001
"acyl" means an R'-C(O)-, where R' is linear, branched or cyclic alkyl; linear, branched or cyclic alkenyl; or linear, branched or cyclic alkynyl moiety, each of which moieties can be substituted; wherein the acyl substituent is bonded through the carbonyl carbon to the substrate of which it is a substituent, or -NH-SO2-R', where -R' is as previously defined; non- limiting examples of suitable acyl groups include formyl, acetyl, propanoyl, 2-methylpropanoyl, butanoyl and cyclohexanoyl;
"alkenyl" means an aliphatic hydrocarbon moiety which is not aromatic but includes in its structure at least one constituent of the structure -(R'OCR'2) or -(R'OCR')-, where R' is a defined substituent, for example -H or -alkyl; the alkenyl moiety can be incorporated into a linear hydrocarbon chain, or incorporated into a cyclic hydrocarbon chain (termed "cycloalkenyl") and can comprise further, linear, branched, or cyclic substituents depending from the carbon atoms of the chain, preferably the chain comprises about 2 to about 15 carbon atoms; more preferably from about 2 to about 12 carbon atoms; and more preferably chains comprise from about 2 to about 6 carbon atoms;
the term "substituted alkenyl", unless specified otherwise by a recitation of specific substituents defining the term, means that the alkenyl group is substituted by one or more substituents which are independently for each occurrence: CMO alkyl, C3_io cycloalkyl, and Ci_io alkoxy ;
"-alkoxy" means a moiety of the structure: alkyl-O- (i.e., the bond to the substrate moiety is through the ether oxygen), wherein the alkyl portion of the moiety is as defined below for alkyl; non-limiting examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy and heptoxy;
"alkoxyalkyl" means a moiety of the structure: alkoxy-alkyl- (i.e., the bond to the substrate moiety is through an alkyl moiety, which is terminated by, or substituted with, an alkoxy substituent that is not itself bonded to the substrate, non- limiting examples of alkoxyalkyl groups include H3C-(CH2)y -0-CH2-(CH2)x- wherein "y" and "x" are independently an integer of from 0 to 6;
"alkoxycarbonyl" means a moiety of the structure alkyl-O-C(O)-, equivalently represented as [alkyl-O-(OO)-] and also as R-O(OO)-, where "R" is a defined alkyl moiety,
(i.e., the bond to the parent moiety is through the carbonyl carbon) wherein the alkoxy portion of the moiety is as previously defined; non-limiting examples of suitable alkoxycarbonyl groups include methoxycarbonyl and ethoxycarbonyl;
"-alkyl" (including the alkyl portions of other moieties, such as trifluoromethyl- alkyl- and (-alkoxy) means an aliphatic hydrocarbon chain comprising from about 1 to about 20 carbon atoms (that is, "Ci_2o alkyl"), preferably 1 to about 10 carbon atoms (herein "Cuo alkyl"), unless the term is modified by an indication that a shorter chain is contemplated, for example, an alkyl moiety of up to 8 carbon atoms (designated herein "Ci_8-alkyl"); the term "alkyl", unless specifically limited by another term, for example, "linear", "branched", or "cyclic", includes alkyl moieties which are linear (a hydrocarbon chain with no aliphatic hydrocarbon "branches" appended to it); branched (a main hydrocarbon chain comprising up to the maximum specified number of carbon atoms with a lower-alkyl chain appended to one or more carbon atoms comprising, but not terminating, the main hydrocarbon chain); and cyclic (the main hydrocarbon chain forms an cyclic aliphatic moiety of from 3 carbon atoms, the minimum number necessary to provide a cyclic moiety, up to the maximum number of specified carbon atoms), accordingly when unmodified, the term " Ci_x alkyl" refers to linear, branched, or cyclic alkyl, and the "Ci_x" designation means: for a cyclic moiety a ring comprising at minimum 3 carbon atoms up to "X" carbon atoms; for a branched moiety, a main chain of at least 3 carbon atoms up to "X" carbon atoms with at least one linear or branched alkyl moiety bonded to a carbon atom which does not terminate the chain; and for a linear alkyl, a moiety comprising one carbon atom (i.e., -methyl), up to "X" carbon atoms; when the term "alkyl" is modified by "substituted" or "optionally substituted" it means an alkyl group having substituents in accordance with the relevant definitions appearing below; where use of the terms "substituted" or "optionally substituted" modify "alkyl" and substituent moieties are not specifically enumerated, the substituents bonded to the alkyl substrate are independently for each occurrence (in accordance with definitions appearing herein): Ci_2o alkyl; halogen; -alkoxy; -OH; -CN; alkylthio-; amino, -NH(alkyl), - NH(cycloalkyl), -N(alkyl)2, -(C=0)-OH; -C(0)0-alkyl; -S(alkyl); or -S(02)-alkyl; or -aryl; cycloalkyl moieties may alternatively, or in addition, be substituted with one or more, "ring- system substituents" as that term is defined herein. Examples of suitable alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, heptyl, nonyl, decyl, fluoromethyl, trifiuoromethyl and cyclopropylmethyl, where the term "alkyl" is indicated with two hyphens (i.e., "-alkyl-" it indicates that the alkyl moiety is bonded in a manner that the alkyl moiety connects a substrate with another moiety, for example, "-alkyl-OH" indicates an alkyl moiety connecting a hydroxyl moiety to a substrate;
"lower alkyl" means a group comprising about 1 to about 6 carbon atoms in the chain (i.e. Ci_6); non-limiting examples of suitable lower alkyl groups include methyl, ethyl, n- propyl, isopropyl, n-butyl, t-butyl, n-pentyl, and hexyl; "alkylaryl" (or alkaryl) means an alkyl-aryl- group (i.e., the bond to the parent moiety is through the aryl group) wherein the alkyl group is unsubstituted or substituted as defined above, and the aryl group is unsubstituted or substituted as defined below; preferred alkylaryl moieties comprise a lower alkyl group; non-limiting examples of suitable alkylaryl groups include o-tolyl, p-tolyl and xylyl;
in general, as exemplified by the term "alkyl-aryl" defined above, a substituent which is the called out by the combination of terms used to define two other substituent fragments indicates that the substituent called out by the last term used is bonded to the substrate whilst the preceding term called out is bonded in turn to the substituent fragment it precedes, proceeding right to left to understand the order in which the various fragments are bonded to the substrate;
"alkynyl" means an aliphatic hydrocarbon group (chain) comprising at least one moiety of the structure:
Figure imgf000030_0001
s a defined substituent, the alkynyl moiety can be incorporated into a linear or branched
hydrocarbon chain, or incorporated into a cyclic hydrocarbon chain (non-aromatic, termed
"cycloalkynyl",); preferably hydrocarbon chains of an alkynyl moiety comprises about 2 to about 15 carbon atoms; more preferably alkynyl groups comprise about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain;
"amino" means an -NR2 group wherein R is selected independently for each occurrence from -H or alkyl, alkylamino means -NR'2, wherein one R' is -alkyl and the other is -H or -alkyl selected independently for each occurrence, non-limiting examples of alkylamino moieties are -NH-CH3 (methylamino-) and -N(Cf¾)2 (dimethylamino);
"ammonium ion" means -N R3' wherein R is independently -H, alkyl, substituted alkyl, or the cationic portion of a dissociated acid capable of producing an ammonium ion from an amine; when not explicitly shown in representations herein the presence of an ammonium ion presumes that a charge-balancing anion is associated with the ammonium ion moiety, which anion is derived from the anionic portion of the acid used to provide said ammonium ion, it will be appreciated that many of the nitrogen atoms present in compounds of the invention can be converted to an ammonium ion thereby providing a salt of the parent compound, which is within the scope of the invention;
"aryl" (sometimes abbreviated "ar") means an aromatic monocyclic or multicyclic ring system comprising about 6 to about 14 carbon atoms (denoted herein also as "C6-i4-aryl"), preferably about 6 to about 10 carbon atoms ("C6-io-aryl"); the aryl group can be optionally substituted with one or more independently selected "ring system substituents" (defined below). Non-limiting examples of suitable aryl groups include naphthyl
Figure imgf000031_0001
( ), which is also abbreviated herein "Ph" for convenience, wherein bonding can be through any of the carbons in the aromatic ring, and wherein any ring carbon atoms not participating in a bond to the substrate may have bonded to it a substituent other than -H, independently selected in each instance from the list of "ring-system substituents" defined herein, or as defined in each instance where the term is used in conjunction with an enumerated list of substituents;
"aryloxy" means an aryl-O- group (i.e., the moiety is bonded to a substrate through the ether oxygen) wherein the aryl group is unsubstituted or substituted as defined above; non- limiting examples of suitable aryloxy groups include phenoxy and naphthoxy;
"aryloxycarbonyl" means an aryl-O-C(O)- group (i.e., the bond to a substrate is through the carbonyl carbon) wherein the aryl group is unsubstituted or substituted as previously defined; non-limiting examples of suitable aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl;
a "carboxylic acid" moiety means a substituent having the formula "-C(0)-OH", wherein the moiety is bonded to a substrate is through the carbonyl carbon;
"cycloalkyl" defined above with the "alkyl" definition, means a non-aromatic mono- or multicyclic ring system comprising about 3 to about 20 carbon atoms which may be substituted as defined herein; the term includes multicyclic cycloalkyls, for example, 1 -decalin, norbornyl, adamantyl and the like;
"halogen" means fluorine, chlorine, bromine, or iodine; preferred halogens, unless specified otherwise where the term is used, are fluorine, chlorine and bromine, a substituent which is a halogen atom means -F, -CI, -Br, or—I, and "halo" means fiuoro, chloro, bromo, or iodo substituents bonded to the moiety defined, for example, "haloalkyl" means an alkyl, as defined above, wherein one or more of the bonding positions on the alkyl moiety typically occupied by hydrogen atoms are instead occupied by a halo group, perhaloalkyl means that all bonding positions not participating in bonding the alkyl substituent to a substrate are occupied by a halogen, for example, perfluoroalkyl, where alkyl is methyl, means -CF3;
"heteroaryl" means an aromatic monocyclic or multicyclic ring system comprising about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the ring atoms is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination; preferred heteroaryl moieties comprise 5 ring atoms, for example, thiazole thiadiazole, imidazole, isothiazole, oxazole, oxadiazole, or pyrazole; the "heteroaryl" can be optionally substituted at chemically available ring atoms by one or more independently selected "ring system substituents" (defined below); the prefix aza, azo, oxa, oxo, thia or thio before the heteroaryl root name means that at least a nitrogen, oxygen or sulfur atom, respectively, is present as a ring atom, and in some embodiments 2 or more heteroatoms are present in a ring, for example, a pyrazole or a thiazole moiety; a nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide; non- limiting examples of heteroaryl yridyl- . , tthhiioonpeennvyll-- . , ffuurraannvyll-- , triazolyl
Figure imgf000032_0001
lyl , pyrazinyl, thienyl, pyrimidinyl, isoxazolyl, isothiazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, pyrazolyl, 1,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, quinoxalinyl, phthalazinyl, imidazo[ 1 ,2-a]pyridinyl, imidazo[2, 1 -b]thiazolyl, benzo furazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolinyl, imidazolyl, thienopyridyl, quinazolinyl, thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, isoquinolinyl, benzoazamdolyl, 1,2,4-triazinyl, benzothiazolyl, furopyridine, for example:
Figure imgf000032_0002
, and the like (unless otherwise noted, bonded to the substrate through any available atom that results in a stable bonding arrangement);
"heterocyclyl" (or heterocycloalkyl) means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination; there are no adjacent oxygen and/or sulfur atoms present in the ring system; preferred heterocyclyl moieties contain about 5 to about 6 ring atoms; the prefix aza, oxa or thia before the heterocyclyl root name means that at least one nitrogen, oxygen or sulfur atom, respectively, is present as a ring atom; the heterocyclyl can be optionally substituted by one or more independently selected "ring system substituents" (defined below); the nitrogen or sulfur atom of the heterocyclyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide; non-limiting examples of suitable monocyclic heterocyclyl rings include piperidyl, pyrrolidinyl, piperazinyl,
r 6 -NH
1
W 2
morpholinyl - 0 3 (where unless otherwise noted the moiety is bonded to the substrate through any of ring carbon atoms C2, C3, C5, or C6), thiomorpholinyl, thiazolidinyl, 1 ,3- dioxolanyl, 1 ,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like;
moiety means a 6-member cyclic ether of the formula:
Figure imgf000033_0001
the bond line having an open end in the center of the structure and terminated at the other end with a wavy line indicates that the substituent is bonded to the substrate to which it is attached through any of carbon atoms 1 to 5, and wherein any of the bonding positions on carbons 1 to 5 normally occupied by a hydrogen atom, that is, the bonding positions on carbon atoms 1 to 5 which are not occupied by the bond to the substrate can optionally be occupied by specified or optional substituents;
"piperidinyl" means:
Figure imgf000033_0002
where, the open bond line terminated on one end with a wavy line indicates the ring atom through which the moiety is bonded to the substrate (i.e., any of carbon atoms 2 to 6 (left-hand structure) or the ring nitrogen atom (right-hand structure), and wherein any of the bonding positions on the nitrogen atom or on carbon atoms 2 to 6 not participating in a bond to the substrate and normally occupied by a hydrogen atom can be bonded to a specified or optional substituent, and wherein R', if present, is either -H or another specified substituent;
"pyridinyl" means:
Figure imgf000033_0003
where, the bond-terminated- with-wavy-line indicates that the pyridinyl moiety is bonded to the substrate at any of carbon atoms 2 to 6, and wherein any of the bonding positions on carbons 2 to 6 normally occupied by a hydrogen atom, that is, any position on carbon 2 to 6 which is not the bond to the substrate, can optionally be occupied by a specified substituent;
"quinoline" means:
Figure imgf000033_0004
where, the bond-terminated- with-wavy-line indicates that the moiety is bonded to the substrate through any of carbon atoms 2 to 8, and wherein any of the bonding positions on carbon atoms 2 to 8 normally occupied by a hydrogen atom, that is, any bonding positions on carbon atoms 2 to 8 which are not bonded to the substrate, can optionally be occupied by one of a list of enumerated substituents;
for any of the foregoing ring-system moieties, bonding of the moiety through a specific ring carbon atom (or heteroatom) is sometimes described for convenience and "bonded through C-X to C-Y carbon atoms", where "X" and "Y" are integers referring to the carbon atoms, for example, as numbered in the examples above;
"hydroxyl moiety" and "hydroxy" means an HO- group, "hydroxyalkyl" means a substituent of the formula: "HO-alkyl-",wherein the alkyl group is bonded to the substrate and may be substituted or unsubstituted as defined above; preferred hydroxyalkyl moieties comprise a lower alkyl; Non-limiting examples of suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl; and
bonding sequence is indicated by hyphens where moieties are represented in text, for example -alkyl, indicates a single bond between a substrate and an alkyl moiety, -alkyl-X, indicates that an alkyl group bonds an "X" substituent to a substrate, and in structural representatio indicated by a wavy line terminating a bond representation,
for example:
Figure imgf000034_0001
s that the methylphenyl moiety is bonded to a substrate through a carbon atom ortho to the methyl substituent, while a bond representation terminated with a wavy line and drawn into a structure without any particular indication of an atom to which it is bonded indicates that the moiety may be bonded to a substrate via any of the atoms in the moiety which bonding, for example:
Figure imgf000034_0002
, indicates that the naphthalene moiety may be bonded to the substrate through any of carbons 1 to 8.
Where substituents are presented in text, unless defined differently at the point of use, bonding arrangement is indicated with hyphens (indicating single bonds), equal signs
(indicating double bonds), parentheses (indicating bonding to the adjacent atom, see the carbonyl example below) and "carrots" (i.e. "<" bonds.
Thus, for example, the
Figure imgf000034_0003
be represented in text as >C=0 or alternatively as -C(O)- and a cyano-substituent may be represented as -C(N) or
In the same regard, unsaturated nitrogen moiety, for example:
Figure imgf000034_0004
may be represented in text as -N=C(CH3)2., and a saturated nitrogen moiety, for example, where one definition of "A" in the structure: A i.s methyl-substituted nitrogen, thus .™ i&—
Figure imgf000035_0001
, when defining "A" the nitrogen moiety can be represented herein in text as: >N-C¾, or alternatively -(N-CH3)-. The foregoing are illustrative of the various text notation used herein for defining structural variables and substituents using text representation.
Any carbon or heteroatom with unsatisfied valences in the text, schemes, examples, structural formulae, and any Tables herein is assumed to have a hydrogen atom or atoms of sufficient number to satisfy the valences;
The term "pharmaceutical composition" as used herein encompasses both the bulk composition and individual dosage units comprised of more than one (e.g., two)
pharmaceutically active agents such as, for example, a compound of the present invention and an additional agent as described herein, along with any pharmaceutically inactive excipients. As will be appreciated by the ordinarily skilled artisan, excipients are any constituent which adapts the composition to a particular route of administration or aids the processing of a composition into a dosage form without itself exerting an active pharmaceutical effect. The bulk composition and each individual dosage unit can contain fixed amounts of the afore-said "more than one pharmaceutically active agents". The bulk composition is material that has not yet been formed into individual dosage units.
This invention also includes the compounds of this invention in isolated and purified form obtained by routine techniques. Polymorphic forms of the compounds of Formula GI, and of the salts thereof, are intended to be included in the present invention. Certain compounds of the invention may exist in different isomeric (e.g., enantiomers, diastereoisomers, atropisomers) forms. The invention contemplates all such isomers both in pure form and in admixture, including racemic mixtures.
All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including prodrugs of compounds of the invention as well as the salts and solvates of the inventive compounds and their prodrugs), such as those which may exist due to asymmetric carbons present in a compound of the invention, and including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention. Individual stereoisomers of the compounds of the invention may be isolated in a pure form, for example, substantially free of other isomers, or may be isolated as an admixture of two or more stereoisomers or as a racemate. The chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1914 Recommendations. The use of the terms "salt", "solvate" "prodrug" and the like, is intended to equally apply to salts, solvates and prodrugs of isolated enantiomers, stereoisomer pairs or groups, rotamers, tautomers, or racemates of the inventive compounds.
Where diasteromeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, for example, by chiral chromatography and/or fractional crystallization. As is known, enantiomers can also be separated by converting the enantiomeric mixture into a diasteromeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individually isolated diastereomers to the corresponding enantiomers.
Where the compounds of the invention form salts by known, ordinary methods, these salts are also within the scope of this invention. Reference to a compound of the invention herein is understood to include reference to salts thereof, unless otherwise indicated. The term "salt(s)", as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when a compound of the invention contains both a basic moiety, for example, but not limited to, a nitrogen atom, for example, an amine, pyridine or imidazole, and an acidic moiety, for example, but not limited to a carboxylic acid, zwitterions ("inner salts") may be formed and are included within the term "salt(s)" as used herein. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable salts) are preferred. Salts of the compounds of the invention may be formed, for example, by reacting a compound of the invention with an amount of acid or base, for example, an equivalent amount, in a medium in which the salt precipitates or in an aqueous medium wherein the product is obtained by lyophilization. Acids (and bases) which are generally considered suitable for the formation of pharmaceutically useful salts from basic (or acidic) pharmaceutical compounds are discussed, for example, by S. Berge et al., Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33 201-217; Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; in The Orange Book (Food & Drug Administration, Washington, D.C. on their website); and P. Heinrich Stahl, Camille G. Wermuth (Eds.), Handbook of Pharmaceutical Salts: Properties, Selection, and Use, (2002) Int'l. Union of Pure and Applied Chemistry, pp. 330-331. These disclosures are incorporated herein by reference.
Where it is possible to provide an acid addition salt with a compound, in general, acid addition salts include, but are not limited to, acetates, including trifluoroacetate salts, adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, digluconates, dodecylsulfates, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides, hydrobromides, hydroiodides, 2- hydroxyethanesulfonates, lactates, maleates, methanesulfonates, methyl sulfates, 2- naphthalenesulfonates, nicotinates, nitrates, oxalates, pamoates, pectinates, persulfates, 3- phenylpropionates, phosphates, picrates, pivalates, propionates, salicylates, succinates, sulfates, sulfonates (such as those mentioned herein), tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) undecanoates, and the like.
Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, aluminum salts, zinc salts, salts with organic bases (for example, organic amines) such as benzathines, diethylamine, dicyclohexylamines, hydrabamines (formed with N,N- bis(dehydroabietyl)ethylenediamine), N-methyl-D-glucamines, N-methyl-D-glucamides, t-buryl amines, piperazine, phenylcyclohexyl-amine, choline, tromethamine, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be converted to an ammonium ion or quartemized with agents such as lower alkyl halides (e.g. methyl, ethyl, propyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g. dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g. decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides), aralkyl halides (e.g. benzyl and phenethyl bromides), and others.
All such acid and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.
Compounds of the invention may exist in exist in different tautomeric forms. All such forms are embraced and included within the scope of the invention. Examples of well- known tautomeric forms include, but are not limited to, ketone/enol tautomeric forms, imine- enamine tautomeric forms, and for example heteroar forms such as the following moieties:
Figure imgf000037_0001
Where a compound of the invention can exist in more than one such form, representation or presentation of one tautomeric form of such compound is considered herein equivalent to presentation of all the tautomeric forms in which the compound exists.
The term "purified", "in purified form" or "in isolated and purified form" for a compound refers to the physical state of said compound after being isolated from a synthetic process or natural source or combination thereof. Thus, the term "purified", "in purified form" or "in isolated and purified form" for a compound refers to the physical state of said compound after being obtained from a purification process or processes described herein or well known to the skilled artisan, and in sufficient purity to be characterized by standard analytical techniques described herein or well known to the skilled artisan. A functional group in a compound termed "protected" means that the group is in modified form to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W. Greene et al, Protective Groups in organic Synthesis (1991), Wiley, New York.
When a variable (e.g., aryl, heterocycl, R3, etc.) appears more than once in any moiety or in any compound of the invention, the selection of moieties defining that variable for each occurrence is independent of its definition at every other occurrence unless specified otherwise in the variable definition.
As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, and any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
The present invention also embraces isotopically-labeled compounds of the present invention which are structurally identical to those recited herein, but for the fact that a statistically significant percentage of one or more atoms in that form of the compound are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number of the most abundant isotope usually found in nature, thus altering the naturally occurring abundance of that isotope present in a compound of the invention. Examples of isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen (such as 2H and 3H), carbon (such as 1 lC, 13c and 1 Q, nitrogen (such as 13N and 15N), oxygen (such as 15(3, 17(3 and 18(3), phosphorus (such as 32p)5 sulfur (such as 35s), fluorine (such as 18F), iodine (such as 123i and 125]) and chlorine (such as 36Q). It will be appreciated that other isotopes may be incorporated by known means also.
Certain isotopically-labeled compounds of the invention (e.g., those labeled with H and 14C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3H) and carbon- 14 (i.e., 14C) isotopes are particularly useful for their ease of preparation and detection. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Isotopically labeled compounds of the invention can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples herein below, by substituting an appropriate isotopically labeled reagent for a non-isotopically labeled reagent. Such compounds are included also in the present invention.
In one aspect, as mentioned above, the present invention provides pharmaceutical formulations (pharmaceutical compositions) for use in antagonizing A2A receptors an to potentially treat central nervous system (CNS) disorders, for example, movement disorders associated with Parkinson's disease or the treatment thereof, wherein the compositions comprising at least one compound, or pharmaceutically acceptable salt thereof, of Formula GI, as defined herein.
As mentioned above, in one aspect the invention provides pharmaceutical formulations (pharmaceutical compositions) suitable for use in blocking adenosine A2a receptors found in the basal ganglia, comprising at least one compound of Formula GI presented above, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier (described below). It will be appreciated that pharmaceutically formulations of the invention may comprise more than one compound of the invention, for example, the combination of two or three compounds of the invention, each present by adding to the formulation the desired amount of the compound in a pharmaceutically acceptably pure form. It will be appreciated that compositions of the invention may comprise, in addition to one or more of compounds of the invention, one or more other compounds which also have pharmacological activity, for example, as described herein below.
While formulations of the invention may be employed in bulk form, it will be appreciated that for most applications the inventive formulations will be incorporated into a dosage form suitable for administration to a patient, each dosage form comprising an amount of the selected formulation which contains an effective amount of said one or more compounds of the invention. Examples of suitable dosage forms include, but are not limited to, dosage forms adapted for: (i) oral administration, e.g., a liquid, gel, powder, solid or semi-solid pharmaceutical composition which is loaded into a capsule or pressed into a tablet and may comprise
additionally one or more coatings which modify its release properties, for example, coatings which impart delayed release or formulations which have extended release properties; (ii) a dosage form adapted for intramuscular administration (IM), for example, an injectable solution or suspension, and which may be adapted to form a depot having extended release properties; (iii) a dosage form adapted for intravenous administration (IV), for example, a solution or suspension, for example, as an IV solution or a concentrate to be injected into a saline IV bag; (iv) a dosage form adapted for administration through tissues of the oral cavity, for example, a rapidly dissolving tablet, a lozenge, a solution, a gel, a sachette or a needle array suitable for providing intramucosal administration; (v) a dosage form adapted for administration via the mucosa of the nasal or upper respiratory cavity, for example a solution, suspension or emulsion formulation for dispersion in the nose or airway; (vi) a dosage form adapted for transdermal administration, for example, a patch, cream or gel; (vii) a dosage form adapted for intradermal administration, for example, a microneedle array; and (viii) a dosage form adapted for delivery via rectal or vaginal mucosa, for example, a suppository.
For preparing pharmaceutical compositions from the compounds described by this invention, generally pharmaceutically active compounds are combined with one or more pharmaceutically inactive excipients. These pharmaceutically inactive excipients impart to the composition properties which make it easier to handle or process, for example, lubricants or pressing aids in powdered medicaments intended to be tableted, or adapt the formulation to a desired route of administration, for example, excipients which provide a formulation for oral administration, for example, via absorption from the gastrointestinal tract, transdermal or transmucosal administration, for example, via adhesive skin "patch" or buccal administration, or injection, for example, intramuscular or intravenous, routes of administration. These excipients are collectively termed herein "a carrier".
Pharmaceutical compositions can be solid, semi-solid or liquid. Solid form preparations can be adapted to a variety of modes of administration and include powders, dispersible granules, mini-tablets, beads, and the like for example, for tableting, encapsulation, or direct administration. Typically formulations may comprise up to about 95 percent active ingredient, although formulations with greater amounts may be prepared.
Liquid form preparations include solutions, suspensions and emulsions.
Examples of liquid forms of medicament include, but are not limited to, water or water/surfactant mixtures, for example a water-propylene glycol solution, which can be employed in the preparation of formulations intended, for example, for parenteral injection, for example, as a solvent or as a suspending medium for the preparation of suspensions and emulsions where a medicament comprises constituents which are insoluble in water or water/surfactant mixtures. Liquid form preparations may also include solutions or suspensions for intranasal administration and may also include, for example, viscosity modifiers to adapt the formulation for application to particular mucosa tissues accessible via nasal administration.
Aerosol preparations, for example, suitable for administration via inhalation or via nasal mucosa, may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable propellant, for example, an inert compressed gas, e.g.
nitrogen. Also included are solid form preparations which are intended to be converted, shortly before use, to a suspension or a solution, for example, for oral or parenteral administration.
Examples of such solid forms include freeze dried formulations and liquid formulations adsorbed into a solid absorbent medium.
The compounds of the invention may also be deliverable transdermally or transmucosally, for example, from a liquid, suppository, cream, foam, gel, or rapidly dissolving solid form. It will be appreciated that transdermal compositions can take also the form of creams, lotions, aerosols and/or emulsions and can be provided in a unit dosage form which includes a transdermal patch of any know in the art, for example, a patch which incorporates either a matrix comprising the pharmaceutically active compound or a reservoir which comprises a solid or liquid form of the pharmaceutically active compound.
Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions mentioned above may be found in A. Gennaro (ed.), Remington: The Science and Practice of Pharmacy, 20 Edition, (2000), Lippincott Williams & Wilkins, Baltimore, MD.
Preferably, the pharmaceutical preparation is in a unit dosage form. In such form, the preparations subdivided into suitably sized unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill in the art. For convenience, the total daily dosage may be divided and administered in portions during the day as required.
In another embodiment the present invention provides for use of the compounds described herein for the potential treatment, management, alleviation or amelioration of conditions or disease states which can be, or are believed to be, treated, managed, alleviated or ameliorated by specific blocking of adenosine A2a receptors, for example, central nervous system diseases or disorders, including but not limited to the treatment of movement disorders (e.g., tremors, bradykinesias, gait, dystonias, dyskinesias, tardive dyskinesias, other
extrapyramidal syndromes, Parkinson's disease and disorders associated with Parkinson's disease). The compounds of the invention also have the potential for use in preventing or lessening the effect of drugs that cause movement disorders.
In accordance with the present invention, blocking adenosine A2a receptors is accomplished by administering to a patient in need of such therapy an effective amount of one or more compounds of the invention, or a pharmaceutically acceptable salt thereof.
In some embodiments it is preferred for the compound to be administered in the form of a pharmaceutical composition comprising the compound of the invention, or a salt thereof, and at least one pharmaceutically acceptable carrier (described below). It will be appreciated that pharmaceutically formulations of the invention may comprise more than one compound of the invention or a salt thereof, for example, the combination of two or three compounds of the invention, each present by adding to the formulation the desired amount of the compound or a salt thereof which has been isolated in a pharmaceutically acceptably pure form.
As mentioned above, administration of a compound of the invention to effect antagonism of A2a receptor sites, which is believed to be beneficial in the treatment of central nervous system diseases is preferably accomplished by incorporating the compound into a pharmaceutical formulation incorporated into a dosage form, for example, one of the above- described dosage forms comprising an effective amount of at least one compound of the invention (e.g., 1, 2 or 3, or 1 or 2, or 1, and usually 1 compound of the invention), or a pharmaceutically acceptable salt thereof, for example. Methods for determining safe and effective administration of compounds which are pharmaceutically active, for example, a compound of the invention, are known to those skilled in the art, for example, as described in the standard literature, for example, as described in the "Physicians' Desk Reference" (PDR), e.g., 1996 edition (Medical Economics Company, Montvale, NJ 07645-1742, USA), the Physician's Desk Reference, 56th Edition, 2002 (published by Medical Economics company, Inc. Montvale, NJ 07645-1742), or the Physician's Desk Reference, 57th Edition, 2003 (published by Thompson PDR, Montvale, NJ 07645-1742); the disclosures of which is incorporated herein by reference thereto. The amount and frequency of administration of the compounds of the invention and/or the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated. Compounds of the instant invention can be administered at a total daily dosage of up to 1 ,000 mg, which can be administered in one daily dose or can be divided into two to four doses per day.
In general, in whatever form administered, the dosage form administered will contain an amount of at least one compound of the invention, or a salt thereof, which will provide a therapeutically effective serum level of the compound in some form for a period of at least 2 hours, preferably at least four hours, and preferably longer. In general, as is known in the art, dosages of a pharmaceutical composition providing a therapeutically effective serum level of a compound of the invention, e.g., a compound of Formula GI or Gil, or a pharmaceutically acceptable salt thereof, can be spaced in time to provide serum level meeting or exceeding the minimum therapeutically effective serum level on a continuous basis throughout the period during which treatment is administered. As will be appreciated the dosage form administered may also be in a form providing an extended release period for the pharmaceutically active compound which will provide a therapeutic serum level for a longer period, necessitating less frequent dosage intervals. As mentioned above, a composition of the invention can incorporate additional pharmaceutically active components or be administered simultaneously,
contemporaneously, or sequentially with other pharmaceutically active compositions as may be additionally needed in the course of providing treatment. Such additional therapeutic agents can include compounds with dopaminergic activity, for example, i) L-DOPA; ii) DOPA
decarboxylase inhibitors; and iii) COMT inhibitors.
Those skilled in the art will appreciate that treatment protocols utilizing at least one compound of the invention, for example, a compound of Formula GI or Gil, can be varied according to the needs of the subject or patient. Thus, compounds of the invention used in the methods of this invention can be administered in variations of the protocols described above. For example, the compounds of this invention can be administered discontinuously rather than continuously during the treatment cycle.
There follows synthetic schemes by which compounds of the invention may be prepared and examples of preparation of compounds of the invention. EXAMPLES
In the following examples the following common abbreviations are used for convenience: DMF (dimethylformamide); DCM (dichloromethane); DMB (dimethoxybenzene); EtOAc (ethylacetate); Hex (hexanes); RT (room temperature, nominally about 25°C); THF (tetrahydrofuran); BSTA (N,0-Bis(trimethylsilyl)acetamide); NMP (N-methyl-2-pyrrolidone); TFA (Trifluoroacetic acid). Other abbreviations employed in the examples and schemes are defined proximal to their point of use.
There follows general synthetic schemes that are useful herein for preparation of intermediates and reagents used in the preparation of 8-ethyl-9-isopropyl-7-methoxy-2- substituted-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine(7, 8, or 9-substituted) "right-side" precursor reagents from which compounds of the invention can be prepared.
General Preparation Scheme 1 : Preparation of Hydroxy- Alkyl-Hydrazide reagent
Scheme GP-1
Figure imgf000043_0001
Preparation of 3-hydroxypropanehvdrazide (Cmpd-4)
To a stirred methanol (125 mL) solution of oxetan-2-one (15 g, 167 mmol) was added hydrazine hydrate (20.2 mL, 333 mmol). The reaction mixture was heated to 60°C for 2 hours in a sealed tube, and then cooled to RT. The reaction mixture was transferred to a rotary evaporator, and the solvent was stripped using a 95°C water bath for 30 minutes. The residue was cooled to room temperature. DCM was added to the residue, precipitating a white crystalline solid that was collected by filtration. The solid was washed with DCM and dried under high vacuum overnight to afford the title product.
There follows examples of preparation of compounds of the invention.
EXAMPLE 1: Preparation of dimethoxybenzene -protected 2-(5-amino-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-2-yl)ethyl methanesulfonates (compound s and preparation of 7- methoxy-2-(2-(3-(methylthio)-5,6-dihydro-[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine (Ex-1)
SCHEME 1
Figure imgf000044_0001
(step H)
Figure imgf000044_0002
(Step A) To a suspension of 1 (3 g, 17.95 mmol) in water (100 mL) and acetic acid (1.10 mL, 19.20 mmol) at 55-60 °C was added an aqueous solution (7 mL) of potassium cyanate (3.49 g, 43.1 mmol). After 5 hours at 55-60°C, the reaction was cooled to RT. Solid sodium hydroxide (31.6 g, 790 mmol, 35-44 equiv.) as one portion was added quickly to the reaction mixture. It was cooled down to 0°C, and then concentrated HC1 (around 38 mL) was added slowly to lower the pH 4-5 at 0 °C, precipitating a white solid. The solid was isolated by filtration, washed with water (500 mL), and dried under vacuum to afford the desired product, 2. LC/MS = 193 [M+l].
(Step B) A stirred suspension of 2 (2.0 g, 10.41 mmol) in POCl3 (9.70 mL, 104 mmol) was heated to 105°C for 16 hours. The reaction mixture was cooled down and concentrated in vacuo to afford a solid. This crude product was suspended in ethyl acetate (500 mL) and charged with sodium bicarbonate. The organic layer was washed with more sodium bicarbonate solution, brine, dried (magnesium sulfate), filtered and concentrated to afford the desired product 3 as a pale yellow solid. LC/MS = 230 [M+l].
(Step C) To a stirred THF (664 mL) solution of 3 (15.2 g, 66.4 mmol) was added DIPEA diisopropylethylamine (13.9 mL, 80 mmol) and hydrazide 4 (5.98 g, 66.4 mmol). The reaction mixture was heated to 65°C for 16 hours. It was cooled to RT and the solvent was evaporated. The residue was dissolved in DCM, and after being stirred for 30 minutes, the mixture was filtered to afford a pale yellow precipitate. It was washed with DCM and dried under vacuum to afford the desired product 5. LC/MS = 297 [M+l].
(Step D) To a stirred dioxane (520 mL) suspension of 5 (14.7 g, 52.0 mmol) was added DIPEA (22.7 mL, 130 mmol) and 2,4-dimethoxybenzylamine (10.2 mL, 67.6 mmol). The reaction mixture was heated to 100°C for 16 hours. After being cooled to room temperature, the reaction mixture was filtered. The precipitate was washed with dioxane and hexane, and dried in vacuo to afford the desired product 6 as a white solid. LC/MS = 428 [M+l].
(Step E) To a sealed tube of 6 (20.3 g, 49.1 mmol) was added BSTA (144 mL, 589 mmol). The tube was sealed and the reaction mixture was heated to 130°C for 16 hours. After cooling down, BSTA was removed from the reaction mixture under rotary evaporator in 70°C water bath for 1 hour. The crude material was dissolved in methanol (170 mL) and charged with concentrated hydrochloric acid (2.5 mL). After 10 minutes, the reaction mixture was filtered. The precipitate was washed with water (5 x 50 mL), DCM (2 x 50 mL), and water. It was then under vacuum to afford the desired product 7 as a pale yellow powder. LC/MS = 410 [M+l].
(Step F) To a stirred DCM (73 mL) solution of 7 (3 g, 7.33 mmol) was added triethylamine (3.06 mL, 21.98 mmol) and methanesulfonyl chloride (0.856 mL, 10.99 mmol) at 0°C. The reaction mixture was stirred at RT for 2 hours. Saturated aqueous sodium bicarbonate was added, and the reaction mixture was extracted with DCM. The organic layer was dried (magnesium sulfate), filtered and concentrated. The crude product was purified by column chromatography (ethyl acetate/hexanes) to give the desired product 8. LC/MS = 488 [M+l].
(Step G) To a round bottom flask of 8 (3.5 g, 7.18 mmol) was added TFA (71.8 mL). The reaction mixture was stirred at 50°C for 16 hours and cooled down to RT. TFA was evaporated, and the residue was charged with DCM and saturated aqueous sodium bicarbonate solution. The precipitate was collected by filtration, and the aqueous layer was extracted with DCM (x5). The organic extracts were combined with the precipitate and concentrated in vacuo. The crude solid was purified by column chromatography (100% ethyl acetate to 10%
MeOH/DCM) to afford the desired product 9 as a pale yellow solid. LC/MS = 338 [M+l].
(Step H) To a stirred DMF (637 μί) solution of 9 (100 mg, 0.318 mmol) was added 3-(methylthio)-5,6,7,8-tetrahydro-[l ,2,4]triazolo[4,3-a]pyrazine (136 mg, 0.477 mmol), DIPEA (111 μί, 0.637 mmol), and potassium iodide (106 mg, 0.637 mmol). The reaction mixture was heated to 60°C for 16 hours. After cooling, the reaction mixture was charged with saturated aqueous sodium bicarbonate solution and extracted with DCM. The organic layer was dried (magnesium sulfate), filtered and concentrated. The crude product was purified by column chromatography (1/1 EtOAc/Hex to 10% MeOH/DCM) to give the compound Ex-1, LC/MS = 412 [M+1]
Additional compounds of the Formula AI :
Figure imgf000046_0001
where Rz is elucidated in Table VI, were prepared by using methods described in Scheme I and the example presented above and characterized by LC/MS (data presented also in Table VI). See also Example 16, Scheme 16, for an alternative synthesis scheme for compound Ex- 14.
Figure imgf000046_0002
Figure imgf000047_0001
Figure imgf000048_0001
Figure imgf000049_0001
Figure imgf000050_0001
Compound
Structure LC-MS No.
NH2
Ϊ
N— N^N
361
Ex-24
[M+1]
2-(2-(isomdolin-2-yl)ethyl)-7-methoxy-[l,2,4]triazolo[l,5-c]quinazoliri-
5 -amine
NH2
396
Ex-25
[M+1]
7-methoxy-2-(2-(2-methyl-6,7-dihydrothiazolo[4,5-c]pyridin-5(4H)- yl)ethyl)-[l,2,4]triazolo[l,5-c]quinazolin-5-amme
NH2
450
Ex-26
[M+1]
7-met oxy-2-(2-(2-(trifluoromethyl)-6,7-dihydrothiazolo[4,5-c]pyridin- 5(4H)-yl)ethyl)4^1,2,4]triazolo[l,5-c]quinazolin-5-amine
NH2
380
Ex-27
[M+1]
7-methoxy-2-(2-(2-methyl-6,7-dihydrooxazolo[4,5-c]pyridin-5(4H)- yl)ethyl)-[l,2,4]triazolo[l,5-c]quinazolin-5-amme
NH2
380
Ex-28
[M+1]
7-methoxy-2-(2-(2-methyl-6,7-dihydrooxazolo[5,4-c]pyridin-5(4H)- yl)ethyl)-[l,2,4]triazolo[l,5-c]quinazolin-5-amine
Figure imgf000052_0001
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000056_0001
Figure imgf000057_0001
Figure imgf000058_0001
Figure imgf000059_0001
EXAMPLE 2: Preparation of 7-methoxy-2-(2-(2-(4-methylpiperazin-l-yl)-5H-pyrrolo[3,4- b]pyridin-6(7H)-yl)ethyl)-[l,2,4]triazolo[ l ,5-c]quinazolin-5-amme (Ex-63)
SCHEME 2
Figure imgf000060_0001
To a microwave tube was added 2-(2-(2-chloro-5 -pyrrolo[3,4-¾]pyridin-6(7H)- yl)ethyl)-7-methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine (compound Ex-5, prepared in Example 1 , (30 mg, 0.076 mmol), 1-methylpiperazine (1.5 mL, 13.53 mmol), and NMP (500 μί). The reaction mixture was microwaved at 200°C for 1.5 hr. The crude reaction mixture was purified by reverse phase column (Water + 0.1 % TFA/ACN + 0.1 % TFA) to give the desired product, Ex-63, LC/MS = 474 [M+1 ].
The compounds presented in Table VII were prepared by using methods described in Scheme 2 and Example 2. These compounds were characterized by LC/MS, which data is also presented in Table VII.
Figure imgf000060_0002
Figure imgf000061_0001
Compound
Structure LC-MS No.
530
Ex-72
[M+1]
7-methoxy-2-(2-(2-(4-morpholinopiperidin-l-yl)-5H-pyrrolo[3,4- b]pyridin-6(7H)-yl)ethyl)-[ l ,2,4]triazolo[l ,5-c]quinazolin-5-amine
EXAMPLE 3: Preparation of dimethoxybenzene-protected 2-(5-amino-7-methoxy- [l ,2,4]triazolo[l ,5-c]quinazolin-2-yl)ethyl methanesulfonates ("right-side" precursor compounds) and preparation of 2-(2-(4-(4-ethylpiperazin- 1 -yl)-5 ,6-dihydro- 1 ,7-naphthyridin-7(8H)-yl)ethyl)- 7-methoxy-[l ,2,4]triazolo[ l ,5-c]quinazolin-5-amine (Ex-73)
Figure imgf000062_0001
(Step A) To a stirred suspension of dimethylbenzene (DMB)-protected compound Ex-6 (prepared in Example 1 , 45 mg, 0.074 mmol), 1 -ethylpiperazine (19 \iL, 0.15 mmol), potassium fert-butoxide (21 mg, 0.19 mmol) and 2-dicyclohexylphosphino-2',6'-di-i- propoxy-l, l'-biphenyl (7.0 mg, 0.015 mmol) in dioxane (573 μί) was added
tris(dibenzylideneacetone)dipalladium(0) (6.8 mg, 7.4 μηιοΐ). The reaction mixture was heated at 100°C overnight. The solvent was evaporated and the crude was diluted with EtOAc. The organic layer was washed with sat. NaCl (aq), dried over MgSC>4, filtered and concentrated. The crude product was purified by column chromatography (MeOH: DCM = 1/1 to 50% MeOH) to give iV-(2,4-dimethoxybenzyl)-2-{2-[4-(4-ethylpiperazin-l-yl)-5,8-dihydro-l ,7-naphthyridin- 7(6H)-yl]ethyl}-7-methoxy[l,2,4]triazolo[l ,5-c]quinazolin-5-amine, LC/MS = 638 [M+1].
(Step B) To a round bottom flask of N-(2,4-dimethoxybenzyl)-2-{2-[4-(4- ethylpiperazin-l-yl)-5,8-dihydro-l,7-naphthyridin-7(6H)-yl]ethyl}-7- methoxy[l ,2,4]triazolo[l,5-c]quinazolin-5-amine (25.1 mg, 0.039 mmol) was added TFA (400 μί . The reaction mixture was stirred at room temperature overnight. TFA was evaporated, diluted with MeOH, evaporated again. Rediluted with DCM and neutralized with 7Ν NH3 in MeOH, and solvent was evaporated. The crude product was purified by prep-TLC (10% MeOH in DCM) to give compound Ex-73, which was characterized by LC/MS = 488 [M+1].
The compounds presented in Table VIII were prepared by using methods described in Scheme 3 and Example 3. These compounds were characterized by LC/MS, which data is also presented in Table VIII.
Table VIII
Figure imgf000063_0001
EXAMPLE 4: Preparation of 2-(5-amino-7-methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-2-yl)-l- (5H-pyrrolo[3,4-b]pyridin-6(7H)-yl) (Ex-77) SCHEME 4
Figure imgf000064_0001
Step A: ethyl 3-[2-(2-amino-8-methoxyquinazolin-4-yl)hvdrazinyl]-3- oxopropanoate
2,4-dichloro-8-methoxyquinazoline was treated sequentially with ethyl 3- hydrazino-3-oxopropionate (DIPEA, THF, 60°C, overnight) and NH3 (2M in z-PrOH, 100 °C overnight in a sealed tube) to give the title compound and the corresponding isopropyl ester (~3 :1).
Step B: (5-amino-7-methoxy[ l ,2,41triazolo[l ,5-clquinazolin-2-yl)acetic acid
The mixture of ethyl and isopropyl esters was sequentially reacted with BSTA (120°C, 3 h) and LiOH (THF, water, room temperature, overnight) to provide the title compound, LCMS (M+H) = 274.
Step C: 2-(5-amino-7-methoxy[l ,2.41triazolo[l ,5-c1quinazolin-2-yn-l-(5,7- dihydro-6H-pyrrolo[3,4-i?lpyridin-6-yl)ethanone
A mixture of (5-amino-7-methoxy[l,2,4]triazolo[ l ,5-c]quinazolin-2-yl)acetic acid (0.050 g, 0.161 mmol), 6,7-dihydro-5H-pyrrolo[3,4-¾pyridine dihydrochloride (0.047g, 0.24 mmol), DIPEA (0.141 ml, 0.807 mmol), and 1-propanephosphonic acid cyclic anhydride (0.144 mL, 0.242 mmol) in DCM (5 mL) was stirred at room temperature overnight and then diluted with water and DCM. The organic layer was filtered and concentrated. The residue was purified by preparative reverse phase HPLC (eluting with 10-95 % Acetonitrile/Water + 0.1% TFA (20 mL/min) over 10 min.) to give compound, Ex-77 (a light yellow solid), which was characterized by LCMS (M+H) = 376.
Compound Ex-78 presented in Table IX was prepared using methods described in Example 4 and Scheme 4:
Table IX
Compound
Structure LC-MS No.
Figure imgf000065_0001
EXAMPLE 5: Preparation of 2-(2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)ethyl)-7- (fluoromethoxy)-[l,2,4]triazolo[l,5-c]quinazolin-5-amine (Ex-79)
Figure imgf000065_0002
Step A: 2-(2-f5H-pyrrolor3.4-^1pyridin-6(7H)-yl)ethvn-5-amino- ri.2,41triazolori,5-c1quinazolin-7-ol
To a solution of compound Ex-49 prepared in Example 1, above, (185 mg, 0.512 mmol) in DMF (4 mL) was added sodium methylthiolate (71.8 mg, 1.024 mmol). Reaction mixture was stirred in a sealed tube at 100°C for 18 h. The reaction mixture was diluted with DCM, washed with H20. The organic layer was separated and dried over MgSO/i, filtered and concentrated in vacuo. Purification by preparative TLC (DCM : MeOH (7N N¾) 1 :20) to yield the title compound, LC/MS = 348 [M+l].
Step B: 2-C2-i5H-pyrrolor3.4- 7lDyridin-6('7H)-ylkthvn-7-('fluoromethoxyV
[l,2,41 azolo[l,5-c]quinazolin-5-amine
To a solution of 2-(2-(5/ -pyrrolo[3,4-/?]pyridin-6(7H)-yl)ethyl)-5-amino- [l,2,4]triazolo[l,5-c]quinazolin-7-ol (20 mg, 0.058 mmol) in acetone (2 mL) was added fluoromethyl methanesulfonate (17.6 mg, 0.086 mmol) and CS2CO3 (56.3 mg, 0.173 mmol). The reaction mixture was stirred in a sealed tube at 40°C for 48 h, cooled to room temperature, filtered through diatomaceous earth, washing with DCM and MeOH. The filtrate was concentrated in vacuo. Purification by preparative TLC (DCM : MeOH (7N NH3) 1 :20) yielded compound, Ex-79 which was characterized by LC/MS = 380 [M+l].
EXAMPLE 6: Preparation of 2-(7-chloro-5-(2,4-dimethoxybenzylamino)-[l,2,4]triazolo[l,5- c]quinazolin-2-yl)acetaldehyde as "right-side" precursor and preparation of 7-chloro-2-(2-(5- fluoroisoindolin-2-yl)ethyl)-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine (Ex-80) therefrom
Figure imgf000066_0001
Step A: 3.3-dimethoxypropanehydrazide
The mixture of methyl 3,3-dimethoxypropanoate (6 g, 83.3 mmol) and 80% hydrazine hydrate (52 mL, 833 mmol, 10 equiv.) was heated at 120°C for 6 hours. The excess of hydrazine was removed on a rotary evaporator. The residue was dissolved in DCM (30 mL). The remaining aqueous layer was extracted with DCM (30 mL). The organic layers were combined, ad concentrated to a volume of 30 mL. The title compound was precipitated by the addition of petroleum ether to afford a white solid. The product was characterized by proton NMR: ¾-NMR (OMSO-d6, 400 MHz) δ 9.02 (s, 1H), 4.70 (t, / = 5.2 Hz, 1H), 4.2 (s, 2H), 3.22 (s, 6H), 2.33 (d, J = 52 Hz, 2H).
Step B: 8-chloroquinazoline-2,4-diol
The mixture of 2-amino-3-chlorobenzoic acid (13 g, 75.8 mmol) and urea (27.3 g, 454 mmol, 6 equiv.) was stirred at 200°C for 2 hours, cooled to 120°C. Water (500 mL) was added in small portions. The solid was filtered, washed with water and EtOAc, and dried in oven (100°C) to afford the desired compound as a brown solid, which was characterized by LC/MS. LC-MS: m z (M+l) = 197.
Step C: 2.4.8-trichloroquinazolme
8-Chloroquinazoline-2,4-diol (step B, 15 g, 75.8 mmol) was added to POCI3 (70 mL, 763 mmol, 10 equiv.) in small portions. Dimethylaniline (3.7 g, 30.5 mmol, 0.4 equiv.) was added. The reaction mixture was stirred in 140°C for 16 hours. The mixture was cooled to room temperature, and added drop wise to ice-water (500 mL). The precipitate was collected and washed with ice-water. The solid was dissolved in DCM (500 mL), dried over MgS04, filtered, and concentrated to give the crude product, which was purified by silica column chromatography (petroleum ether: EtOAc = 7: 1) to afford the title compound as a yellow solid which was characterized by LC/MS. LC-MS: m/z (M+l) = 233.
Step D: /V-(2,8-dichloroqumazolin-4-yl)-3,3-dimethoxypropanehvdrazide
The mixture of 2,4,8-trichloroquinazoline (step C, 4.0 g, 17.2 mmol), DIPEA (15 mL, 86.1 mmol) and 3,3-dimethoxypropanehydrazide (step A, 3.1 g, 20.7 mmol) in 1,4-dioxane (50 mL) was stirred at 40°C for 2 hours, and then concentrated. The residue was partitioned between DCM (50 mL) and aqueous NaHC(¾ (50 mL). The organic layer was washed with water and concentrated to get the title compound as a yellow solid which was characterized by LC/MS. LC-MS: m/z (M+l) = 345.
Step E: /Vl-i8-chloro-2-(2.4-dimethoxybenzylammo)quinazolin-4-yl)-3,3- dimethoxypropanehydrazide
The mixture of N'-(2,8-dichloroquinazolin-4-yl)-3,3-dimethoxypropanehydrazide (step D, 5.9 g, 17.2 mmol), DIPEA (6 mL, 34.3 mmol), and (2,4-dimethoxyphenyl)methanamine (3.1 mL, 20.6 mmol) in 1,4-dioxane (50 mL) was stirred at 80°C overnight. After concentration, the residue was partitioned between DCM (100 mL) and aqueous NaHC03 (100 mL). The organic layer was washed with water and concentrated to get the title compound as a yellow solid which was characterized by LC/MS. LC-MS : m/z (M+l) = 476.
Step F: 7-chloro-iV-(2.4-dimethoxybenzyl)-2-(2.2-dimethoxyethyl)- rL2,41triazolori ,5-c1quinazolin-5-amine
The solution of N'-(8-chloro-2-(2,4-dimethoxybenzylamino)quinazolin-4-yl)-3,3- dimethoxypropanehydrazide (step E, 7.8 g, 16.4 mmol) in BSA (30 mL) was stirred at 140°C overnight. The mixture was then concentrated by rotovap at 70°C to remove all BSA. The residue was added methanol (50 mL), stirred in cold ice bath for a while. The resulting suspension was filtered, dried under vacuum to obtain the title compound as a yellow solid which was characterized by proton NMR and LC/MS. ¾-NMR (DMSO-i/6, 400 MHz) δ 8.49 (d, / = 6 Hz, 1H), 8.10 (d, J = 7.6 Hz, 1H), 7.79 (t, / = 8 Hz, 1H), 7.37-7.26 (m, 2H), 6.54 (d, / = 1.6 Hz, 1H), 6.25 (t, J = 8 Hz, 1H), 4.99 (t, J = 12 Hz, 1H), 4.70 (d, / = 5.6 Hz, 2H), 3.82 (s, 3H), 3.70 (s, 3H), 3.34 (s, 6H), 3.18 (d, J = 6 Hz, 2H), LC-MS: m/z (M+l) = 458.
Step G: 2-(7-chloro-5-(2,4-dimethoxybenzylammo)-[ 1.2,41triazolorL5- clquinazolin-2-yl)acetaldehvde
The mixture of 7-chloro-iV-(2,4-dimethoxybenzyl)-2-(2,2-dimethoxyethyl)- [l ,2,4]triazolo[l ,5-c]quinazolin-5-amine (step F, 2.5 g, 5.5 mmol) and TsOH (470 mg, 2.7 mmol) in acetone/H20 (20 mL/2 mL) was stirred at 60°C under argon overnight. The mixture was then cooled to room temperature, and concentrated under reduced pressure at room temperature. The residue was dried in vacuum to obtain the title compound as a crude product, which was used in next step without purification, LC-MS: m z (M+l) = 412. Step H: 7-chloro-5-(2.4-dimethoxyphenylV2-r2-(5-fluoroisoindolin-2-vnethylV ri.2,41triazolori ,5-c1quinazoline
To a THF (5 mL) mixture of 2-(7-chloro-5-(2,4-dimethoxybenzylamino)- [l ,2,4]triazolo[l ,5-c]quinazolin-2-yl)acetaldehyde (step G, 250 mg, 0.6 mmol) and 5- fluoroisoindoline (167 mg, 1.2 mmol) was added tetraethoxytitanium (0.1 mL). The reaction mixture was stirred at 20°C for 1 hour. Sodium cyanoborohydride (192 mg, 3.0 mmol) was then added to the reaction mixture, which was stirred at 20°C for 16 hours. The mixture was concentrated to afford the title compound as white solid which was characterized by LC/MS. LCMS : m z (M+l) = 530.
Step I: 7-chloro-2-(2-f5-fluoroisoindolin-2-vnethylVri.2.41triazolori .5- clquinazolin-5-amine
A trifluoracetic acid (5 mL) solution of 7-chloro-5-(2,4-dimethoxyphenyl)-2-(2- (5-fluoroisoindolin-2-yl)ethyl)-[l ,2,4]triazolo[l ,5-c]quinazoline (step H, 320 mg, 0.6 mmol) was stirred at 50°C for 16 hours. The solution was evaporated to dryness, then purified by silica chromatography using MeOH/CH2Cl2 (1 : 10) eluent to yield compound, Ex-80, as a white solid which was characterized by LC/MS. LCMS: m/z (M+1) = 383.
The synthesis of Example 6 was employed with appropriate "left-side" reagents to prepare the compounds presented in Table X. These compounds were characterized by LC/MS, which data is also reported in Table X.
Table X
Figure imgf000068_0002
Using the procedure of Scheme 6 and Example 6, Compound Ex-83, 2-[2-(5,7- dihydro-6H-pyrrolo[3,4- ?]pyridin-6-yl)ethyl]-7-fluoro[l ,2,4]triazolo[ l ,5-c]quinazolin-5-amine:
Figure imgf000068_0001
was prepared by substituting 2-amino-3-fluorobenzoic acid for 2-amino-3-chlorobenzoic acid in step B and 6,7-dihydro-5H-pyrrolo[3,4-fr]pyridine for 5-fluoroisoindoline in step H. Compound Ex-83 was characterized by LC MS: m/z (M+1) = 350.
Additional compounds prepared using this same procedure are presented in Table XI, below, along with the characteristic LC/MS data.
Figure imgf000069_0001
Figure imgf000070_0001
Compound Ex-90 , 2-(2-(3 ,4-dihydroisoquinolin-2( 1 H)-yl)ethyl)-7-metbyl- [l,2,4]triazolo[l,5-c]quinaz
Figure imgf000070_0002
Ex-90,
was prepared using the procedure of Example 6, Scheme 6, above, only substituting , substituting 2-amino-3-methylbenzoic acid for 2-amino-3-chlorobenzoic acid in step B and 1, 2,3, 4-tetrahydroisoquino line for 5-fluoroisoindoline in step H. Compound Ex-90 was characterized by LC/MS: LCMS: m/z (M+1) = 359.
Compound Ex-91 , 8-fluoro-2-[2-(5-fluoro- 1 ,3-dihydro-2H-isoindol-2- yl)ethyl][l,2,4]triazolo[l ,5
Figure imgf000070_0003
Ex-91,
was prepared using the procedure of Example 6, Scheme 6, above, only substituting , substituting , substituting 2-amino-4-fiuorobenzoic acid for 2-amino-3-chlorobenzoic acid in step B. Compound Ex-91 was characterized by LC/MS: m z (M+1) = 367.
Additional compounds prepared using this same procedure with appropriate reagent substitutions are presented in Table XII, below, along with the characteristic LC/MS data.
Figure imgf000071_0001
Compounds Ex-97 to Ex-100, presented along with characteristic LC/MS data in Table XIII, below, were prepared using the procedure detailed in Example 6, and in the preparation of compound Ex-83, above, by substituting the appropriate aminobenzoic acid for 2- amino-3-chlorobenzoic acid in step B thereof.
Figure imgf000072_0001
Compound
Structure LC-MS No.
[l,2,4]triazolo[l ,5-c]quinazolin-5-amine
EXAMPLE 7: Preparation ofracemic (±)-2-(3,3-difluoro-2-(5/7-pyrrolo[3,4-^]pyridin-6(7H)- yl)propyl)-7-methoxy-[l ,2,4]triazolo[l,5-c]quinazolin-5-amine (Ex-101)
SCHEME 7
Figure imgf000073_0001
Step A: methyl 4,4-difluoro-3-(5 /-pyrrolo[3,4-j?lpyridin-6(7H)-ynbutanoate To a solution of (£)-methyl 4,4-difluorobut-2-enoate (600 mg, 4.99 mmol) in acetonitrile (20 mL) was added 6,7-dihydro-5H-pyrrolo[3,4-^]pyridine (1.1 g, 7.49 mmol), followed by DBU (0.373 mL, 2.497 mmol). The reaction mixture was stirred at room temperature for 18 h and then concentrated in vacuo to afford the title compound.
Step B: (±)-4,4-difluoro-3-(5g-pyrrolo[3,4-fclpyridin-6(7H)-yl)butanehydrazide To an ethanol (50 mL) solution of methyl 4,4-difluoro-3-(5H-pyrrolo[3,4-
£>]pyridin-6(7H)-yl)butanoate (step A, 1.35 g, 4.99 mmol) was added hydrazine hydrate (2.423 mL, 49.9 mmol). The reaction mixture was stirred in a sealed tube at 80°C for 4 h and concentrated in vacuo. The crude product was purified by flash chromatography (CH2Cl2:MeOH 10:1 to CH2CI2 :MeOH : 1 ) to yield the title compound which was characterized by LC/MS . LC/MS = 257 [M+l].
Step C: (±)-jV'-(2-amino-8-methoxyquinazolin-4-yl)-4,4-difiuoro-3-(5g- pyrrolo[3.4-fc1pyridin-6(7H)-yl)butanehydrazide To a THF (50 mL) suspension of N-(8-methoxy-4-(lH-l ,2,4-triazol- l - yl)quinazolin-2-yl)acetamide (600 mg, 2.1 1 1 mmol) was added (±)-4,4-difluoro-3-(5H- pyrrolo[3,4-b]pyridin-6(7H)-yl)butanehydrazide prepared in step B (595 mg, 2.322 mmol) and DIPEA (0.441 mL, 2.53 mmol). The reaction mixture was stirred at 60°C for 3 hours, and then concentrated in vacuo. To a MeOH (50 mL) and water (50 mL) suspension of the residue was added potassium carbonate (2.2 g, 15.9 mmol). The mixture was stirred in a sealed tube at 80°C until all the starting material was consumed. The reaction mixture was concentrated in vacuo and diluted with dichloromethane and methanol. The resulting precipitate was filtered off, and the filtrate was then concentrated in vacuo. The resulting residue was purified by flash chromatography (dichloromethane:methanol 10: 1) to yield the title compound which was characterized by LC/MS. LC/MS = 430 [M+1 ] .
Step D: (±V2-('3,3-difluoro-2-f5H-pyrrolor3.4-^lpyridin-6('7H)-vnpropyn-7- methoxy-ri,2,41triazolori ,5-c]quinazolin-5-amine
To (±)-N'-(2-amino-8-methoxyquinazolin-4-yl)-4,4-difluoro-3-(5H-pyrrolo[3,4- b]pyridin-6(7H)-yl)butanehydrazide (step C, 1.1 g, 2.56 mmol) was added BSTA (6.35 mL, 25.6 mmol). The suspension was stirred at 120°C for 2 hr. The reaction mixture was concentrated in vacuo with heating. The residue was purified by flash chromatography
(dichloromethane methanol 20: 1) to afford compound Ex-101 which was characterized using, LC/MS = 412 [M+1].
Using the procedure of Example 7 and Scheme 7, the compounds reported in
Table XIV were prepared in the racemic form. The enantiomeric forms were separated through chiral HPLC.
Table XIV
Compound
Structure LC-MS No.
NH2
412
Ex- 102
[M+1]
(S)-2-(3,3-difluoro-2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)propyl)-7- methoxy-[l ,2,4]triazolo[l ,5-c]quinazolin-5-amine
NH2
412
Ex- 103
[M+1]
(R)-2-(3,3-difluoro-2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)propyl)-7-
Figure imgf000075_0001
Figure imgf000076_0001
Figure imgf000077_0001
EXAMPLE 8: Preparation of 2-((5-fiuoroisoindolin-2-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine (Ex- 117)
Figure imgf000077_0002
Step A: Preparation of 2-(chloromethyl)-7-methoxy-[l ,2,41triazolori,5-c1- quinazolin-5-amine
(5-amino-7-methoxy-[l ,2,4]triazolo[l ,5-c]quinazolin-2-yl)methanol (4 g, 15.4 mmol, prepared in accordance with Example 10) was suspended in DCM (50 mL) and SOCI2 (50 ml). The mixture was stirred at RT for 1 h, concentrated in vacuo to remove SOCL completely. The residue was suspended in DCM/Hex (1 :2), cooled to 0°C, filtered and dried to afford the titled compound. LC/MS = 264 [M+1].
Step B: 2-((5-fluoroisoindolin-2-yl)methyl)-7-methoxy-rL2,41triazolo[l ,5-c1- quinazolin-5-amine The "right-side" precursor 2-(chloromethyl)-7-methoxy-[l,2,4]triazolo[l ,5- c]quinazolin-5-amine (150 mg, 0.54 mmol), and "left-side" precursor 5-fiuoroisoindoline (92 mg, 1.1 mmol) were placed in a reaction vessel with DIPEA (105 mg, 0.81 mmol) and KI (269 mg, 1.62 mmol) in DMF (50 mL) and the mixture was stirred at 80°C for 18 h. The mixture was cooled to RT, diluted with DCM, washed with H20 (3X), dried and concentrated.
Chromatography purification MeOH/DCM (1 :30-l :20-l : 10) afforded the compound Ex- 117, which was characterized using LC/MS = 365 [M+1]..
The process of Scheme 8 was repeated with an appropriate "left-side" precursor to provide the compounds of Table XV.
Figure imgf000078_0001
Figure imgf000079_0001
Figure imgf000080_0001
2-((6-fluoro-3,4-dihydroisoquinolin-2(lH)-yl)methyl)-7-methoxy-
Figure imgf000081_0001
Figure imgf000082_0001
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
EXAMPLE 9: Preparation of 7-Bromo-2-((5,6-dihydro-l,7-naphthyridin-7(8H)yl) methyl) )- [l,2,4]-triazolo[l,5-c]quinazolin-5-amine (Ex- 194)
SCHEME 9
Figure imgf000090_0002
Diisopropylethyl amine (17 mg; 0.13 mmol) was added to an amber colored solution of 7-bromo-2-(chloromethyl)-N-(2,4-dimethoxybenzyl)-[ 1 ,2,4]triazolo [ 1 ,5 - c]quinazolin-5-amine (20 mg; 0.043 mmol, prepared in accordance with Scheme 1 , above, using 2-amino-3-bromo-benzoic acid in lieu of 2 amino-3-methoxy benzoic acid) and 5,6,7,8- tetrahydro-[l,7]-naphthyridine (20 mg; 0.095 mmol) in dry DMF (1 mL) and the reaction mixture was stirred for 20 hr at room temperature. After verifying the absence of the tricyclic chloride by MS, the reaction mixture was diluted with EtOAc and washed with water, saturated NH4Cl solution and brine. Concentration and purification by preparative TLC (5% CH3OH in CH2CI2) served to isolate compound Ex-194-DMB (DMB-protected analog of compound Ex- 194) as a white solid which was characterized using LC-MS: 560 (M+); R, = 2.52.
The DMB protected product from step-1 was dissolved in CH2CI2-TFA (0.5 mL each), stirred and heated at 55°C for 4hr. After verifying absence of SM and presence of product (MH = 410 / 412)), CH2CI2 and TFA were removed on the rotovap. Toluene (2 5 mL) was added and removed in vacuo followed by 7% NH3 in CH30H which was also removed in vacuo. The resulting residue was applied to a prep plate and developed with 7%NH3-methanol-CH2Cl2 (5:95). The uv-active band of medium polarity was isolated and the product extracted with the same solvent system. Concentration of the extract in vacuo gave compound Ex- 194 as white solid.
The process of Scheme 9 was repeated with an appropriate "left-side" precursor to provide the compound of Table XVI. Table XVI
Figure imgf000091_0001
EXAMPLE 10: Preparation of "right-side" precursors having various substituents at 7-C from (7-bromo-5-(2,4-dimethoxybenzylamino)-[l,2,4]triazolo[l,5-c]quinazolin-2-yl)methanol and preparation of compounds of the invention therefrom.
The "right-side" precursor 2-Chloromethyl-5-(2,4-dimethoxybenzyl amino)-7- cyano-[l ,2,4]-triazolo[l,5-c]quinazoline (Intermediate-12) was prepared in accordance with Scheme 10:
Figure imgf000092_0001
Step-1 : A mixture of 7-Bromo-5-(2,4-dimethoxybenzyl amino)-2- hydroxymethyl-[l,2,4]-triazolo[l,5-c]quinazoline (200 mg; 0.45 mmol, prepared in accordance with Schemes 1 and 7, above, using 2-amino-3-bromo-benzoic acid starting material in lieu of 2 amino-3-methoxy benzoic acid ), zinc cyanide (31.7 mg; 0.27 mmol) and PdCl2(dppf)2:CH2Cl2 were dissolved in DMF (1 mL) and water (0.1 mL). The resulting clear red solution was degassed with nitrogen, stirred and heated at 120° C for 14 hr. MS analysis of the reaction mixture showed absence of the starting bromo tricyclic alcohol and presence of the product nitrile (MH+ = 391). The reaction mixture was quenched with water and organics were extracted with EtOAc. The organic extract was further washed with water, brine and dried over solid anhydrous Na2SC>4. The crude product was purified by preparative TLC, developing the plate with EtOAc/CH2Cl2 (1 : 1). The 7-cyano tricyclic alcohol was isolated as beige solid.
Step-2: A solution of compound (140 mg; 0.36 mmol) in CH2CI2 (2 mL) and
CDCI3 (2 mL) was cooled in an ice bath and treated sequentially with Et3N (40 mg; 55 uL; 0.395 mmol) and MsCI (49 mg; 0.43 mmol), taking care not to use even a slight excess of Et3N to avoid quaternary salt formation. The ice bath was removed after 5 minutes and the reaction mixture was stirred at T for 45 minutes when the analysis (TLC, MS) showed absence of alcohol. The reaction mixture was diluted with EtOAc and washed with water, brine, dried and concentrated to obtain the crude mesylate.
Step -3: The crude mesylate was redissolved in acetone (3 mL), treated with solid LiCI (76 mg; 1.79 mmol) and was stirred with heating at 58°C for 3 hr. After confirming the complete formation of the tricyclic chloride (MH+ = 408/410), the reaction mixture was cooled to RT and acetone was removed under house vacuum. The residue was dissolved in CH2C12 : CHCI3 (4: 1) and washed with water, brine and concentrated to obtain 140 mg of a beige solid. The crude product thus obtained was purified by preparative TLC (30% EtOAc-CH2Cl2) to furnish lntermediate-12 as off-white solid.
Intermediate- 12, prepared above, was used to prepare compounds of the invention in accordance with Scheme 10a:
Figure imgf000093_0001
Step-1 : A clear amber solution of 7-cyano tricyclic chloride 12 previously prepared (110 mg; 0.27 mmol), 5,6,7,8-tetrahydro-l ,7-naphthyridine (85 mg; 0.37 mmol) and Hunig's base (0.14 mL; 104 mg; 0.807 mmol) in anhydrous DMF (1 mL) was stirred and heated at 80° C for 18 hr. The reaction mixture was cooled to RT, diluted with water and extracted with EtOAc. The organic extract was washed with water and brine. Combined aqueous layers were back extracted with CH2CI2. Both organic extracts were combined, dried over solid anhydrous Na2SC>4 and concentrated to get 140 mg of beige solid. The crude product was purified by preparative TLC (5% CH3OH-CH2CI2) and the major fluorescent band, which was the 2,4- dimethoxybenzyl protected form of compound Ex-196, was isolated as an off-white solid, MS = 507 (MH+).
Step-2: The DMB-protected form of compound Ex-196, prepared above, was dissolved in CH2Ci2:TFA (1 mL each) and stirred at 57° C for 4hr. The clear reaction mixture had become deep purple and MS showed complete deprotection of the DMB group to give the compound Ex-196, 5-amino-2-((5 ,6-dihydro- 1 ,7-naphthyridin-7(8H)-yl)methyl)- [l,2,4]triazolo[l,5-c]quinazoline-7-carbonitrile. The solvents were removed on a rotary evaporator and the residual TFA was removed by azeotrope formation with toluene to give a yellow sticky semi-solid. This material was treated with 7% N¾ in methanol, stirred for 10 minutes and concentrated to obtain a beige solid. The crude product was purified by preparative TLC (CH2CI2 with 7% NH3 in methanol, 96:4) to afford compound Ex-196 as an off-white solid (77 mg; 87%). LC-MS: 357 (MH+); Rt = 2.02.
As shown in Table XVII, compound Ex-197 was prepared using this same procedure.
Table XVII
Com ound Structure M+l (Rt)
No. Ε -197 343 (1.72)
2-((5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)methyl)-5-amino-
[l ,2,4]triazolo[l ,5-c]quinazoline-7-carbonitrile
The "right-side" precursor 2-(chloromethyl)-7-(methoxymethyl)- [l ,2,4]triazolo[l ,5-c]quinazolin-5-amine (Intermediate-13) was prepared in accordance with Scheme 10:
SCHEME 10c
Figure imgf000094_0001
Intermediate-13
Step A: Methyl 3-(methoxymethyl -2-nitrobenzoate
A mixture of methyl 3-(bromomethyl)-2-nitrobenzoate (2.00 g, 7.30 mmol) and K2C03 (1.01 g, 7.30 mmol) in 100 mL of MeOH was heated at 80° C for 2 h. The solvent was removed under vacuum. To the residue was added 150 mL of EtOAc. The mixture was washed with 150 mL of water, and the organic phase was dried over anhydrous Na2S04. It was then concentrated. The residue was purified by flash chromatography eluting with 40%
EtOAc/hexanes to give the title compound. XH NMR (400 MHz, CDC13) δ 7.90-7.92 (m, 1H), 7.76-7.78 (m, 1H), 7.56-7.59 (m, 1H), 4.49 (s, 2H), 3.90 (s, 3H), 3.39 (s, 3H).
Step B: Methyl 2-amino-3-(methoxymethyl)benzoate
A solution of methyl 3-(methoxymethyl)-2-nitrobenzoate (850 mg, 3.77 mmol), diisopropylethylamine (0.125 ml, 0.755 mmol) and Pd/C (402 mg, 0.377 mmol) in 20 mL of MeOH was stirred at RT under a balloon of H2 for 50 min. It was filtered through celite. The solvent was removed under vacuum. The residue was purified by column with 20% EtOAc/hexanes to give the title compound. XH NMR (400 MHz, CDC13) δ 7.85-7.87 (m, 1H), 7.18-7.20 (m, 1H), 6.57-6.61 (m, 1H), 6.00-6.55 (brs, 2H), 4.49 (s, 2H), 3.86 (s, 3H), 3.32 (s, 3H).
Step C: 2-Amino-8-(methoxymethyl quinazolin-4(3H one
To a solution of methyl 2-amino-3-(methoxymethyl)benzoate (388 mg, 1.99 mmol) in 7 mL of ether, was added 4 N HCl in ether (1.49 ml, 5.96 mmol). It was stirred at RT for 5 min and then treated with 10 mL of hexanes. The resulting solid was collected by filtration to give 420 mg of its HCl salt form as a white solid. A mixture of this material (382 mg, 1.649 mmol) and cyanamide (416 mg, 9.89 mmol) was stirred in 3 mL ether for 5 min. Ether was removed under vacuum. The residue was stirred at 85 ° C for 3 h. It was cooled to RT and diluted with 5 mL of ether. The solid was collected by filtration and washed with water. It was dried under vacuum to give the title compound. lU NMR (400 MHz, DMSO) δ 10.80-11.05 (brs, 1H), 7.75-7.80 (m, 1H), 7.53-7.55 (m, 1H), 7.02-7.05 (m, 1H), 6.28-6.42 (brs, 2H), 4.62 (s, 2H), 3.30 (s, 3H).
Step D: N-f8-(Methoxymethyl)-4-oxo-3,4-dihvdroquinazolin-2-yl)acetamide
A mixture of 2-amino-8-(methoxymethyl)quinazolin-4(3H)-one (680 mg, 3.31 mmol) in 7 mL of AC2O was heated at 140° C for 30 min. The solid was collected by filtration. The filtrate was concentrated under vacuum. To the residue was added 5 mL of toluene. It was again concentrated under vacuum to remove the residual Ac20. The solid residue was combined with the solid from filtration to give the title compound. !H NMR (400 MHz, CDC13) δ 8.18- 8.20 (m, 1H), 7.69-7.75 (m, 1H), 7.36-7.40 (m, 1H), 4.76 (s, 2H), 3.49 (s, 3H), 2.33 (s, 3H).
Step E: N-(8-(MethoxymethYl -4-(4H-1.2,4-triazol-4-yl)quinazolin-2- vDacetamide
To a mixture of N-(8-(methoxymethyl)-4-oxo-3,4-dihydroquinazolin-2- yl)acetamide (320 mg, 1.29 mmol), and 4H-l,2,4-triazole (894 mg, 12.94 mmol) in 11 mL of acetonitrile, was added diisopropylethylamine (0.642 ml, 3.88 mmol) followed by phosphoryl trichloride (0.354 ml, 3.88 mmol). The reaction was stirred at RT for 3 h. The solid was collected by filtration and washed with acetonitrile and EtOH to give the crude title compound contaminated with some 4H-l,2,4-triazole. This material was used in future reactions without further purification. MS = 299 [M+ 1 ] .
Step F: N-(4-(2-(2-Hvdroxyacetyl)hvdrazinyl)-8-(methoxymethyl)quinazolin-2- vDacetamide
To a mixture of the crude N-(8-(methoxymethyl)-4-(4H-l ,2,4-triazol-4- yl)quinazolin-2-yl)acetamide (306 mg, 1.026 mmol), 2-hydroxyacetohydrazide (1 10 mg, 1.22 mmol) in THF, was added diisopropylethylamine (0.203 ml, 1.231 mmol). The reaction was stirred at 600 C overnight. The solid was filtered off. The filtrate was concentrated. The residue was purified by silica gel chromatography eluting with 10% MeOH/CH2Cl2 to give the title compound. LC/MS = 320 [M+l].
Step G: (5-Amino-7-rmethoxymethvn-ri.2,41triazolori,5-clquinazolin-2- vDmethanol
To a solution of N-(4-(2-(2-hydroxyacetyl)hydrazinyl)-8-
(methoxymethyl)quinazolin-2-yl)acetamide (115 mg, 0.360 mmol) in MeOH, was added 2 N aqueous NaOH (0.6 ml, 1.200 mmol). The reaction was stirred at RT for 1 h. It was neutralized by 2 N HCl. The solvent was removed under vacuum. To the residue was added trimethylsilyl N-(trimethylsilyl)acetimidate (1500 mg, 7.37 mmol). The reaction mixture was heated at 120° C for 1.5 h. Trimethylsilyl N-(trimethylsilyl)acetimidate was removed under vacuum. To the residue were added 2 mL of MeOH and 1 drop of 12 N HCl. It was concentrated and the residue was purified by silica gel chromatography eluting with 10% MeOH/CH2Cl2 to give the title compound. LC/MS = 360 [M+l].
Step H: 2-(Chloromethyl)-7-(methoxymethvn-n.2.41triazolori.5-c1qumazolin- 5 -amine
A solution of (5-amino-7-(methoxymethyl)-[l,2,4]triazolo[l,5-c]quinazolin-2- yl)methanol (40 mg, 0.15 mmol) in 3 mL of thionyl chloride was stirred at RT for 40 min. The solvent was removed under vacuum. The residue was purified by silica gel chromatography eluting with 8% MeOH/CH2Cl2 to give the title compound. ¾ NMR (400 MHz, CDC13) δ 8.29- 8.31 (m, 1H), 7.79-7.81 (m, 1H), 7.42-7.45 (m, 1H), 5.72-5.85 (brs, 2H), 4.92 (s, 2H), 4.82 (s, 2H), 3.51 (s, 3H).
The compound Intermediate-13 was used to prepare compound Ex-198 in accordance with Scheme lOd:
SCHEME lOd
Figure imgf000096_0001
Preparation of 2-((5H-Pyrrolo[3,4-b]pyridin-6(7H)-yl)methyl)-7-(methoxymethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine (Ex-198):
To a solution of 2-(chloromethyl)-7-(methoxymethyl)-[l ,2,4]triazolo[l,5- c]quinazolin-5-amine (6 mg, 0.022 mmol) and 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine (8.34 mg, 0.043 mmol) in DMF, was added diisopropylethylamine (11.17 mg, 0.086 mmol). The reaction was stirred at 80°C overnight. It was purified by a Gilson HPLC (eluant: H20 : CH3CN) to give a crude product, which was further purified by a prep-TLC plate eluting with 8% MeOH/ CH2CI2 to give the title compound. HPLC-MS tR = 1.76 min (UV 254nm) . Molecular weight calculated for formula Ci9H19N70: 361.4; observed: MH+ (LCMS) 362.2.
The same method was used to prepare the following compound in Table XVIII.
Table XVIII
Figure imgf000097_0002
The compound Intermediate-14 was used in synthesis of compound Ex-200 accordance with Scheme lOe:
Figure imgf000097_0001
Intermediate-14
Step A: N'-(2-Chloro-8-methylquinazolin-4-vn-2-hvdroxyacetohvdrazide
To a mixture of 2,4-dichloro-8-methylquinazoline (640 mg, 3.00 mmol) and 2- hydroxyacetohydrazide (284 mg, 3.15 mmol), was added 10 mL of THF, followed by diisopropylethylamine (0.745 ml, 4.51 mmol). The reaction was then heated at 65°C for 3 h. It was cooled to RT and was diluted with 10 mL of CH2CI2. The resulting mixture was stirred at RT for 30 min. The solid was collected by filtration and washed with CH2CI2 to give the title compound. H NMR (400 MHz, DMSO) δ 10.41 (brs, 1H), 10.09 (s, 1H), 8.08-8.12 (m, 1H), 7.68-7.72 (m, 1H), 7.41-7.47 (m, 1H), 5.60-5.66 (m, 1H), 4.02 (d, 2H), 2.50 (s, 3H).
Step B: N'-(2-((2,4-Dimethoxybenzyl)amino -8-methylquinazolin-4-yl -2- hydroxyacetohydrazide
To a solution of N'-(2-chloro-8-methylquinazolin-4-yl)-2-hydroxyacetohydrazide (720 mg, 2.70 mmol) in 7 mL of DMSO, was added (2,4-dimethoxyphenyl)methanamine (655 mg, 3.91 mmol) and diisopropylethylamine (0.892 ml, 5.40 mmol). The reaction was stirred at 100°C for 45 min. It was cooled to RT. To the reaction mixture was slowly added 50 mL of water. The solid was collected by filtration and dried under vacuum to give the title compound. 1H NMR (400 MHz, DMSO) δ 10.76 (brs, 1H), 9.18 (brs, 1H), 7.59-7.62 (m, 1H), 7.11-7.30 (m, 2H), 6.82-6.88 (m, 2H), 6.38-6.51 (m, 2H), 5.80 (brs, 1H), 4.35 (brs, 2H), 3.65-3.88 (m, 8H), 2.14 (s, 3H).
Step C: 5-(i2.4-Dimethoxybenzyl)amino)-7-methyl-n .2.41triazoloi 1.5- clquinazolin-2-yl)methanol
A mixture of '-(2-((2,4-dimethoxybenzyl)amino)-8-methylquinazolin-4-yl)-2- hydroxyacetohydrazide (1.05 g, 2.64 mmol) in 10 mL of trimethylsilyl N- (trimethylsilyl)acetimidate was heated at 1 10°C for 1.5 h. Trimethylsilyl N- (trimethylsilyl)acetimidate was removed under vacuum. To the residue were added 2 mL of MeOH and 1 drop of 12 N HC1. It was concentrated and the residue was purified by flash chromatography eluting with 10% MeOH/CH2Cl2 to give the title compound. H NMR (400 MHz, DMSO) δ 8.23-8.27 (m, 1H), 7.95-8.02 (m, 1H), 7.52-7.57 (m, 1H), 7.20-7.25 (m, 2H), 6.53 (s, 1H), 6.39-6.41 (m, 1H), 5.54-5.62 (m, 1H), 4.57-4.71 (m, 4H), 3.81 (s, 3H), 3.68 (s, 3H), 2.47 (s, 3H).
Step D: 2-(Chloromethyl)-N-(2,4-dimethoxybenzyl -7-methyl- ri,2,41triazolori,5-c1quinazolin-5-amine
To a solution of (5-((2,4-dimethoxybenzyl)amino)-7-methyl-[l,2,4]triazolo[l,5- c]quinazolin-2-yl)methanol (900 mg, 2.372 mmol) in 50 mL of CH2CI2 was added triethylamine (1.091 ml, 7.83 mmol). It was cooled to 0°C and then methanesulfonyl chloride (0.739 ml, 9.49 mmol) was added. The reaction was stirred at 0°C for 40 min. It was diluted with 50 mL of CH2CI2 and washed with water. The organic phase was dried over Na2S04. It was then filtered and concentrated. The residue was dissolved in 50 mL of acetone. Lithium chloride (704 mg, 16.60 mmol) was added. The reaction was stirred at 65°C for 2 h. Most of the solvent was removed under vacuum. The leftover was dissolved in 100 mL of CH2C12 and 50 mL of water. The organic was isolated and purified by flash chromatography eluting with 70% EtOAc/hexanes to give the title compound. LC/MS = 398 [M+l]. Step E: 2-(f5H-Pyrrolor3.4-blpyridine-6(7HVvnmethylVN-(2.4- dimethoxybenzvn-7-methyl-[l ,2.41triazolori.5-clquinazolin-5-amine
To a solution of 2-(chloromemyl)-N-(2,4-dimethoxybenzyl)-7-methyl- [l,2,4]triazolo[l,5-c]quinazolin-5-amine (20 mg, 0.050 mmol) and 6,7-dihydro-5H-pyrrolo[3,4- b]pyridine (19.41 mg, 0.101 mmol) in 1 mL of DMF, was added diisopropylethylamine (26.0 mg, 0.201 mmol). The reaction was stirred at 80°C overnight. It was purified by a Gilson HPLC (eluant: H20 : C¾CN) to give the title compound. Ή NMR (400 MHz, CDC13) δ 8.48 (d, 1H), 7.99 (d, 1H), 7.67 (d, 1H), 7.52 (d, 1H), 7.39 (d, 1H), 7.20-7.24 (m, 2H), 6.58-6.69 (brs, 1H), 6.40-6.47 (m, 2H), 4.94 (s, 4H), 4.72-4.78 (m, 4H), 3.87 (s, 3H), 3.76 (s, 3H), 2.66 (s, 3H).
Step F: 2-((5H-pYrrolor3,4-blpyridine-6(7H)-vnmethylV7-methyl- rL2,41triazolori,5-c1quinazolin-5-amine (Ex-200)
A solution of 2-((5H-pyrrolo[3,4-b]pyridine-6(7H)-yl)methyl)-N-(2,4- dimethoxybenzyl)-7-methyl-[l ,2,4]triazolo[l,5-c]quinazolin-5-amine (32 mg, 0.066 mmol) in 1 mL of TFA was stirred at 45°C for 5 h in a sealed vial. The solvent was removed under vacuum. To the residue was added 0.5 mL of MeOH. To the mixture was added 15 mL of Et20/hexanes (1 : 1). The solid was collected by filtration to give crude product. This was further purified by a Gilson HPLC (eluant: H20 : CH3CN) to give the title compound. HPLC-MS tR = 1.82 min (UV 25½m). Molecular weight calculated for formula Ci8Hi7N7: 331.2; observed MH+ (LCMS) 332.2.
Compound Ex-201 shown in Table XIX was prepared from Intermediate 14 and an appropriate "left-side" precursor in accordance with Scheme lOe.
Table XIX
Figure imgf000099_0001
EXAMPLE 11: 2-((5 ,6-dihydro- 1 ,7-naphthyridin-7(8H)-yl)methyl)-7-(2-fiuoroethoxy)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine (Ex-202)
Compound Ex-202 was prepared from the previously exemplified compound Ex- 135 (see above).
SCHEME 11
Figure imgf000100_0001
Step A: 5 -amino-2-((5.6-dihydro- 1 ,7-naphthyridin-7(8H)-yl)methyl)- [l,2,41triazolo[l,5-clquinazolin-7-ol
To a suspension of compound Ex-135 (2-((5, 6-dihydro- l,7-naphthyridin-7(8H)- yl)methyl)-7-methoxy-[l,2,4]triazolo[l,5-c]quinazolin-5-amine, prepared above, 350 mg, 0.968 mmol) in DCE (4 ml) was added BBr3 (4.84 ml, 9.68 mmol). The reaction mixture was stirred in a sealed tube at 90°C for 18 h. The mixture was cooled down and concentrated in vacuo to yield the corresponding 7-alcohol. LC/MS = 348 [M+l].
Step B : 2-((5 ,6-dihydro- 1 -naphthyridin-7(8H)-yl)methyl -7-(2-fluoroethoxy)-
[l,2,41triazolo[l,5-clquinazolin-5-amine
To a solution of 5 -amino-2-((5 ,6-dihydro- 1, 7-naphthyridin-7(8H)-yl)methyl)- [l,2,4]triazolo[l,5-c]quinazolin-7-ol (the 7-alcohol prepared in Step A, 30 mg, 0.086 mmol) in DMF (2 ml) was added Cs2C03 (84 mg, 0.259 mmol) and 2-fluoroethyl tosylate (22.62 mg, 0.104 mmol). Reaction mixture was stirred at room temperature for 18 h, diluted with DCM.
The organic layer was washed with H20, dried over MgS04, filtered and concentrated in vacuo.
Purification by Preparative TLC (DCM : MeOH (7N N¾) 1 :20) to yield compound. Ex-202 LC/MS = 394 [M+l]. HPLC Retention time 1.53 min.
Additional compounds of the invention were prepared in accordance with Scheme 11 from the corresponding 7-methoxy compound and are presented in Table XX.
Table XX
Compound Structure LC-MS Retention
No. Time
(min)
Figure imgf000101_0001
EXAMPLE 12: Preparation of compounds of the invention with alkyl-substituted linker
SCHEME 12
Figure imgf000101_0002
Figure imgf000102_0001
Step 1 : (±)-3-hvdroxybutanehydrazide
To a stirred solution of methyl (±)-3-hydroxybutyrate (13.21 ml, 1 19 mmol) in methanol (74.1 ml) was added hydrazine hydrate (21.60 ml, 356 mmol) at room temperature. The reaction mixture was heated to 70°C for 16 h and then cooled down, MeOH and excess of hydrazine were evaporated in 80°C water bath. The crude material was cooled down to -20°C and added EtOH and stirred for 5min. The white solid was filtered and washed with cold EtOH and dried under high vac for 16 h to afford the title compound which was characterized by H
NMR.
Step 2: (±)-N,-(2-chloro-8-methoxyquinazolin-4-yl)-3-hvdroxybutanehvdrazide To a stirred suspension of 2,4-dichloro-8-methoxyquinazoline (25g, 109 mmol) in
1,4-dioxane (404 ml) was added DIPEA (42.9 ml, 246 mmol) and (±)-3-hydroxybutane- hydrazide (14.18 g, 120 mmol) at room temperature. The reaction mixture was heated to 60°C for 16 h. After cooling, the reaction mixture was used for the next step without aqueous workup and purification. LC/MS = 31 1 [M+l].
Step 3: (±)-N'-(2-((2,4-dimethoxybenzyl)amino)-8-methoxyquinazolin-4-yl)-3- hydroxybutanehydrazide
To a reaction mixture vessel of step B (33.9 g, 109 mmol) was added DIPEA (32.4 ml, 185 mmol) and (2,4-dimethoxyphenyl)methanamine (24.58 ml, 164 mmol) at room temperature. The reaction mixture was heated to 100°C for 16 h. cooled to room temperature, and the solvent was evaporated. The crude product was used for the next step without aqueous work-up and any further purification. LC/MS = 442 [M+l].
Step 4: (±)-l-(5-((2,4-dimethoxYbenzyl)amino)-7-methoxy-ri,2,41triazolori,5- clquinazolin-2-yl)propan-2-ol
To a pressure tube of the reaction mixture of step C (48.2 g, 109 mmol) was added (E)-trimethylsilyl N-(trimethylsilyl)acetimidate (BSTA, 320 ml, 1310 mmol) at room temperature. The pressure tube was capped and heated to 120°C for 16 h. After cooling, the reaction mixture was concentrated in vacuo with heating. The residue was dissolved in MeOH (500 ml) and added 4N HC1 in dioxane (40.9 ml, 164 mmol) at 0°C.
The reaction mixture was stirred at RT for 40min and cold aq. saturated NaHC03 (1L) was added. White precipitates were generated, filtered, washed with water. The wet white solid was redissolved in 10% MeOH/DCM (2L). The organic layer was dried over MgSO/i, filtered and concentrated to afford the title compound which was characterized hy using LC/MS = 424 [M+l ] and H NMR.
Step 5 : (±)- 1 -(5-((2,4-dimethoxybenzyl)amino)-7-methoxy-r 1 ,2,41triazok>ri ,5- c1quinazolin-2-yl)propan-2-yl 4-methylbenzenesulfonate
To a stirred suspension of (±)-l-(5-((2,4-dimethoxybenzyl)amino)-7-methoxy-
[l ,2,4]triazolo[l ,5-c]quinazolin-2-yl)propan-2-ol (47.7 g, 1 13 mmol) in DCM (1 126 ml) was added DMAP (20.64 g, 169 mmol), triethylamine (39.3 ml, 282 mmol) at room temperature. The reaction mixture was cooled down to 0°C and then p-toluenesulfonyl chloride (32.2 g, 169 mmol) was added slowly. The reaction mixture was stirred at room temperature for 6 h. The reaction mixture was diluted with DCM. The organic layer was washed with IN HCl (aq, 2L), water (1L), sat. NaHC03 (1L) and brine solution (1L), dried over MgS04, filtered and concentrated. The crude product was purified by flash chromatography (EtOAc:Hexanes 5 : 1) to afford the title compound which was characterized using, LC/MS = 578 [M+l].
Step 6 : (±)-! -( 5 -amino-7-methoxy-r 1.2.41triazolo [ 1.5-c1quinazolin-2-yl)propan- 2-yl 4-methylbenzenesulfonate
To a (±)-l-(5-((2,4-dimethoxybenzyl)amino)-7-methoxy-[l ,2,4]triazolo[ 1 ,5- c]quinazolin-2-yl)propan-2-yl 4-methylbenzenesulfonate (57 g, 99 mmol) was added TFA (658 ml) at room temperature. The reaction mixture was heated to 55°C for 4 h and cooled down to room temperature. TFA was evaporated and aq. saturated NaHC03 was added. The purple precipitates were generated and diluted with 10%MeOH/DCM. The heterogeneous mixture was stirred at for 4 h and filtered insoluble purple solid. The organic layer was dried over MgSC , filtered and concentrated. The crude product was purified by flash chromatography (from
EtOAc:Hexanes 1 : 1 to 10% MeOH/DCM) to afford the title compound which was characterized using, LC/MS = 428 [M+l ] .
Step 7: (±)-7-methoxy-2-(2-(2-methyl-6J-dihvdrooxazolo[4,5-clpyridin-5(4H)- yl)propyl)-[ l ,2,41triazolo[l,5-c1quinazolin-5-amine (Ex-210) Γ
To (±)- 1 -(5-amino-7-methoxy-[ 1 ,2,4]triazolo[ 1 ,5-c]quinazolin-2-yl)propan-2-yl 4-methylbenzenesulfonate (200 mg, 0.468 mmol) in 1 ,4-dioxane (3200 μΐ,) was added DIPEA (163 ί, 0.936 mmol), and 2-methyl-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridine (129 mg, 0.936 mmol) at room temperature. The reaction mixture was stirred at 100°C for 16 h. After cooling, the solvent was evaporated and the crude product was purified by flash chromatography (from EtOAc:Hexanes 1 : 1 to 10% MeOH/DCM) to afford the compound Ex-210 which was characterized using, LC/MS = 394 [M+l ] and H NMR.
The compounds shown in Table XXI were prepared by using methods described in Examples 12. Enantiomeric forms were obtained from the racemate by separation through chiral HPLC.
Table XXI
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
EXAMPLE 13: Preparation of 2-(3-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)propyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine (EX-227)
Figure imgf000107_0002
Step A: Preparation of 2-(3-chloropropyl)-7-methoxy-[l,2,4]triazolo[l ,5- clquinazolin-5-amine (Intermediate- 15)
Into SOCI2 (25 ml) was suspended 3-(5-amino-7-methoxy-[l,2,4]triazolo[l,5- c]quinazolin-2-yl)propan-l-ol (240 mg, 0.878 mmol). The mixture was stirred at RT for 1 h and concentrated in vacuo to remove SOCI2 completely providing to afford compound
Intermediate-15, LC/MS = 293 [M+1].
Step B: Preparation of 2-(3-r5H-pyrrolo[3.4-b]pyridin-6(7H)-yl)propyl)-7- methoxy-[l,2,41triazolori ,5-c1quinazolin-5-amine (Ex-227)
2-(3-chloropropyl)-7-methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine (80 mg,
0.286 mmol), 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine (75 mg, 0.86 mmol), and KI (142 mg, 0.858 mmol) in DMF (2 mL) was stirred at 80°C for 18 h. The mixture was cooled down to RT, diluted with DCM, washed with H2O (3X), dried and concentrated. Chromatography purification MeOH/DCM (1 :30-1 :20-l :10) afforded compound Ex-227. LC/MS = 379 [M+1].
Additional compounds of the invention, presented in Table XXII, below, were prepared using Intermediate-15 and an appropriate left-side intermediate.
Figure imgf000108_0001
EXAMPLE 14: Preparation of 7-Methoxy-2-(2-(2,7,7-trimethyl-6,7-dihydro-oxazolo[5,4- c]pyridm-5(4H)-yl)ethyl)-[l,2,4]triazolo[ l ,5-c]quinazolin-5-amine, TFA (Ex-235)
SCHEME 14
Figure imgf000109_0001
Ex-235
Step A: Benzyl 3.3-dimethyl-4-oxopiperidine-l-carboxylate
Benzyl 4-oxopiperidine-l-carboxylate (5g, 21 mmol) in THF (50 ml) was cooled to 0°C. Sodium hydride (1.1 g, 43 mmol), then iodomethane (3.0 ml, 47 mmol) was added slowly. Mixture was stirred at 0°C for 2 hours, then slowly warm up to room temperature and stirred overnight. Saturated aq. NH4C1 solution was added and the product was extracted with EtOAc. The extract was washed with brine, dried over anhydrous sodium sulfate, and concentrated. The crude product thus obtained was purified by column chromatography on a 100 gram-size silica gel column, eluting with gradient EtOAc/hexane to afford the titled product as colorless oil.
Step B: Benzyl 5-bromo-3.3-dimethyl-4-oxopiperidine-l-carboxylate Benzyl 3,3-dimethyl-4-oxopiperidine-l-carboxylate (0.7 g, 2.7 mmol) in DCM (10 ml) was mixed with phenyltrimethylammonium tribromide (1.1 g, 3.0 mmol) and stirred at room temperature for 4 hours. Mixture was diluted with DCM, and washed with water and dried over anhydrous sodium sulfate. The crude mixture was concentrated, diethyl ether added, and the resulting precipitate filtered off. The solution was concentrated to afford the titled compound, and used in the next step without further purification.
Step C: Benzyl 2.7,7-trimethyl-6.7-dihvdrooxazolor5,4-clpyridine-5(4H)- carboxylate
Benzyl 5-bromo-3, 3-dimethyl-4-oxopiperidine-l-carboxylate (0.85 g, 2.5 mmol) from step B was mixed with acetamide (0.74 g, 12.5 mmol), and heated to 120°C and stirred for an additional 1.5 hours. After cooling to room temperature, mixture was diluted with DCM, washed with water, dried over anhydrous sodium sulfate, and the solution was concentrated. The concentrate was purified by silica gel flash chromatography, elutmg with gradient (1 :2 ether/DCM - hexane). UV wavelength for collection was set to 210 nm. The titled product was obtained as colorless oil.
Step D: 2.7.7-Trimethyl-4.5,6.7-tetrahvdrooxazolo[5.4-clpyridine
Benzyl 2,7,7-trimethyl-6,7-dihydrooxazolo[5,4-c]pyridine-5(4H)-carboxylate (0.17 g, 0.57 mmol) in MeOH (8 ml) was mixed with 10% palladium on carbon (0.050 g) and stirred under balloon hydrogen for 2 hours. The mixture was filtered, and solution was concentrated to give the titled product as oil.
Step E: 7-Methoxy-2-(2-(2,7,7-trimethyl-6,7-dihvdrooxazolor5.4-c1pyridin- 5(4H)-vnethyl)-ri,2,41triazolori,5-clquinazolin-5-amine. TFA
2-(2-Chloroethyl)-7-methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine (0.12 g, 0.43 mmol) was mixed with 2,7,7-trimethyl-4,5,6,7-tetrahydrooxazolo[5,4-c]pyridine (0.072 g, 0.43 mmol), KI (0.22 g, 1.3 mmol), and Hunig's base (0.075 ml, 0.43 mmol) in DMF (1.5 ml), then heated to 80°C for 15 hours. The mixture was diluted with DMF, and filtered. The solution was purified by preparative reverse phase HPLC (C-18), eluting with acetonitrile/water + 0.1% TFA, to afford Ex-235 which was characterized by LC/MS. LC/MS = 408 [M+l].
Scheme 14a illustrates a variation on the preparation shown in Scheme 14.
SCHEME 14a
Figure imgf000110_0001
Step A: 3.3-Dimethyl-l-tosylpiperidin-4-one
3,3-Dimethylpiperidin-4-one hydrochloride (4 g, 24.4 mmol) in DCM (50 ml) under an atmosphere of nitrogen was stirred and cooled to 0°C. Tosyl chloride (4.7 g, 24.4 mmol), DMAP (3.0 g, 24.4 mmol) and TEA (6.82 ml, 49 mmol) were added. The reaction mixture was stirred at 0°C for 2 hours, and then with continued stirring, warmed to room temperature overnight. Water was added to the reaction mixture (100 ml). The product was extracted into CH2CI2 (3 x 50 ml). The organic layer was washed with brine (50 ml), dried over anhydrous sodium sulfate, and concentrated to afford the titled product that was used in the next step without further purification
Step B: 5-Bromo-3. 3 -dimethyl- l-tosylpiperidin-4-one
To a stirred solution of 3, 3 -dimethyl- l-tosylpiperidin-4-one (4.4 g, 16.0 mmol) in THF (32 ml) at room temperature, under an atmosphere of nitrogen, was added
tetrabutylammonium tribromide (8.3 g, 17.2 mmol) and the mixture was stirred overnight. The reaction mixture was diluted with ethyl acetate (100 ml) and washed with 1 N HC1 (47 ml), water (50 ml), and brine (50 ml), then dried over anhydrous sodium sulfate, and concentrated. The crude was chromatographed on silica, eluting with hexane/ethyl acetate (0 - 100%, 30 min) to give the titled product as a white solid.
Step C: 2.7.7-Trimethyl-5-tosyl-4.5.6.7-tetrahydrothiazolor5.4-clpyridine
To a stirred solution of 5-bromo-3, 3 -dimethyl- l-tosylpiperidin-4-one (2.5 g, 7.0 mmol) in DMF (15 ml) under an atmosphere of nitrogen was added thioacetamide (0.63 g, 8.3 mmol). The mixture was stirred at 70°C for 2 hours. The reaction mixture was cooled to room temperature, diluted with ethyl acetate (100 ml), washed with water (50 ml), brine (50 ml), then dried over anhydrous sodium sulfate. The solvent was evaporated, and the crude was chromatographed on silica, eluting with hexane/ethyl acetate (0 - 100 %, 25 minute) to afford the titled product as a white solid.
Step D: 2,7,7-Trimethyl-4,5,6,7-tetrahvdrothiazolor5,4-clpyridine Into a round bottle flask containing 2,7,7-trimethyl-5-tosyl-4,5,6,7- tetrahydrothiazolo[5,4-c]pyridine (1.42 g, 4.22 mmol) was added HBr (25 ml, 244 mmol), and phenol (0.4 g, 4.22 mmol). The reaction was stirred at 90 °C for 1 hour and then cooled to room temperature. The reaction mixture was diluted with water (30 ml) and extracted with diethyl ether ( 2 x 50 ml). The aqueous layer was made basic (pH = 14) with sodium hydroxide and the product was extracted into CH2Cl2/MeOH(10%) (3 x 100 ml)). After drying over anhydrous sodium sulfate, and the solvent was evaporated to afford the titled product that was used in the next step without further purification.
Step E: Preparation of 7-Methoxy-2-(2-(2.7.7-trimethyl-6.7-dihvdrothiazolor5.4- clpyridin-5(4H)-yl)ethvn-ri,2,41triazolo[1.5-c1quinazolin-5-amine (Ex- 240) Into a stirred solution of 2-(5-amino-7-methoxy-[ l ,2,4]triazolo[l ,5-c]quinazolin- 2-yl)ethyl methanesulfonate (1.39 g, 4.1 mmol) in dioxane/water (4: 1, 20 ml) was added 2,7,7- trimethyl-4,5,6,7-tetrahydrothiazo [5,4-c]pyridine (0.50 g, 2.7 mmol), KI (0.46 g, 2.7 mmol), and Hunig's base (0.50 ml, 2.7 mmol). The reaction mixture was stirred at 70°C for 15 hours. The reaction mixture was loaded on to a 100 gram C18-reverse phase Biotage column eluting with water/acetonitrile + 0.1%TFA (0-30%, 30 min). The product was collected and acetonitrile was evaporated. The water layer was extracted with ethyl acetate (3 x 30 ml), and the ethyl acetate layer was washed with saturated NaHC03 (50ml), water (50ml), and brine (50ml). After drying over MgSO/i, the mixture was filtered and the solvent was evaporated to afford Ex-240 as a white solid, which was characterized by LC/MS. LC/MS = 424 [M+l].
EXAMPLE 15: Preparation of 2-(2-(2,4-dimethyl-6,7-dihydrooxazolo[5,4-c]pyridin-5(4H)- yl)ethyl)-7-methoxy-[l,2,4]triazolo[l ,5-c]qumazolin-5-amine (Ex-236) and Preparation of 2-(2- (2,6-dimethyl-6,7-dihydrooxazolo[5,4-c]pyridin-5(4H)-yl)ethyl)-7-methoxy-[l ,2,4]triazolo[l ,5- c]quinazolin-5-amine (Ex-237)
SCHEME 15
Figure imgf000112_0001
Figure imgf000113_0001
Step A: 2-Methylpiperidin-4-one hydrochloride
To a round bottle flask containing tert-butyl-2-methyl-4-oxopiperidine-l- carboxylate (5 g, 23 mmol) under an atmosphere of nitrogen at 0°C was added hydrochloric acid in diethyl ether (24 ml, 47 mmol). The reaction mixture was stirred at 0°C for 2 hours, and then slowly stirred to room temperature overnight. The solvent was evaporated to afford a white solid as the titled product, which was further dried on high vacuum for 3 hours, before using in the next step.
Step B: 2-Methyl-l-tosylpiperidin-4-one
2-Methylpiperidin-4-one hydrochloride (3.51 g, 23 mmol) in DCM (50 ml) under an atmosphere of nitrogen was stirred and cooled to 0°C. Tosyl chloride (5 g, 26 mmol), and TEA (11 ml, 77 mmol) were added. The reaction mixture was stirred at 0°C for 2 hours, then with continued stirring, warmed to room temperature overnight. 1 N HCl (94 ml) was added to the reaction mixture. The product was extracted into CH2CI2 (3 x 50 ml). The organic layer was washed with brine (50 ml), dried over anhydrous sodium sulfate, and concentrated. The crude was chromatographed on silica, eluting with hexane/ethyl acetate (0 - 100%) to afford the titled product.
Step C: 3-Bromo-2-methyl-l-tosylpiperidin-4-one and 5-bromo-2-methyl-l- tosylpiperidin-4-one
To a stirred solution of 2-methyl-l-tosylpiperidin-4-one (6.0 g, 23.0 mmol) in
THF (32 ml) at room temperature, under an atmosphere of nitrogen, was added
tetrabutylammonium tribromide (10.0 g, 23. mmol) and the mixture was stirred ovemight. The reaction mixture was diluted with ethyl acetate (100 ml) and washed with 1 N HCl (47 ml), water (50 ml), and brine (50 ml), dried over anhydrous sodium sulfate, and concentrated. The titled products were obtained as a mixture of regioisomers that were used in the next step without purification. Step D: 2.4.Dimethyl-5-tosyl-4.5,6.7-tetrahvdrooxazolo[5,4-clpyridme and 2.6.dimethYl-5-tosyl-4.5.6.7-tetrahvdrooxazolor5.4-clpyridine
To a round bottom flask containing compounds 3-bromo-2 -methyl- 1- tosylpiperidin-4-one and 5 -bromo-2 -methyl- 1 -tosylpiperidin-4-one (3.2 g, 9.2 mmol) was added acetamide (2.73 g, 46.2 mmol) and the mixture was stirred to 120°C for 2 hours. The reaction mixture was cooled to room temperature and diluted with ethyl acetate (100 ml), then washed with water (50 ml), and brine (50 ml). After drying over anhydrous sodium sulfate, the solvent was evaporated. The crude was chromatographed on silica, eluting with hexane/ethyl acetate (0 - 50 %) to afford the titled products as a white solid.
Step E: 2.4-Dimethyl-4,5.6.7-tetrahvdrooxazolor5.4-clpyridine and 2.6- dimethyl-4,5.6,7-tetrahvdrooxazolor5,4-clrjyridine
To a round bottom flask containing compounds 2,4,dimethyl-5-tosyl-4,5,6,7- tetrahydrooxazolo[5,4-c]pyridine and 2,6,dimethyl-5-tosyl-4,5,6,7-tetrahydrooxazolo[5,4- c]pyridine (0.60 g, 2.0 mmol) was added HBr (11.5 ml, 102 mmol), and phenol (0.2 g, 2.0 mmol). The reaction mixture was stirred at 90°C for 1 hour and then cooled to room temperature. The reaction mixture was diluted with water (30 ml) and extracted with diethyl ether (2 x 50 ml). The aqueous layer was made basic (pH = 14) with sodium hydroxide and the product was extracted into CH2Cl2/MeOH(10%) (3 x 100 ml)). After drying over anhydrous sodium sulfate, and filtered, the solvent was evaporated to afford the titled products, which were used in the next step without further purification.
Step F: Preparation of 2-(2-(2,4-dimethyl-6,7-dihvdrooxazolor5.4-clpyridin- 5(4H)- yl)ethyl)-7-methoxy-ri.2.41triazolo[l ,5-clquinazolin-5-amine (Ex-236) and Preparation of 2-(2-(2.6-dimethyl-6.7-dihydrooxazolor5.4-c1pyridin-5(4H)-yl)ethyl)-7- methoxy- ri,2,41triazolori,5-c1quinazolin-5-amine (Ex-237)
To a stirred solution of 2-(5-amino-7-methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-2- yl)ethyl methanesulfonate (0.435 g, 1.05 mmol) in dioxane/water (4: 1 , 15 ml) was added a mixture of 2,4-dimethyl-4,5,6,7-tetrahydrooxazolo[5,4-c]pyridine and 2,6-dimethyl-4 ,5,6,7- tetrahydrooxazolo[5,4-c]pyridine (0.16 g, 1.05 mmol), KI (0.175 g, 1.05 mmol), and Hunig's base (0.2 ml, 2.10 mmol). The reaction mixture was stirred at 70°C for 15 hours. The reaction mixture was loaded on to a 100 grams C18-reverse phase Biotage column eluting with water/acetonitrile + 0.1%TFA (0-30%, 30 min) to afford the product mixture. The enantiomeric forms of titled products Ex-236 and Ex-237 were separated through chiral HPLC using an AD-H column, which were characterized by LC/MS. LC/MS = 394 [M+l]. EXAMPLE 16: Preparation of 7-methoxy-2-(2-(2-methyl-4H-pyrrolo[3,4-d]thiazol-5(6H)- yl)ethyl)-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine (Ex- 14)
Figure imgf000115_0001
(Step A) 2-methyl-5-tosyl-4,5,6,6a-tetrahydro-3aH-pyrrolor3,4-d1thiazol-3a-ol To a stirred solution of 4-bromo-l-tosylpyrrolidin-3-one (lg, 3.14 mmol) in DMF
(12.57 ml) was added ethanethioamide (0.236 g, 3.14 mmol) at RT. The reaction mixture was heated to 60°C for 2hrs.
After being cooled down to room temperature, sat. NaHC03 (aq) was added. The aqueous layer was extracted with EtOAc (250mL). The organic layer was washed with sat. NaHCC (aq) and brine, dried over MgS0 , filtered and then concentrated. The crude bright brown solid was used for the next step without further purification.
(Step B) 2-methyl-5-tosyl-5.6-dihvdro-4H-pyrrolo[3.4-dlthiazole To a stirred solution of 2-methyl-5-tosyl-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4- d]thiazol-3a-ol (982 mg, 3.14 mmol) in CH2C12 (13 mL) was added triethylamine (4381 μΐ, 31.4 mmol) and drop wise Ms-Cl (490 μΐ, 6.29 mmol) at 0°C. The reaction mixture was stirred at 0 °C for 30min and warmed to RT. After stirring at RT for lhr, the reaction mixture was diluted with DCM and water was added. The organic layer was washed with water and brine solution, dried over MgSC>4, filtered and concentrated. The crude product was purified by silica-gel column chromatography (24g, 10% EtOAc/DCM) to provide the desired product.
(Step C) 2-methyl-5.6-dihvdro-4H-t)yrrolor3.4-dlthiazole
To a stirred solution of 2-methyl-5-tosyl-5,6-dihydro-4H-pyrrolo[3,4-d]thiazole (835 mg, 2.84 mmol) in HBr (17 mL, 148 mmol) in water (48%) was added Phenol (267 mg, 2.84 mmol) at room temperature. The reaction mixture was refiuxed at 90 °C for 1.2hrs. After cooled down to room temp, 16 mL water was added and extracted with Et20 (40mL x2). The organic layer was dried over MgSO< , filtered and concentrated. The aqueous layer was basified by solid NaOH and extracted with DCM. The DCM layer was dried over MgS04, filtered and concentrated to afford the desired product (oil). The crude oil was used for the next step without further purification.
( Step D) 7-methoxy-2-(2-f 2-methyl-4H-pyrrolor3.4-dlthiazol-5('6H -Ynethyl')- ri ,2,41triazolori ,5-c1quinazolin-5-amine
To a stirred suspension of 2-(5-amino-7-methoxy-[l,2,4]triazolo[l ,5- c]quinazolin-2-yl)ethyl methanesulfonate (9) (500mg, 1.48 mmol) in Dioxane (9.5 mL) and water (2.5mL) was added 2-methyl-5,6-dihydro-4H-pyrrolo[3,4-d]thiazole (393 mg, 2.223 mmol), KI (246 mg, 1.482 mmol) and DIPEA (0.518 mL, 2.96 mmol). The reaction mixture was capped and stirred at 70°C ovemight. After being cooled down to room temperature, sat. aq. NH4C1 was added to reaction mixture and extracted with DCM. The organic layer was dried over MgSC , filtered and concentrated. The crude product was purified by flash silica gel column chromatography (10% MeOH/DCM) to provide the desired product.
Additional compounds of the invention, presented in Table XXIII, below, were prepared using methods described in Scheme 16 using the appropriate amide in Step A.
Figure imgf000116_0001
EXAMPLE 17: Preparation of 7-methoxy-2-(2-(2-methyl-4H-pyrrolo[3,4-d]oxazol-5(6H)- yl)ethyl)-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine (Ex-244)
SCHEME 17
Figure imgf000117_0001
(Step A) tert-butyl 3-acetamido-4-hvdroxypyrrolidine-l-carboxylate To a stirred solution of tert-butyl 3-amino-4-hydroxypyrrolidine-l-carboxylate (5.6 g, 27.7 mmol) in DCM (277 ml) was added TEA (3.86 ml, 27.7 mmol) and acetyl chloride (1.969 ml, 27.7 mmol) drop wise at -20°C. The reaction mixture was stirred at -20°C for 1.5hr. The reaction was quenched by addition of 20mL of MeOH. The reaction mixture was stirred vigorously for lOmin. Sat. NaHC(¾ (aq, 400mL) was added and extracted with 10%
MeOH/DCM (x3) and organic layer was dried over MgSC>4, filtered and concentrated to give tert-butyl 3-acetamido-4-hydroxypyrrolidine-l-carboxylate. The crude product was used for the next step without further purification.
(Step B) tert-butyl 3-acetamido-4-oxopyrrolidine-l-carboxylate
To a stirred solution of 3-acetamido-4-hydroxypyrrolidine-l-carboxylate (4.5 g, 18.42 mmol) in DCM (184 ml) was added Dess-Martin Periodinane (11.72 g, 27.6 mmol) at RT. The reaction mixture was stirred at RT overnight. The reaction mixture was diluted with DCM and washed with sat. aq. Sodium thiosulfate (x2), and aq. NaHC03 (x2) and brine. The organic layer was dried over MgSC , filtered and concentrated. The crude product was purified by silica gel flash column chromatography (100%DCM to 50%EtOAc/DCM) to provide tert-butyl 3- acetamido-4-oxopyrrolidine- 1 -carboxylate.
(Step C) tert-butyl 2-methyl-4H-pyrrolor3,4-dloxazole-5(6H)-carboxylate
To a stirred solution of hexachloroethane (2.57 ml, 22.70 mmol) and triphenylphosphine (7.15 g, 27.2 mmol) in DCM (lOOmL) was added triethylamine (10.13 ml, 72.6 mmol) at room temperature. A solution of tert-butyl 3-acetamido-4-oxopyrrolidine-l- carboxylate (2.2 g, 9.08 mmol) in DCM (80mL) was added drop wise. The reaction mixture was stirred at room temperature for 2days. Sat. aq. NaHCC was added. The reaction mixture was extracted with DCM. The organic layer was dried over MgS04, filtered and concentrated. The crude product was purified by silica-gel flash column chromatography (40g, 100% Hex to 1/1 EtOAc/Hex to 100%EtOAc) to provide tert-butyl 2-methyl-4H-pyrrolo[3,4-d]oxazole-5(6H)- carboxylate.
(Step D) 2-methyl-5.6-dihvdro-4H-nyrrolo[3,,4-d1oxazole
To a round bottom flask of tert-butyl 2-methyl-4H-pyrrolo[3,4-d]oxazole-5(6H)- carboxylate (675 mg, 3.0 mmol) was added 4N HC1 (13 mL, 45 mmol) in dioxane at room temperature. The reaction mixture was stirred at room temperature overnight. The solvent was evaporated and the crude product was used for the next step without further purification.
(Step E) 7-methoxy-2-(2-(2-methyl-4H-pyrrolor3,4-dloxazol-5(6H)-yl)ethyl - ri,2,41triazolori,5-c1quinazolin-5-amine
To a stirred suspension of 2-(5-amino-7-methoxy-[l,2,4]triazolo[l ,5- c]quinazolin-2-yl)ethyl 4-methylbenzenesulfonate (450mg, 1.1 mm), which can be prepared using a synthesis scheme similar to Scheme 1 , in dioxane (7mL) and water (0.8mL) was added DIPEA (0.57 mL, 3.8 mmol) and 2-methyl-5,6-dihydro-4H-pyrrolo[3,4-d]oxazole (262mg, 1.6 mmol) at room temperature. The reaction mixture was capped and heated to 75°C overnight. After being cooled down to room temperature, the reaction mixture was diluted with DCM and washed with aq. saturated NaHC03. The organic layer was dried over MgS04, filtered and concentrated. The crude product was purified by silica-gel flash column chromatography (40g, 10%MeOH/DCM) to provide 7-methoxy-2-(2-(2-methyl-4H-pyrrolo[3,4-d]oxazol-5(6H)- yl)ethyl)-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine (Ex-244), which was characterized by LC-MS = 366 [M+1].
Additional compounds of the invention, presented in Table XXIV, below, were prepared using similar methods to that described in Scheme 17.
Table XXIV
Compound Structure LC-MS No.
NH2
Ex-245 392
[M+1]
2-(2-(2-cyclopropyl-4H-pyrrolo[3,4-d]oxazol-5(6H)-yl)ethyl)-7- methoxy-[ 1 ,2,4]triazolo [ 1 ,5 -clquinazolin-5 -amine A2a Activity of Compounds of the Invention
Binding affinities of compounds of the invention for the human A2a receptor were determined in a competition binding assay using Scintillation Proximity technology. Thus, 0.3 μg of membranes from HEK293 cells expressing the human A2a receptor were incubated with a compound of the invention at concentrations ranging from 3000 nM to 0.15 nM in a reaction mixture containing also 0.5 nM of a tritiated form of 5-amino-7-[2-phenethyl]-2-(furan- 2-yl)-7H-pyrazolo[4,3-e][l,2,4]triazolo[l,5-c]pyrimidine (the tritiated compound) and 100 μg of wheat germ agglutin-coated yttrium silicate SPA beads for one hour at room temperature with agitation. The beads were then allowed to settle to the bottom of the wells for 1 hr, after which the membrane-associated radioactivity was determined by scintillation counting in a TopCount microplate reader. Ki values were determined using the Cheng-Prusoff equation.
Summary of materials and methods used in A2a activity determination:
Materials
HEK293 cells expressing the human, rat, dog or monkey adenosine 2a receptor (Purchased from Perkin-Elmer # RBHA2AM400UA).
The Tritiated compound was prepared in-house by MRL Radiochemistry according to published methods.
Wheat germ agglutinin-coated yttrium silicate SPA beads (GE Healthcare
#PvPNQ0023). Dilute to 25 mg/ml in assay buffer.
Assay Buffer was prepared in house: Dulbecco's calcium and magnesium free phosphate buffered saline + 10 mM MgCl2
Adenosine deaminase from calf intestine, 10 mg/2 ml (Roche # 10 102 105 001). DMSO
A2a antagonist standard (9-chloro-l-(2-furanyl)-[l ,2,4]triazolol,5-c]quinazolin-5- amine from Tocris Bioscience)
Compound Dilution
Make eight 1 :3 serial dilutions in 100% DMSO from a 3 mM compound stock Transfer 50 nl of compound into a 384-well OptiPlate (Perkin Elmer).
Typically, final concentrations of compound used in the assay ranged from 3000 nM to 0.152 nM.
Radioisotope
Dilute a solution of the Tritiated compound to 1.25 nM in assay buffer. This is a 2.5X solution. The final concentration in the assay is 0.5 nM. Calculate the concentration by counting two 5 μΐ aliquots.
Membrane Preparation Use 0.25 ug of membrane/well. Dilute membranes to 9.7 μ^ητΐ in assay buffer. Treat with 20 ug/ml adenosine deaminase (ADA) for 15 minutes at room temperature to degrade endogenous adenosine.
Membrane-Bead Mixture
Use 100
Figure imgf000120_0001
wheat germ agglutinin-coated yttrium silicate SPA beads.
Mix ADA-treated membranes and SPA beads together for 30 min prior to assay.
Assay Assembly
To the Perkin-Elmer Optiplate-384 containing the compound titration add 20 μΐ of 2.5X solution of the Tritiated compound and 30 μΐ of the membrane-bead mixture. Incubate for one hour at room temperature with agitation.
Include total binding (assay buffer + 1% DMSO) and non-specific binding (CGS 15943, 1 μΜ) wells.
Counting
Allow the beads to settle for one hour.
Count in TopCount.
Calculations
A curve fitting program (i.e., Prism, Activity Base, Chemcart) is used to determine the EC50. The Ki value is calculated using the Cheng-Prusoff equation.
K i = EC50 / (1+ (radioligand concentration / Kd))
Using the foregoing assay method, the following results were obtained using various of the compounds of the invention described herein. Each example compound tested is reported in the following format: Example number: A2a EC50 reported in nM. Thus, for example, the compound Ex-1 was determined to have an EC50 using the above-described assay, of 4.0 nM, and is accordingly reported as "Ex-1 : A2a= 4.0":
Ex-1: A2a = 4.0; Ex-2: A2a = 2.9; Ex-3: A2a = 3.4; Ex-4: A2a = 4.6; Ex-5: A2a
= 4.7; Ex-6: A2a = 5.9; Ex-7: A2a = 1.4; Ex-8: A2a = 2.2; Ex-9: A2a = 2.1; Ex-10: A2a = 1.2;
Ex-11: A2a = 2.7; Ex- 12: A2a = 2.0; Ex-13: A2a = 2.2; Ex-14: A2a = 1.5; Ex-15: A2a = 2.2;
Ex-16: A2a = 2.3; Ex-17: A2a = 9.6; Ex-18: A2a = 13.3; Ex-19: A2a = 7.6; Ex-20: A2a = 12.8;
Ex-21: A2a = 31.2; Ex-22: A2a = 6.7; Ex-23: A2a = 4.4; Ex-23: A2a = 6.6; Ex-24: A2a = 11.1; Ex-25: A2a = 0.9; Ex-26: A2a = 0.5; Ex-27: A2a = 1.6; Ex-28: A2a = 2.2; Ex-29: A2a = 1.7;
Ex-30: A2a = l .l ; Ex-31: A2a = 1.3; Ex-32: A2a = 1.4; Ex-33: A2a = 4.2; Ex-34: A2a = 1.7;
Ex-35: A2a = 2.3; Ex-36: A2a = 6.7; Ex-37: A2a = 6.4; Ex-38: A2a = 2.0; Ex-39: A2a = 1.8;
Ex-40: A2a = 1.1 ; Ex-41: A2a = 2.6; Ex-42: A2a = 1.4; Ex-43: A2a = 8.4; Ex-44: A2a = 4.2;
Ex-45: A2a = 4.3; Ex-46: A2a = 18.0; Ex-48: A2a = 4.6; Ex-49: A2a = 5.4; Ex-50: A2a = 1.5; Ex-51: A2a = 2.9; Ex-52: A2a = 8.8; Ex-53: A2a = 2.4; Ex-54: A2a = 4.0; Ex-55: A2a = 1.8;
Ex-56: A2a = 3.4; Ex-57: A2a = 1.7; Ex-58: A2a = 0.9; Ex-59: A2a = 9.6; Ex-60: A2a = 2.3;
Ex-61: A2a = 2.5; Ex-62: A2a = 6.2; Ex-63: A2a = 5.8; Ex-64: A2a = 6.9; Ex-65: A2a = 13.6; Ex-66: A2a = 16.6; Ex-68: A2a = 7.0; Ex-69: A2a = 5.2; Ex-70: A2a = 6.8; Ex-71: A2a = 2.9; Ex-72: A2a = 5.0; Ex-73: A2a = 3.0; Ex-74: A2a = 4.3; Ex-76: A2a = 3.7; Ex-77: A2a = 36.2; Ex-78: A2a = 13.8; Ex-79: A2a = 22.3; Ex-80: A2a = 12.0; Ex-82: A2a = 24.7; Ex-83: A2a = 15.9; Ex-84: A2a = 6.3; Ex-85: A2a = 22.2; Ex-86: A2a = 6.7; Ex-87: A2a = 19.1 ; Ex-88: A2a = 42.3; Ex-89: A2a = 47.7; Ex-90: A2a = 27.9; Ex-91: A2a = 26.1; Ex-92: A2a = 73.7; Ex-93: A2a = 37.5; Ex-94: A2a = 27.3; Ex-95: A2a = 16.5; Ex-96: A2a = 56.2; Ex-97: A2a = 238.4; Ex-98: A2a = 19.0; Ex-99: A2a = 111.7; Ex-100: A2a = 31.2; Ex-102: A2a = 55.2; Ex-103: A2a = 8.3; Ex-104: A2a = 10.1; Ex-104: A2a = 14.3; Ex-106: A2a = 19.5; Ex-107: A2a = 6.9; Ex-108: A2a = 17.9; Ex-109: A2a = 12.2; Ex-110: A2a = 39.9; Ex-Il l : A2a = 11.9 ;Ex-112: A2a = 4.9; Ex-113: A2a = 22.8; Ex-114: A2a = 4.3; Ex-115: A2a = 21.6; Ex-117: A2a = 5.9; Ex-118: A2a = 5.4; Ex-119: A2a = 2.1; Ex-120: A2a = 1.5; Ex-121: A2a = 0.8; Ex-122: A2a = 6.0; Ex-123: A2a = 5.6; Ex-125: A2a = 27.3; Ex-126: A2a = 31.6; Ex-127: A2a = 8.5; Ex-128: A2a = 2.0; Ex-129: A2a = 40.8; Ex-130: A2a = 20.5; Ex-131 : A2a = 16.0; Ex-132: A2a = 7.9; Ex-133: A2a = 27.8; Ex-134: A2a = 6.7; Ex-135: A2a = 11.8; Ex-136: A2a = 191.4; Ex-137: A2a = 16.1; Ex-138: A2a = 145.6; Ex-139: A2a = 109.5; Ex-140: A2a = 103.8; Ex-141: A2a = 149.4; Ex-142: A2a = 350.5; Ex-143: A2a = 74.4; Ex-144: A2a = 149.0; Ex-145: A2a = 47.8; Ex-146: A2a = 29.9; Ex-148: A2a = 7.2; Ex-149: A2a = 17.5; Ex-150: A2a = 27.6; Ex-151: A2a = 48.2; Ex-152: A2a = 27.8; Ex-153: A2a = 283.6; Ex-154: A2a = 2.3; Ex-155: A2a = 2.2; Ex-156: A2a = 6.0; Ex-157: A2a = 1.6; Ex-158: A2a = 11.0; Ex-160: A2a = 1.5; Ex-161 : A2a = 2.1; Ex-162: A2a = 2.7; Ex-163: A2a = 2.7; Ex-164: A2a = 8.6; Ex-165: A2a = 4.4; Ex-166: A2a = 4.5; Ex-167: A2a = 7.6; Ex-168: A2a = 4.3; Ex-172: A2a = 6.1; Ex-173: A2a = 9.1 ; Ex- 175: A2a = 4.6; Ex-177: A2a = 17.0; Ex-179: A2a = 6.1; Ex-180: A2a = 1.9; Ex-182: A2a = 2.8; Ex-184: A2a = 2.9; Ex-185: A2a = 11.2; Ex-186: A2a = 3.9; Ex-187: A2a = 2.9; Ex-194: A2a = 8.8; Ex-195: A2a = 16.6; Ex-196: A2a = 274.0; Ex-197: A2a = 611.5; Ex-198: A2a = 207.3; Ex-199: A2a = 199.4; Ex-200: A2a = 35.5; Ex-201: A2a = 21.7; Ex-202: A2a = 147.4; Ex-203: A2a = 88.3; Ex-204: A2a = 40.7; Ex-205: A2a = 10.9; Ex-211: A2a = 3.0; Ex-212: A2a = 6.1; Ex-214: A2a = 2.9; Ex-215: A2a = 5.7; Ex-216: A2a = 3.0; Ex-221: A2a = 3.9; Ex-227: A2a = 7.7; Ex-228: A2a = 7.8; Ex-229: A2a = 14.8; Ex-230: A2a = 5.7; Ex-235: A2a = 2.8; Ex-236: A2a = 1.4; Ex-237: A2a = 3.5; Ex-241: A2a = 7.3; Ex-242: A2a = 0.1; Ex-243: A2a = 1.3; Ex- 244: A2a = 0.3; Ex-245: A2a = 1.0; Ex-246: A2a = 5.4; Ex-247: A2a = 0.2; Ex-248: A2a = 1.0.

Claims

A compound of Formula GI:
Figure imgf000122_0001
Formula GI,
or a pharmaceutically acceptable salt thereof, wherein:
W is nitrogen or carbon; m is 1, 2, 3, or 4; n is an integer of from 0 to 4, wherein the sum of n + m is at least 2 up to 4, and wherein, when W is N, m is at least 2;
Gdl through Gd4 are independently hydrogenor a Ci_6-alkyl; p is 1 or 2;
X, Y, and Z together with W and the carbon to which they are bonded form a 5 to 6 member aromatic or heteroaromatic moiety, and are independently:
(a) -(RG1)C= wherein RG1 is:
(i) hydrogen;
(ii) Ci_8-alkyl, optionally substituted with one or more halogen atoms;
Figure imgf000122_0002
(iv) -CN;
(v) -S-Ci_8-alkyl;
(vi) -0-C1-6-alkyl;
(vii)
Figure imgf000122_0003
where R2 is independently for each occurrence hydrogen, Ci_6-alkyl or heteroaryl, and wherein ql is 0 or 1 and q2 is 0 or 1;
(viii) -C(0)0-Ci_8-alkyl;
(ix) halogen;
(x) a mono- or polycyclic heterocyclic moiety comprising up to 10 carbon atoms and one or more heteroatoms selected from N, S, or O, optionally substituted with one or more Ci_6-alkyl, morpholino, phenyl (optionally substituted with halogen), heteroaryl or halogen;
(xi) aryl, optionally substituted with one or more halogen atoms or Ci_6-alkyl (which is optionally substituted with one or more halogen atoms);
(xii) -NH-C(0)-R3 , wherein R3 is Ci_5-alkyl or heteroaryl; or,
(xiii) heteroaryl, which is optionally substituted with Ci_6-alkyl (which is optionally
substituted with one or more halogen atoms) or amino; or
(b) >NRG2, wherein RG2 is: (i) hydrogen; (ii) Q-s-alkyl; or (iii) an aromatic moiety of up to 10 carbon atoms;
(c) -N=;
(d) -O-; or,
(e) -S-; and,
R is a moiety of the structu
Figure imgf000123_0001
wherein:
t is 0, 1 or 2;
RG5 and R06 are independently for each occurrence:
(a) H;
(b) Ci_io-alkyl, optionally substituted with one or more fluorine atoms; or,
(c) RG5 and R06 taken together form a carbonyl moiety (C=0), with the proviso that if t=2, RG5 and RG6 are not selected to provide two adjacent carbonyl moieties; and, RGal is 1 to 3 substituents replacing an H on a ring carbon atom that are independently for each occurrence:
(a) Ci-4-alkoxy, wherein the alkyl portion of the alkoxy moiety is optionally substituted with one or more halogen;
(b) Ci_8-alkyl, optionally substituted with one or more halogen atoms;
(c) halogen;
(d) -N(RG4)2, wherein at least one of RG4 is Ci_6alkyl and the other is H or Ci_6-alkyl; or,
(e) -CN.
2. A compound of Claim 1 or a pharmaceutically acceptable salt thereof wherein RG3 is a moiety of the structure:
Figure imgf000124_0001
wherein:
t is 0, 1 or 2;
RG5 and R06 are independently for each occurrence:
(a) H;
(b) Ci_io-alkyl, optionally substituted with one or more fluorine atoms; or
(c) R°5 and R06 taken together form a carbonyl moiety (C=0), with the proviso that if t=2, RG5 and RG6 are not selected to provide two adjacent carbonyl moieties; and,
RG\ RGb, and RGc are independently:
(a) H;
(b) Ci_4-alkoxy, wherein the alkyl portion of the alkoxy moiety is optionally substituted with one or more halogen;
(c) Ci.g-alkyl, optionally substituted with one or more halogen atoms;
(d) halogen, which is F or CI;
(e) -N(RG4)2, wherein at least one of RG4 is Ci_6alkyl and the other is H or Ci_6-alkyl; or, (f) -CN;
with the proviso that at least one of RG\ RG , or RGc is H, and at least one of RGa, RG , or RGc is not H.
3. A compound of Claim 1 or a pharmaceutically acceptable salt thereof wherein, when X, Y, or Z is -C(RG1)=, and RG1 is selected to be a halogen substituted Ci_6-alkyl moiety, the halogen is F or CI.
4. A compound of Claim 1 or a pharmaceutically acceptable salt thereof wherein at least one of X, Y, or Z is -N=, and at least one of X, Y, or Z is -0- or -S-.
5. A compound of Claim 1 or a pharmaceutically acceptable salt thereof having the structure of Formula Gil:
Figure imgf000125_0001
, Formula Gil, or a pharmaceutically acceptable salt thereof, wherein:
R aa , R a, and R ca are independently for each occurrence:
(a) H;
(b) Ci.6-alkyl;
(c) Ci-4-alkoxy, optionally substituted with one or more fluorine atoms;
(d) F;
(e) CI;
(f) Br;
(g) -CN; or,
(h) -N(RG9)2, wherein RG9 is independently for each occurrence Ci-e-alkyl or H;
and wherein RGaa , RGb\ and RGca are selected such that at least one of RGaa , RGba, and RGca isH, and at least one of RGaa , RGba, and RGca is not H;
RGf is:
(a) CH2;
(b) ethyl, which is optionally substituted with: Ci e-alkyl (which is optionally substituted with one or more fluorine atoms);
(c) propyl; or,
(d) -C(0)-CH2-; and,
R e is a heteroaryl bicyclic moiety having up to 12 ring atoms of the structure:
Figure imgf000125_0002
wherein:
W is nitrogen or carbon; m' is 1, 2, 3, or 4; n' is an integer of from 0 to 4, wherein the sum of n' + m' is at least 2 up to 4, and wherein, when W is N, m' is at least 2; p' is 1 or 2;
Gdl' through Gd4' are independently H or a C^-alkyl;
X', Y', and Z' together with W and the carbon to which they are bonded form a 5 to 6 member aromatic or heteroaromatic moiety, and are independently:
(a) -(RG1')C=, wherein RG1' is:
(i) H;
(ii) Ci_8-alkyl, optionally substituted with one or more halogen atoms;
(iii) -C(0)-Ci_8-alkyl;
(iv) -CN;
(v) -S-d_8-alkyl;
(vi) -O-Ci-6-alkyl;
(vii) -(CH2)q-C(0)-N(R2)2, wherein R2 is independently for each occurrence H, Ci_4-alkyl or pyridyl, and wherein q is 0 or 1 ;
(viii) -C(0)0-d_8-alkyl;
(ix) halogen;
(x) morpholine, optionally substituted on any carbon atom thereof by one or more Ci_6- alkyl moieties;
(xi) piperazine, wherein the 4-N nitrogen is bonded to a substituent which is: (ai) H; (aii) Ci_6-alkyl; (aiii) morpholino; (aiv) phenyl, optionally substituted with a halogen; (av) halogen; or (avi) heteroaryl;
(xii) piperidinyl, optionally substituted by Ci_6-alkyl or a morpholine moiety;
(xiii) pyrrolidine, optionally substituted with one or more halogen atoms;
(xiv) phenyl, which is optionally substituted with one or more halogen atoms or Ci_6-alkyl; or
(xv) -NH-C(0)-R3 , wherein R is Ci_4-alkyl or pyridinyl;
(xvi) heteroaryl, which is optionally substituted with CF3, Ci_6-alkyl or amino; or
(xvii) -N(R4)2, wherein R4 is independently for each occurrence H or Ci_6-alkyl; (b) >NRG2 , wherein RG2 is: (i) H; (ii) Ci.g-alkyl; or (iii) an aromatic moiety of up to 10 carbon atoms;
(c) -N=;
(d) -0-; or
(e) -S-.
6. A compound of Claim 5, or a pharmaceutically acceptable salt thereof, wherein RGe is a moiety of Formula RGe :
Figure imgf000127_0001
Formula R , GeA
and wherein the compound is selected from a group of compounds where X1, Y1 and Z1 are as defined in Table CA:
Table CA
Figure imgf000127_0004
7. A compound of Claim 5, or a pharmaceutically acceptable salt thereof, wherein RGe is a moiety of Formula R0^:
Figure imgf000127_0002
Formula R
and wherein the compound is selected from a group of compounds where A , X , Y and Z are as defined in Table CB:
Table CB
Figure imgf000127_0003
Figure imgf000128_0001
A compound of Claim 5, or a pharmaceutically acceptable salt thereof, wherein RGe is a moiety of Formula
Figure imgf000128_0002
Formula RGeC,
and wherein the compound is selected from a group of compounds where X3, Y3, Z3 and A3 are as defined in Table CC :
Table CC
Figure imgf000128_0003
Figure imgf000129_0001
9. A compound of Claim 5, or a pharmaceutically acceptable salt thereof, wherein RGe is a moiety of Formula &Ώ:
Figure imgf000129_0002
Formula R
and wherein the compound is selected from a group of compounds where X , Y and Z are as defined in Table CD:
Table CD
Figure imgf000129_0003
Figure imgf000130_0001
10. A compound of Claim 5, or a pharmaceutically acceptable salt thereof, wherein Ge is a moiety of Formula R0^:
Figure imgf000130_0002
and wherein the compound is selected from a group of compounds where X5, Y5 and Zs are as defined in Table CE:
Table CE
Figure imgf000130_0003
11. A compound of Claim 5, or a pharmaceutically acceptable salt thereof, wherein RGe is the following moiety:
Figure imgf000131_0001
12. A compound of any of Claims 5 to 11 wherein Rut is -CH(CH3)-CH2- ; -CH2-CH2-; or -CH2-.
13. A compound selected from:
7-methoxy-2-(2-(3-(methylthio)-5,6-dihydro-[l ,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl)ethyl)-[l,2,4]triazolo[ l ,5-c]quinazolin-5-amine;
7-(2-(5-amino-7-methoxy-[ 1 ,2,4]triazolo[l ,5-c]quinazolin-2-yl)ethyl)-N-tert- butyl-5,6J,8-tetrahydro-[l ,2,4]triazolo[4,3-a]pyrazine-3-carboxamide;
2-(2-(3-bromo-5,6-dihydro-[ l ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)ethyl)-7- methoxy-[l ,2,4]triazolo[l ,5-c]quinazolin-5-amine;
ethyl 7-(2-(5-amino-7-methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-2-yl)ethyl)- 5,6,7,8-tetrahydro-[l ,2,4]triazolo[4,3-a]pyrazine-3-carboxylate; 2-(2-(2-chloro-5H-pyrrolo[3,44j]pyridin-6(7H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(4-bromo-5 ,6-dihydro- 1 ,7-naphthyridin-7(8H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(l-cyclopropyl-6,7-dihydro-lH-pyrazolo[4,3-c]pyridin-5(4H)-yl)ethyl)-7- methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
2-(2-(3-isopropyl-5,6-dihydroimidazo[l ,5-a]pyrazin-7(8H)-yl)et yl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(3-(trifluoromethyl)-6,7-dihydroisoxazolo[4,3-c]pyridin-5(4H)- yl)ethyL)-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
(7-(2-(5-amino-7-methoxy-[l,2,4]triazolo[l,5-c]q inazolin-2-yl)ethyl)-5,6,7,8- tetrahydroimidazo[ 1 ,2-a]pyrazin-2-yl)(cyclopropyl)methanone;
7-methoxy-2-(2-(2-(trifluoromethyl)-5,6-dihydro-[l ,2,4]triazolo[l,5-a]pyrazin- 7(8H)-yl)ethyl)-[l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(2-cyclopropyl-5,6-dihydro-[l,2,4]triazolo[l ,5-a]pyrazin-7(8H)-yl)ethyl)-7- methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
2-(2-(3-ethyl-5,6-dihydroimidazo[l,5-a]pyrazin-7(8H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-methyl-4H-pyrrolo[3,4-d]thiazol-5(6H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
6- (2-(5-amino-7-methoxy-[l ,2,4]triazolo[l,5-c]qumazolin-2-yl)ethyl)-2- cyclopropyl-4,5,6,7-tetra ydrothieno[2,3-c]pyridine-3-carbonitrile;
7- methoxy-2-(2-(2-(trifluoromethyl)-6,7-dihydro-3H-imidazo[4,5-c]pyridin- 5(4H)-yl)ethyl)-[l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(3-(trifluoromethyl)-5,6-dihydro-[ 1 ,2,4]triazolo[4,3-a]pyrazin-
7(8H)-yl)ethyl)-[l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-(trifluoromethyl)-5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)ethyl)-7-methoxy-[ 1 ,2,4]triazolo[ 1 ,5- c]quinazolin-5-amine;
2-(2-(7,8-dihydro-5H-pyrido[2,3-b]azepin-9(6H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(2,3 -dihydro- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(3-ethyl-5,6-dihydro-[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)ethyl)-7- methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine; 7-methoxy-2-(2-(2-methyl-5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(isoindolin-2-yl)ethyl)-7-methoxy-[l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-methyl-6,7-dihydrothiazolo[4,5-c]pyridin-5(4H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-(trifluoromethyl)-6,7-dihydrothiazolo[4,5-c]pyridm-5(4H)- yl)ethyL)-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-methyl-6,7-dihydrooxazolo[4,5-c]pyridin-5(4H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-methyl-6,7-dihydrooxazolo[5,4-c]pyridin-5(4H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-methyl-6,7-dihydrothiazolo[5,4-c]pyridin-5(4H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(2-cyclopropyl-6,7-dihydrothiazolo[5,4-c]pyridin-5(4H)-yl)ethyl)-7- methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
2-(2-(2-cyclopropyl-6,7-dihydrooxazolo[5,4-c]pyridin-5(4H)-yl)ethyl)-7- methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(l-methyl-3-(trifluoromet yl)-6,7-dihydro-lH-pyrazolo[4,3- c]pyridin-5(4H)-yl)ethyl)-[l,2,4]triazolo[l ,5-c]quinazolin-5-amme;
2-(2-(2,3-dihydro-lH-imidazo[l,2-b]pyrazol-l-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-phenylpyrrolo[3,4-d]imidazol-5(lH,4H,6H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(6,7-dihydroisoxazolo[4,5-c]pyridin-5(4H)-yL)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(6,7-dihydro-lH-pyrazolo[4,3-c]pyridin-5(4H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(3-methyl-6,7-dihydro-lH-pyrazolo[4,3-c]pyridin-5(4H)- yl)ethyL)-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(3-(trifluoromethyl)-6,7-dihydro-lH^yrazolo[4,3-c]pyridin- 5(4H)-yl)ethyl)-[l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(3-cyclopropyl-4,5-dihydro-lH-pyrazolo[3,4-c]pyridin-6(7H)-yl)ethyl)-7- methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-methyl-6,7-dihydropyrazolo[l ,5-a]pyrazin-5(4H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine; 7-methoxy-2-(2-(3-(trifluoromethyl)-4,5 -dihydro- 1 H-pyrazolo [3 ,4-c]pyridin- 6(7H)-yl)ethyl)-[l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(l-methyl-3-(trifluoromethyl)-6,7-dihydro-lH-pyrazolo[4,3- b] pyridin-4(5H)-yl)ethyl)- [ 1 ,2,4]triazolo [ 1 , -c]quinazolin-5-amine;
2-(2-(6-fluoro-3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(5 ,6-dihydro- 1 ,7-naphthyridin-7(8H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(5-(trifluoromethyl)isoindolin-2-yl)ethyl)- [ 1 ,2,4]triazolo[ 1 ,5 - c]quinazolin-5-amine;
2-(2-(5-fluoroisoindolin-2-yl)ethyl)-7-methoxy-[l,2,4]triazolo[l,5-c]quinazolin-
5 -amine;
2-(2-(5H-pyrrolo[3,4-b]pyridm-6(7H)-yl)ethyl)-7-methoxy-[l,2,4]triazolo[l,5- c] quinazolin-5-amine;
7-methoxy-2-(2-(3-phenylpyrrolo[3,4-c]pyrazol-5(lH,4H,6H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(pyrrolo[3,4-c]pyrazol-5(lH,4H,6H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(3-cyclopropyl-6,7-dihydro-lH-pyrazolo[4,3-b]pyridin-4(5H)-yl)ethyl)-7- methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
2-(2-(5,6-dihydropyrido[3,4-d]pyrimidin-7(8H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(7,8-dihydropyrido[4,3-b]pyrazin-6(5H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(6,7-dihydrothiazolo [5 ,4-c]pyridin-5 (4H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(6,7-dihydrothiazolo[4,5-c]pyridin-5(4H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-(trifluoromethyl)-5,6-dihydroimidazo[l ,2-a]pyrazin-7(8H)- yl)ethyL)-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
2-(2-(6,7-dihydropyrazolo[l,5-a]pyrimidin-4(5H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-met yl-7,8-dihydro-4H-pyrazolo[l,5-a][l,4]diazepm-5(6H)- yl)ethyL)-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine; 5-(2-(5-amino-7-methoxy-[l ,2,4]triazolo[l,5-c]qumazolin-2-yl)ethyl)-5, 6,7,8- tetrahydro-4H-pyrazolo [ 1 ,5 -a] [ 1 ,4]diazepine-2-carbonitrile;
2-(2-(4,4-dimethyl-3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-(4-methylpiperazin-l-yl)-5H-pyrrolo[3,4-b]pyridin-6(7H)- yl)ethyL)-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-morpholino-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-(pyrrolidin-l-yl)-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(2-(4-ethylpiperazin-l-yl)-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)ethyl)-7- methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
2-(2-(2-(2,2-dimethylmorpholino)-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)ethyl)-7- methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
2-(2-(2-((2S,6R)-2,6-dimethylmorpholino)-5H-pyrrolo[3,4-b]pyridin-6(7H)- yl)ethyl)-7-methoxy-[ 1 ,2,4]triazolo[ 1 ,5-c]qumazolin-5-amine;
2-(2-(2-(4-(cyclopropylmethyl)piperazin-l-yl)-5H-pyrrolo[3,4-b]pyridin-6(7H)- yl)ethyl)-7-methoxy-[ 1 ,2,4]triazolo[ 1 ,5-c]qumazolin-5-amine;
2-(2-(2-(4-(4-fluorophenyl)piperazin-l-yl)-5H-pyrrolo[3,4-b]pyridin-6(7H)- yl)ethyl)-7-methoxy-[ 1 ,2,4]triazolo[ 1 ,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-(4-mo holmo iperidm-l-yl)-5H-pyrrolo[3,4-b]pyridin- 6(7H)-yl)ethyl)-[l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(4-(4-et ylpiperazin-l-yl)-5,6-dihydro-l,7-napht yridin-7(8H)-yl)ethyl)-7- methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
2-(2-(4-(diethylamino)-5,6-dihydro-l ,7-naphthyridin-7(8H)-yl)ethyl)-7-methoxy-
[l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(4-(3,3-difluorop3Trolidin-l-yl)-5,6-dihydro-l,7-naphthyridin-7(8H)- yl)ethyl)-7-methoxy-[ 1 ,2,4]triazolo[ 1 ,5-c]qumazolin-5-amine;
2-(5-amino-7-methoxy-[l ,2,4]triazolo[l ,5-c]qumazolin-2-yl)-l-(5H-pyrrolo[3,4- b]pyridin-6(7H)-yl)ethanone;
2-(5 -amino-7-methoxy-[ 1 ,2,4]triazolo [ 1 ,5 -c]quinazolin-2-yl)- 1 -(4,5 -dihydro- 1 H- benzo [d] azepin-3 (2H)-yl)ethanone;
2-(2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)ethyl)-7-(fluoromethoxy)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-chloro-2-(2-(5-fluoroisoindolin-2-yl)ethyl)-[l ,2,4]triazolo[l,5-c]quinazolin-5- amine; 7-chloro-2-(2-(3,4-dihydroquinolin-l(2H)-yl)ethyl)-[l,2,4]triazolo[l ,5- c]quinazolin-5-amine;
2-[2-(5,7-dihydro-6//-pyrrolo[3,4- ?]pyridin-6-yl)ethyl]-7- fluoro[ 1 ,2,4]triazolo[l ,5-c]quinazolin-5-amine;
2-(2-(3,4-dihydroquinolin- 1 (2H)-yl)ethyl)-7-fluoro-[ 1 ,2,4]triazolo[ 1 ,5- c]quinazolin-5-amine;
7-fluoro-2-(2-(5-fluoroisoindolin-2-yl)ethyl)-[l,2,4]triazolo[l,5-c]quinazolin-5- amine;
2-(2-(3-ethyl-5,6-dihydro-[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)ethyl)-7-fluoro- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(3,4-dihydroisoquinolin-2( 1 H)-yl)ethyl)-7-fluoro-[ 1 ,2,4]triazolo[l ,5- c]quinazolin-5-amine;
7- fluoro-2-(2-(2-(trifluoromethyl)-5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-fluoro-2-(2-(4-fluoroisoindolin-2-yl)ethyl)-[l,2,4]triazolo[l,5-c]qumazolin-5- amine;
2-(2-(3 ,4-dihydroisoquinolin-2( 1 H)-yl)ethyl)-7-methyl-[ 1 ,2,4]triazolo[ 1,5- c]quinazolin-5-amine;
8- fluoro-2-(2-(5-fluoroisoindolin-2-yl)ethyl)-[l,2,4]triazolo[l,5-c]quinazolin-5- amine;
2-(2-(5H-pyrrolo[3,4-b]pyridm-6(7H)-yl)et yl)-8-fluoro-[l ,2,4]triazolo[ 1 ,5- c]quinazolin-5-amine;
2-(2-(3,4-dihydroisoquinolin-2( 1 H)-yl)ethyl)-8-fluoro-[ 1 ,2,4]triazolo[l ,5- c]quinazolin-5-amine;
2-(2-(3,4-dihydroquinolin- 1 (2H)-yl)ethyl)-8-fluoro-[ 1 ,2,4]triazolo[ 1 ,5- c]quinazolin-5-amine;
2-(2-(3-ethyl-5,6-dihydro-[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)ethyl)-8-fluoro- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
8-fluoro-2-(2-(4-fluoroisoindolin-2-yl)ethyl)-[l,2,4]triazolo[l,5-c]qumazolin-5- amine;
2-(2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)ethyl)-7,8-dimethoxy- [l,2,4]n-iazolo[l,5-c]quinazolin-5-amine;
2-(2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)ethyl)-9-fluoro-7-methoxy- [l,2,4]ttiazolo[l,5-c]quinazolin-5-amme;
2-(2-(5H-pyrrolo[3,4-b]pyridm-6(7H)-yl)ethyl)-8,9-difluoro-[l,2,4]triazolo[l,5- c]quinazolin-5-amine; 2-(2-(5H-pyrrolo[3,4-b]pyridm-6(7H)-yl)ethyl)-7,9-difluoro-[l,2,4]triazolo[l,5- c]quinazolin-5-amine;
2-(3,3-difluoro-2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)propyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
(R)-2-(3,3-difluoro-2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)propyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
(S)-2-(3,3-difluoro-2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)propyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(3-fluoro-2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)propyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(5H-pyrrolo[3,4-b]pyridm-6(7H)-yl)propyl)-7-methoxy-[l ,2,4]triazolo[ 1 ,5- c]quinazolin-5-amine;
(S)-2-(2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)propyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
(R)-2-(2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)propyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(3,3,3-trifluoro-2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)propyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
(S)-7-methoxy-2-(3,3,3-trifluoro-2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)propyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
(R)-7-methoxy-2-(3,3,3-trifluoro-2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)propyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)butyl)-7-methoxy-[l,2,4]triazolo[l,5- c]quinazolin-5-amine;
(R)-2-(2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)butyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
(S)-2-(2-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)butyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(5-fluoroisoindolin-2-yl)propyl)-7-methoxy-[l ,2,4]triazolo[l,5-c]quinazolin- 5-amine;
2-(2-(5H-pyrrolo[3,4-b]pyridm-6(7H)-yl)pentyl)-7-methoxy-[l,2,4]triazolo[l,5- c]quinazolin-5-amine;
7-methoxy-2-(2-(2-methyl-6,7-dihydrooxazolo[5,4-c]pyridin-5(4H)-yl)propyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((5-fluoroisoindolin-2-yl)methyl)-7-methoxy-[l,2,4]triazolo[l,5-c]quinazolin-5- amine; 2-((5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)methyl)-7-methoxy-[l,2,4]triazolo[l,5- c]quinazolin-5-amine;
2-((3 ,4-dihydroquinolin- 1 (2H)-yl)methyl)-7-methoxy- [ 1 ,2,4]triazolo [1 ,5- c]quinazolin-5-amine;
2-((2H-benzo[b][l,4]oxazin-4(3H)-yl)methyl)-7-methoxy-[l,2,4]triazolo[l ,5- c]quinazolin-5-amine;
2-((3,4-dihydroisoquinolin-2(lH)-yl)methyl)-7-methoxy-[l,2,4]triazolo[l ,5- c]quinazolin-5-amine;
2-((5-amino-7-methoxy-[l ,2,4]triazolo[l,5-c]quinazolin-2-yl)methyl)-l ,2,3,4- tetrahydroisoquinoline-6-carbonitrile;
2-((5,6-dihydro-l,7-naphthyridin-7(8H)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-((7-methoxy-4,5-dihydro-lH-benzo[d]azepin-3(2H)-yl)methyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((3 ,4-dihydro-2,7-naphthyridin-2( 1 H)-yl)methyl)-7-methoxy-
[l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-((8-((4-(pyridin-2-yl)piperazin- 1 -yl)methyl)-3 ,4-dihydroisoquinolin- 2(1 H)-yl)methyl)- [ 1 ,2,4]triazolo [ 1 ,5 -c] quinazolin-5 -amine;
7-methoxy-2-((5-(trifluoromethyl)isoindolin-2-yl)methyl)-[l,2,4]triazolo[l,5- c]quinazolin-5-amine;
7-methoxy-2-((2 ,3 ,4 , 5 -tetrahydro- 1 H-benzo [b] azepin- 1 -yl)metby 1)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-((3-(trifluoromethyl)-7,8-dihydro-l,6-naphthyridin-6(5H)- yl)methyl)-[ 1 ,2,4]triazolo [ 1 ,5 -c]quinazolin-5 -amine;
2-((6-fluoro-3,4-dihydroisoquinolin-2(lH)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((4,5-dihydro-lH-benzo[d]azepin-3(2H)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((4,5-dihydro-lH-benzo[c]azepin-2(3H)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((3,4-dihydro-l ,5-naphthyridin- 1 (2H)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((3 ,4-diliydro- 1 ,6-naphthyridin- 1 (2H)-yl)methyl)-7-methoxy- [l,2,4]ttiazolo[l,5-c]quinazolin-5-amme;
2-((3 ,4-diliydro- 1 ,7-naphthyridin- 1 (2H)-yl)methyl)-7-methoxy-
[l,2,4]triazolo[l,5-c]quinazolin-5-amine; 2-((7-chloro-4-methyl-2,3 ,4,5 -tetrahydro- 1 H-benzo [e][ 1 ,4]diazepin- 1 -yl)methyl)- 7-methoxy- [ 1 ,2,4]triazolo [ 1 ,5 -c]quinazolin-5-amine;
2-((2-chloro-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-((3-(methylthio)-5,6-dihydro-[l,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl)methyl)-[ 1 ,2,4]triazolo [ 1 ,5 -c]quinazolin-5 -amine;
ethyl 7-((5-amino-7-methoxy-[l ,2,4]triazolo[ 1 ,5-c]quinazolin-2-yl)methyl)- 5,6,7,8-tetrahydro-[l,2,4]triazolo[4,3-a]pyrazine-3-carboxylate;
2-((3-bromo-5,6-dihydro-[l ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metliyl)-7-
Figure imgf000139_0001
,5-c]quinazolin-5-amine;
2-((5,6-dihydro-[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((3-ethyl-5,6-dihydro-[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methyl)-7- methoxy-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
7-((5-amino-7-methoxy-[l ,2,4]triazolo[l,5-c]quinazolm-2-yl)methyl)-N-tert- butyl-5,6,7,8-tetrahydro-[l ,2,4]triazolo[4,3-a]pyrazine-3-carboxamide;
7-methoxy-2-((3-methoxy-5,6-dihydro-[l,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl)methyl)-[ 1 ,2,4]triazolo [ 1 ,5 -c]quinazolin-5 -amine;
2-((5,5-dimethyl-3-(trifluoromethyl)-5,6-dihydro-[l ,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)methyl)-7-methoxy- [ 1 ,2,4]triazolo[ 1 ,5 -c] quinazolin-5 -amine;
2-((8,8-dimethyl-3-(trifluoromethyl)-5,6-dihydro-[l ,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)methyl)-7-methoxy- [ 1 ,2,4]triazolo[ 1 ,5 -c] quinazolin-5 -amine;
2-((4-bromo-5,6-dihydro-l,7-naphthyridin-7(8H)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((2-isopropyl-4H-pyrrolo[3,4-d]thiazol-5(6H)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((7,8-dihydropyrido[4,3-b]pyrazin-6(5H)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((5 ,6-dihydropyrido [3 ,4-d]pyrimidin-7(8H)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-((2-(trifluoromethyl)-5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)methyl)- [l,2,4]n-iazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-((3-(trifluoromethyl)-5,6-dihydro-[l ,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)methyl)-[l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((2,3-dihydro-lH-pyrrolo[2,3-b]pyridin- 1 -yl)methyl)-7-methoxy-
[l,2,4]triazolo[l,5-c]quinazolin-5-amine; 2-((5-bromo-2,3-dihydro-lH-pyrrolo[2^-b]pyridm-l-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-((7-methyl-3 ,4-dihydro- 1 ,8-naphthyridin- 1 (2H)-yl)methyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((7,8-dihydro-5H-p) ido[2,3-b]azepin-9(6H)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((2,3-dihydro-lH-pyrrolo[2,3-b]pyridin-l-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((2-chloro-7,8-dihydro-5H-pyrido[2^-b]azepin-9(6H)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((3,4-dihydro-l ,8-naphthyridin- 1 (2H)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-((2-(pyridin-2-yl)-7,8-dihydro-5H-pyrido[2,3-b]azepin-9(6H)- yl)methyl)-[ 1 ,2,4]triazolo [ 1 ,5 -c]quinazolin-5 -amine;
2-((4,4-dimethyl-3 ,4-dihydroisoquinolin-2( 1 H)-yl)methyl)-7-methoxy-
[l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-((5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)methyl)-9-fluoro-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-((7-( yrimidin-5-yl)-3,4-dihydroisoquinolin-2(lH)-yl)methyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
N-(2-((5-amino-7-methoxy-[l ,2,4]triazolo[ 1 ,5-c]qumazolin-2-yl)methyl)- 1 ,2,3 ,4- tetrahydroisoquinolin-7-yl)picolinamide;
N-(2-((5-amino-7-methoxy-[l ,2,4]triazolo[ 1 ,5-c]quinazolin-2-yl)methyl)- 1 ,2,3 ,4- tetrahydroisoquinolin-7-yl)acetamide;
2-((7-(3,4-difluorophenyl)-3,4-dihydroisoq inolin-2(lH)-yl)methyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(7-(pyrimidin-5-yl)-3 ,4-dihydroisoquinolin-2( 1 H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-((5-amino-7-methoxy-[l,2,4]triazolo[l,5-c]quinazolin-2-yl)methyL)-l, 2,3,4- tetrahydroisoqumolin-7-yl)-N-(pyridine-3-yl)acetamide;
7-methoxy-2-((5-( yrimidin-5-yl)isoindolin-2-yl)methyl)-[l,2,4]triazolo[l,5- c]quinazolin-5-amine;
7-methoxy-2-((8-(pyrimidin-5-yl)-3,4-dihydroisoquinolin-2(lH)-yl)methyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-((7-(2-(trifluoromethyl)pyrimidin-5-yl)-3,4-dihydroisoquinolin- 2(1 H)-yl)methyl)- [ 1 ,2,4]triazolo [ 1 ,5 -c] quinazolin-5 -amine; 7-methoxy-2-((7-(l-methyl-lH-pyrazol-4-yl)-3,4-dihydroisoquinolin-2(lH)- yl)methyl)-[ 1 ,2,4]triazolo [ 1 ,5 -c]quinazolin-5 -amine;
7-methoxy-2-((7-(l-methyl-5-(trifluoromethyl)-lH-pyrazol-4-yl)-3,4- dihydroisoquinolin-2( 1 H)-yl)methyl)- [ 1 ,2,4]triazolo[ 1 ,5-c] quinazolin-5 -amine;
7-methoxy-2-((7-(l-methyl-3-(trifluoromethyl)-lH-pyrazol-4-yl)-3,4- dihydroisoquinolin-2( 1 H)-yl)methyl)- [ 1 ,2,4]triazolo[ 1 ,5-c] quinazolin-5 -amine;
7-methoxy-2-((7-(2-(trifluoromethyl)phenyl)-3,4-dihydroisoquinolin-2(lH)- yl)methyl)-[ 1 ,2,4]triazolo [ 1 ,5 -c]quinazolin-5 -amine;
2-((7-(2-amino-4-(trifluoromethyl)pyrimidin-5-yl)-3,4-dihydroisoquinolin-2(lH)- yl)methyl)-7-methoxy-[ 1 ,2,4]triazolo[ 1 ,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(7-(2-(trifluoromethyl)pyrimidin-5-yl)-3,4-dihydroisoquinolin- 2(lH)-yl)ethyl)-[l ,2,4]triazolo[l ,5-c]quinazolin-5-amine;
7-bromo-2-((5,6-dihydro- 1 ,7-naphthyridin-7(8H)-yl)met yl)-[ 1 ,2,4]triazolo[ 1 ,5- c]quinazolin-5-amine;
2-((5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)methyl)-7-bromo-[l ,2,4]triazolo[ l ,5- c]quinazolin-5-amine;
5-amino-2 (5,6-dihydro- l ,7-naphthyridin-7(8H)-yl)methyl)-[l ,2,4]triazolo[l ,5- c]quinazoline-7-carbonitrile;
2-((5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)methyl)-5-amino-[l ,2,4]triazolo[ l ,5- c]quinazoline-7-carbonitrile;
2-((5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)methyl)-7-(methoxymethyl)- [l ,2,4]t-iazolo[l ,5-c]quinazolin-5-amine;
2-((5,6-dihydro-l,7-naphthyridin-7(8H)-yl)methyl)-7-(methoxymethyl)- [l ,2,4]triazolo[l ,5-c]quinazolin-5-amine;
2-((5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)methyl)-7-methyl-[ l ,2,4]triazolo[l,5- c]quinazolin-5-amine;
2-((5,6-dihydro-l,7-naphthyridin-7(8H)-yl)methyl)-7-methyl-[l ,2,4]triazolo[l ,5- c]quinazolin-5-amine;
2-((5,6-dihydro-l,7-naphthyridin-7(8H)-yl)methyl)-7-(2-fluoroethoxy)- [l ,2,4]triazolo[l ,5-c]quinazolin-5-amine;
2-((5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)methyl)-7-ethoxy-[l ,2,4]triazolo[l ,5- c]quinazolin-5-amine;
2-((5,6-dihydro-l,7-naphthyridin-7(8H)-yl)methyl)-7-ethoxy-[l ,2,4]triazolo[l ,5- c]quinazolin-5-amine;
2-((5,6-diliydro-l,7-naphthyridin-7(8H)-yl)methyl)-7-(fluoromethoxy)- [l ,2,4]triazolo[l ,5-c]quinazolin-5-amine; (R)-7-methoxy-2-(2-(2-methyl-6,7-dihydrooxazolo[5,4-c]pyridin-5(4H)- yl)propyl)-[l ,2,4]triazolo[l,5-c]quinazolin-5-amine;
(S)-7-methoxy-2-(2-(2-methyl-6,7-dihydrooxazolo[5,4-c]pyridin-5(4H)- yl)propyl)-[l ,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-methyl-6,7-dihydrooxazolo[4,5-c]pyridin-5(4H)-yl)propyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
(R)-7-methoxy-2-(2-(2-methyl-6,7-dihydrooxazolo[4,5-c]pyridin-5(4H)- yl)propyl)-[l ,2,4]triazolo[l,5-c]quinazolin-5-amine;
(S)-7-methoxy-2-(2-(2-methyl-6,7-dihydrooxazolo[4,5-c]pyridin-5(4H)- yl)propyl)-[l ,2,4]triazolo[l,5-c]quinazolin-5-amine;
(R)-7-methoxy-2-(2-(2-methyl-6,7-dihydrothiazolo[5,4-c]pyridin-5(4H)- yl)propyl)-[l ,2,4]triazolo[l,5-c]quinazolin-5-amine;
(S)-7-methoxy-2-(2-(2-methyl-6,7-dihydrothiazolo[5,4-c]pyridin-5(4H)- yl)propyl)-[l ,2,4]triazolo[l,5-c]quinazolin-5-amine;
(R)-7-methoxy-2-(2-(2-methyl-6,7-dihydrothiazolo[4,5-c]pyridin-5(4H)- yl)propyl)-[l ,2,4]triazolo[l,5-c]quinazolin-5-amine;
(S)-7-methoxy-2-(2-(2-methyl-6,7-dihydrothiazolo[4,5-c]pyridin-5(4H)- yl)propyl)-[l ,2,4]triazolo[l,5-c]quinazolin-5-amine;
(R)-7-methoxy-2-(2-(2-methyl-4H-pyrrolo[3,4-d]thiazol-5(6H)-yl)propyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
(R)-7-methoxy-2-(2-(2-methyl-6,7-dihydropyrazolo[l,5-a]pyrazin-5(4H)- yl)propyl)-[l ,2,4]triazolo[l,5-c]quinazolin-5-amine;
(S)-7-methoxy-2-(2-(2-methyl-6,7-dihydrop3Tazolo[l ,5-a]pyrazin-5(4H)- yl)propyl)-[l ,2,4]triazolo[l,5-c]quinazolin-5-amine;
(R)-2-(2-(2-(difluoromethyl)-6,7-dihydropyrazolo[l,5-a]pyrazin-5(4H)- yl)propyl)-7-methoxy-[l ,2,4]triazolo[l,5-c]quinazolin-5-amine;
(S)-2-(2-(2-(difluoromet yl)-6,7-dihydropyrazolo[l ,5-a]pyrazin-5(4H)- yl)propyl)-7-methoxy-[l ,2,4]triazolo[l,5-c]quinazolin-5-amine;
(R)-2-(2-(2-(difluoromethyl)-6,7-dihydrothiazolo[5,4-c]pyridin-5(4H)-yl)propyl)- 7-methoxy- [ 1 ,2,4]triazolo [ 1 ,5 -c]q inazolin-5-amine;
(S)-7-methoxy-2-(2-(2-(trifluoromethyl)-6,7-dihydrothiazolo[4,5-c]pyridin- 5(4H)-yl)propyl)-[l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(3-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)propyl)-7-methoxy-[l ,2,4]triazolo[ 1 ,5- c]quinazolin-5-amine;
2-(3-(4-fluoroisoindolin-2-yl)propyl)-7-methoxy-[l ,2,4]triazolo[l,5-c]quinazolin-
5 -amine; 2-(3-(5-fluoroisoindolin-2-yl)propyl)-7-methoxy-[l ,2,4]triazolo[l,5-c]quinazolin-
5 -amine;
7-methoxy-2-(3-(5-(trifluoromethyl)isoindolin-2-yl)propyl)-[l,2,4]triazolo[l ,5- c]quinazolin-5-amine;
7-methoxy-2-(2-(2,7,7-trimethyl-6,7-dihydrooxazolo[5,4-c]pyridin-5(4H)- yl)ethyL)-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
2-(2-(2,4-dimethyl-6,7-di ydrooxazolo[5,4-c]pyridm-5(4H)- yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(2,6-dimethyl-6,7-di ydrooxazolo[5,4-c]pyridin-5(4H)-yl)ethyl)-7- methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2,7,7-trimethyl-6,7-dihydrothiazolo[5,4-c]pyridin-5(4H)- yl)ethyL)-[l,2,4]triazolo[l ,5-c]quinazolin-5-amine;
2-(2-(2-cyclopropyl-4H-pyrrolo[3,4-d]thiazol-5(6H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(2-isopropyl-4H-pyn-olo[3,4-d]thiazol-5(6H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(2-ethyl-4H-pyrrolo[3,4-d]thiazol-5(6H)-yl)ethyl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-methyl-4H-pyrrolo[3,4-d]oxazol-5(6H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
2-(2-(2-cyclopropyl-4H-pyrrolo[3,4-d]oxazol-5(6H)-yl)et yl)-7-methoxy- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(l-methylpyrrolo[3,4-c]pyrazol-5(lH,4H,6H)-yl)ethyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
(R)-7-methoxy-2-(2-(2-methyl-4H-pyrrolo[3,4-d]oxazol-5(6H)-yl)propyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine;
(R)-7-methoxy-2-(2-(2-methyl-4H-pyrrolo[3,4-d]oxazol-5(6H)-yl)butyl)- [l,2,4]triazolo[l,5-c]quinazolin-5-amine; or
a pharmaceutically acceptable salt thereof.
14. A pharmaceutical composition that comprises an inert carrier and a compound of Claim 1 or a pharmaceutically acceptable salt thereof.
15. A compound of Claim 1 , or a pharmaceutically acceptable salt thereof, for use in medicine.
16. Use of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of a central nervous system disorder.
17. A method of treating a central nervous system disorder in a mammalian patient in need thereof by administering a therapeutically effective amount of the compound of Claim 1 or a pharmaceutically acceptable salt thereof.
18. The method of Claim 17 wherein said central nervous system disorder is a movement disorder associated with Parkinson's disease or the treatment thereof using dopaminergic therapy.
PCT/CN2013/076853 2012-12-28 2013-06-06 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds for treatment of central nervous system disorder WO2014101373A1 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
PT138665880T PT2945632T (en) 2012-12-28 2013-12-20 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds suitable for treatment or prevention of central nervous system disorders
BR112015015468A BR112015015468B8 (en) 2012-12-28 2013-12-20 COMPOUND AND PHARMACEUTICAL COMPOSITION
AU2013370977A AU2013370977B2 (en) 2012-12-28 2013-12-20 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A antagonist properties
RU2015131148A RU2671628C2 (en) 2012-12-28 2013-12-20 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
RU2018136104A RU2018136104A (en) 2012-12-28 2013-12-20 COMPOUNDS HETEROBICYCY-SUBSTITUTED- [1,2,4] TRIAZOLO [1,5-c] HINAZOLIN-5-AMINE POSSESSING THE PROPERTIES OF A2A ANTAGONISTS
LTEP13866588.0T LT2945632T (en) 2012-12-28 2013-12-20 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds suitable for treatment or prevention of central nervous system disorders
HUE13866588A HUE037950T2 (en) 2012-12-28 2013-12-20 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds suitable for treatment or prevention of central nervous system disorders
KR1020157020147A KR102165113B1 (en) 2012-12-28 2013-12-20 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
MX2015008481A MX370017B (en) 2012-12-28 2013-12-20 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-ami ne compounds with a2a antagonist properties.
PCT/US2013/076781 WO2014105666A1 (en) 2012-12-28 2013-12-20 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
EP13866588.0A EP2945632B1 (en) 2012-12-28 2013-12-20 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds suitable for treatment or prevention of central nervous system disorders
SI201330980T SI2945632T1 (en) 2012-12-28 2013-12-20 Heterobicyclo-substituted-(1,2,4)triazolo(1,5-c)quinazolin-5-amine compounds suitable for treatment or prevention of central nervous system disorders
DK13866588.0T DK2945632T3 (en) 2012-12-28 2013-12-20 HETEROBICYCLO SUBSTITUTED - [1,2,4] TRIAZOL [1,5-C] QUINAZOLIN-5-AMINE COMPOUNDS SUITABLE FOR TREATMENT OR PREVENTION OF DISORDERS IN CENTRAL NERVOUS SYSTEM
NO13866588A NO2945632T3 (en) 2012-12-28 2013-12-20
CA2896056A CA2896056C (en) 2012-12-28 2013-12-20 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
RS20180410A RS57162B1 (en) 2012-12-28 2013-12-20 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds suitable for treatment or prevention of central nervous system disorders
PL13866588T PL2945632T3 (en) 2012-12-28 2013-12-20 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds suitable for treatment or prevention of central nervous system disorders
JP2015550682A JP6306049B2 (en) 2012-12-28 2013-12-20 Heterobicyclo-substituted- [1,2,4] triazolo [1,5-C] quinazoline-5-amine compounds having A2A antagonist properties
CN201380073910.6A CN105025899B (en) 2012-12-28 2013-12-20 With A2AThe miscellaneous two cyclosubstituted amines of [1,2,4] triazol [1,5 c] quinazoline 5 of antagonist properties
US14/655,648 US9708347B2 (en) 2012-12-28 2013-12-20 Heterobicyclo-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties
MEP-2018-97A ME03034B (en) 2012-12-28 2013-12-20 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
ES13866588.0T ES2667477T3 (en) 2012-12-28 2013-12-20 Heterobicyclo-substituted compounds- [1,2,4] triazolo [1,5-c] quinazolin-5-amine suitable for the treatment or prevention of central nervous system disorders
US15/423,238 US10011615B2 (en) 2012-12-28 2017-02-02 Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties
HRP20180678TT HRP20180678T1 (en) 2012-12-28 2018-04-27 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds suitable for treatment or prevention of central nervous system disorders
CY20181100472T CY1120258T1 (en) 2012-12-28 2018-05-04 Heterocyclic-Substituted Compounds- [1,2,4] Triazolo [1,5-C] Quinazoline-5-Amine Suitable for the Treatment or Prevention of Intermittent Disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2012/087865 WO2014101120A1 (en) 2012-12-28 2012-12-28 Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
CNPCT/CN2012/087865 2012-12-28

Publications (1)

Publication Number Publication Date
WO2014101373A1 true WO2014101373A1 (en) 2014-07-03

Family

ID=51019745

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/CN2012/087865 WO2014101120A1 (en) 2012-12-28 2012-12-28 Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
PCT/CN2013/076853 WO2014101373A1 (en) 2012-12-28 2013-06-06 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds for treatment of central nervous system disorder
PCT/US2013/076781 WO2014105666A1 (en) 2012-12-28 2013-12-20 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/CN2012/087865 WO2014101120A1 (en) 2012-12-28 2012-12-28 Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2013/076781 WO2014105666A1 (en) 2012-12-28 2013-12-20 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties

Country Status (22)

Country Link
US (2) US9708347B2 (en)
EP (1) EP2945632B1 (en)
JP (1) JP6306049B2 (en)
KR (1) KR102165113B1 (en)
AU (1) AU2013370977B2 (en)
BR (1) BR112015015468B8 (en)
CA (1) CA2896056C (en)
CY (1) CY1120258T1 (en)
DK (1) DK2945632T3 (en)
ES (1) ES2667477T3 (en)
HR (1) HRP20180678T1 (en)
HU (1) HUE037950T2 (en)
LT (1) LT2945632T (en)
ME (1) ME03034B (en)
MX (1) MX370017B (en)
NO (1) NO2945632T3 (en)
PL (1) PL2945632T3 (en)
PT (1) PT2945632T (en)
RS (1) RS57162B1 (en)
RU (2) RU2018136104A (en)
SI (1) SI2945632T1 (en)
WO (3) WO2014101120A1 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017107087A1 (en) * 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 6, 7-dihydro-5h-pyrrolo [3, 4-b] pyridin-5-oneallosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018130184A1 (en) 2017-01-13 2018-07-19 江苏恒瑞医药股份有限公司 1,2,4-triazine-3-amine derivative, preparation method therefor, and use thereof in medicine
WO2018166493A1 (en) 2017-03-16 2018-09-20 江苏恒瑞医药股份有限公司 Heteroaryl[4,3-c]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof
US10329289B2 (en) 2015-12-23 2019-06-25 Merck Sharp & Dohme Corp. 6,7-dihydro-5H-pyrrolo[3,4-B]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor
WO2019154294A1 (en) 2018-02-06 2019-08-15 江苏恒瑞医药股份有限公司 Pyrazolo[1,5-a][1,3,5]triazine-2-amine derivative, preparation method therefor and medical use thereof
US10512638B2 (en) 2015-12-23 2019-12-24 Merck Sharp & Dohme Corp. 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor
US10836775B2 (en) 2016-12-22 2020-11-17 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor
US10865185B2 (en) 2015-08-21 2020-12-15 Srx Cardio, Llc Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity
CN112159411A (en) * 2020-10-15 2021-01-01 南京工业大学 Trifluoromethyl substituted pyrimido [1,3] diaza compound and preparation method thereof
US11312719B2 (en) 2018-11-30 2022-04-26 Merck Sharp & Dohme Corp. 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
US11312715B2 (en) 2017-09-28 2022-04-26 Cstone Pharmaceuticals (Suzhou) Co., Ltd. Fused ring derivative as A2A receptor inhibitor
US11319298B2 (en) 2016-12-22 2022-05-03 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor
US11891369B2 (en) 2016-02-23 2024-02-06 Srx Cardio, Llc Compounds for binding proprotein convertase subtilisin/kexin type 9
US11925637B2 (en) 2015-08-21 2024-03-12 Srx Cardio, Llc Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use
US11944619B2 (en) 2015-08-21 2024-04-02 Srx Cardio, Llc Phenylalanine small organic compounds to directly modulate PCSK9 protein activity

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3253390B1 (en) 2015-02-06 2022-04-13 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as a2a antagonist
EP3307067B1 (en) 2015-06-11 2022-11-02 Merck Sharp & Dohme LLC Aminopyrazine compounds with a2a antagonist properties
WO2017008205A1 (en) 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
EP3587419A4 (en) 2017-02-27 2020-08-05 Betta Pharmaceuticals Co., Ltd. Fgfr inhibitor and application thereof
WO2019118313A1 (en) 2017-12-13 2019-06-20 Merck Sharp & Dohme Corp. Imidazo [1,2-c] quinazolin-5-amine compounds with a2a antagonist properties
MX2021008094A (en) 2019-01-11 2021-09-21 Omeros Corp Methods and compositions for treating cancer.
EP3785734B1 (en) 2019-03-26 2023-04-12 Novel Pharma Inc. Long-acting fatty acid-binding gnrh derivative and pharmaceutical composition comprising same
WO2021155841A1 (en) 2020-02-07 2021-08-12 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181282A1 (en) * 1984-10-01 1986-05-14 Ciba-Geigy Ag Triazoloquinazoline compounds
US4713383A (en) * 1984-10-01 1987-12-15 Ciba-Geigy Corporation Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses
WO2002055083A1 (en) * 2001-01-10 2002-07-18 Vernalis Research Limited TRIAZOLO[4,5-d] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS
WO2004094431A2 (en) * 2003-04-23 2004-11-04 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists
WO2010084425A1 (en) * 2009-01-26 2010-07-29 Domain Therapeutics New adenosine receptor ligands and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (en) 1993-06-29 1996-10-17 Schering Plough S P A HETEROCYCLIC ANALOGUES OF 1,2,4-TRIAZOLE(15-C)PYRIMIDINES WITH ANTAGONIST ACTIVITY FOR THE ADENOSINE A2 RECEPTOR
ATE208199T1 (en) 1993-07-27 2001-11-15 Kyowa Hakko Kogyo Kk MEDICINAL PRODUCTS FOR PARKINSON'S DISEASE
WO1995035107A1 (en) 1994-06-20 1995-12-28 Smithkline Beecham Corporation Endothelin receptor antagonists
US5571775A (en) * 1994-07-11 1996-11-05 Dowelanco N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides
IT1277392B1 (en) 1995-07-28 1997-11-10 Schering Plough S P A HEROCYCLIC ANALOGS OF 1,2,4-TRIAZOLE (1,5-C] PYRIMIDINE WITH ANTAGONIST ACTIVITY FOR THE A2A RECEPTOR OF ADENOSINE
IT1291372B1 (en) 1997-05-21 1999-01-07 Schering Plough S P A USE OF HETEROCYCLIC ANALOGS OF 1,2,4-TRIAZOLE (1,5-C) PYRIMIDINS FOR THE PREPARATION OF MEDICATIONS USEFUL FOR THE TREATMENT OF DISEASES
US5929106A (en) 1997-10-27 1999-07-27 Smithkline Beecham Corporation Endothelin receptor antagonists
WO2001092264A1 (en) 2000-05-26 2001-12-06 Schering Corporation Adenosine a2a receptor antagonists
WO2001099264A1 (en) 2000-06-20 2001-12-27 Rees, Alexander, Ellison Electrical drive line
US6358964B1 (en) * 2000-07-26 2002-03-19 King Pharmaceuticals Research And Development, Inc. Adenosine, A3 receptor modulators
BR0312913A (en) 2002-07-25 2005-07-12 Pharmacia Italia Spa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising the same
AU2003304527B2 (en) 2002-12-19 2010-09-09 Merck Sharp & Dohme Corp. Uses of adenosine A2a receptor antagonists
EP1633756B1 (en) * 2003-04-09 2008-12-24 Biogen Idec MA Inc. A2a adenosine receptor antagonists
AR056080A1 (en) 2005-09-23 2007-09-19 Schering Corp 7- [2- [4- (6-FLUORO-3-METIL-1,2-BENCIOSOXAZOL-5-IL) -1-PIPERAZINIL] ETIL] -2- (1-PROPINYL) -7H-PIRAZOL- [4, 3-E] - [1,2,4] -TRIAZOL- [1,5-C] -PIRIMIDIN-5-AMINE
ATE457988T1 (en) 2006-06-26 2010-03-15 Schering Corp A2A ADENOSINE RECEPTOR ANTAGONISTS
WO2009032754A2 (en) 2007-08-31 2009-03-12 Kalypsys, Inc. Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
EP2509983B1 (en) 2009-11-16 2014-09-17 Merck Sharp & Dohme Corp. FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY
WO2012135084A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2014101113A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181282A1 (en) * 1984-10-01 1986-05-14 Ciba-Geigy Ag Triazoloquinazoline compounds
US4713383A (en) * 1984-10-01 1987-12-15 Ciba-Geigy Corporation Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses
WO2002055083A1 (en) * 2001-01-10 2002-07-18 Vernalis Research Limited TRIAZOLO[4,5-d] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS
WO2004094431A2 (en) * 2003-04-23 2004-11-04 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists
WO2010084425A1 (en) * 2009-01-26 2010-07-29 Domain Therapeutics New adenosine receptor ligands and uses thereof

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11945782B2 (en) 2015-08-21 2024-04-02 Srx Cardio, Llc Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity
US11944619B2 (en) 2015-08-21 2024-04-02 Srx Cardio, Llc Phenylalanine small organic compounds to directly modulate PCSK9 protein activity
US11925637B2 (en) 2015-08-21 2024-03-12 Srx Cardio, Llc Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use
US10865185B2 (en) 2015-08-21 2020-12-15 Srx Cardio, Llc Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity
US10933056B2 (en) 2015-12-23 2021-03-02 Merck Sharp & Dohme Corp. 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor
US10329289B2 (en) 2015-12-23 2019-06-25 Merck Sharp & Dohme Corp. 6,7-dihydro-5H-pyrrolo[3,4-B]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor
US10351564B2 (en) 2015-12-23 2019-07-16 Merck Sharop & Dohme, Corp. 6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor
US10512638B2 (en) 2015-12-23 2019-12-24 Merck Sharp & Dohme Corp. 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor
WO2017107087A1 (en) * 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 6, 7-dihydro-5h-pyrrolo [3, 4-b] pyridin-5-oneallosteric modulators of the m4 muscarinic acetylcholine receptor
US11891369B2 (en) 2016-02-23 2024-02-06 Srx Cardio, Llc Compounds for binding proprotein convertase subtilisin/kexin type 9
US11319298B2 (en) 2016-12-22 2022-05-03 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor
US10836775B2 (en) 2016-12-22 2020-11-17 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor
US11014904B2 (en) 2017-01-13 2021-05-25 Jiangsu Hengrui Medicine Co., Ltd. 1,2,4-triazine-3-amine derivative, preparation method therefor, and use thereof in medicine
WO2018130184A1 (en) 2017-01-13 2018-07-19 江苏恒瑞医药股份有限公司 1,2,4-triazine-3-amine derivative, preparation method therefor, and use thereof in medicine
US11312705B2 (en) 2017-03-16 2022-04-26 Jiangsu Hengrui Medicine Co., Ltd. Heteroaryl[4,3-C]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof
WO2018166493A1 (en) 2017-03-16 2018-09-20 江苏恒瑞医药股份有限公司 Heteroaryl[4,3-c]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof
US11312715B2 (en) 2017-09-28 2022-04-26 Cstone Pharmaceuticals (Suzhou) Co., Ltd. Fused ring derivative as A2A receptor inhibitor
AU2018341781B2 (en) * 2017-09-28 2023-03-30 Cstone Pharmaceuticals Fused ring derivative as A2A receptor inhibitor
WO2019154294A1 (en) 2018-02-06 2019-08-15 江苏恒瑞医药股份有限公司 Pyrazolo[1,5-a][1,3,5]triazine-2-amine derivative, preparation method therefor and medical use thereof
US11312719B2 (en) 2018-11-30 2022-04-26 Merck Sharp & Dohme Corp. 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
CN112159411A (en) * 2020-10-15 2021-01-01 南京工业大学 Trifluoromethyl substituted pyrimido [1,3] diaza compound and preparation method thereof

Also Published As

Publication number Publication date
WO2014105666A1 (en) 2014-07-03
WO2014101120A1 (en) 2014-07-03
MX2015008481A (en) 2015-09-23
CA2896056C (en) 2020-11-10
ME03034B (en) 2018-10-20
RU2015131148A (en) 2017-02-03
JP2016504363A (en) 2016-02-12
PT2945632T (en) 2018-05-22
US10011615B2 (en) 2018-07-03
SI2945632T1 (en) 2018-05-31
US20170197991A1 (en) 2017-07-13
KR102165113B1 (en) 2020-10-13
RS57162B1 (en) 2018-07-31
JP6306049B2 (en) 2018-04-04
KR20150100879A (en) 2015-09-02
BR112015015468B1 (en) 2021-10-26
AU2013370977B2 (en) 2017-12-14
EP2945632A4 (en) 2016-09-14
CA2896056A1 (en) 2014-07-03
AU2013370977A1 (en) 2015-07-09
EP2945632A1 (en) 2015-11-25
CY1120258T1 (en) 2019-07-10
DK2945632T3 (en) 2018-05-22
BR112015015468A2 (en) 2017-07-11
PL2945632T3 (en) 2018-07-31
NO2945632T3 (en) 2018-08-04
US9708347B2 (en) 2017-07-18
BR112015015468B8 (en) 2023-04-25
MX370017B (en) 2019-11-28
EP2945632B1 (en) 2018-03-07
ES2667477T3 (en) 2018-05-11
RU2671628C2 (en) 2018-11-06
RU2018136104A3 (en) 2022-04-05
RU2018136104A (en) 2018-11-21
LT2945632T (en) 2018-05-25
HUE037950T2 (en) 2018-09-28
US20150361098A1 (en) 2015-12-17
HRP20180678T1 (en) 2018-06-01

Similar Documents

Publication Publication Date Title
US10011615B2 (en) Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties
AU2019243289B2 (en) Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
KR102216288B1 (en) Tricyclic heterocycles as bet protein inhibitors
EP3670506B1 (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
EP1416935B1 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
EP3038466B1 (en) 2,2-difluorodioxolo a2a receptor antagonists
EP3176171A1 (en) Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders
EP2938344B1 (en) Piperazine-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
KR20140059195A (en) Tricyclic heterocyclic compounds and jak inhibitors
AU2002324029A1 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
US10688082B2 (en) Aminopyrazine compounds with A2A antagonist properties
ES2637816T3 (en) Imidazo-triazine derivatives as PDE10 inhibitors
CN105025899B (en) With A2AThe miscellaneous two cyclosubstituted amines of [1,2,4] triazol [1,5 c] quinazoline 5 of antagonist properties
EP2504339A1 (en) Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
WO2015113980A1 (en) (hetero)aryl imidazoles/pyrazoles for treatment of neurological disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13866561

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13866561

Country of ref document: EP

Kind code of ref document: A1